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Estradiol, one of the sex hormones responsible for gender dimorphism and reproduction, is a pleitropic hormone with widespread biological actions 
far beyond human reproduction alone. For example, withdrawal of the effects of 
estradiol at menopause from non-reproductive tissues like the skeleton, the cardio-
vascular system, and the brain, is a major risk factor for the development of osteo-
porosis, coronary artery disease, stroke, and perhaps neurodegenerative diseases 
like Alzheimer’s disease. On the other hand, continuous exposure of reproductive 
tissues to estrogen during the post reproductive part of life is a risk factor for the 
development of breast, and uterine cancer.
The naturally occurring estrogens 17β-estradiol (E2), estrone (E 1), and estriol 
(E3) are derived from cholesterol. Different steroids are formed by the reduction of 
the number of carbon atoms from 27 to 18 by different cytochrome P450 enzymes. 
Although estradiol also has local autocrine or paracrine actions the majority of 
estradiol is released into the circulation where 98% is reversibly bound to sex-
hormone-binding globulin and with less affi nity to albumin. Estradiol can freely 
diffuse across the plasma and nuclear membranes of all cells, but it is sequestered 
only within cells that contain estrogen receptors (ER). As free estradiol diffuses 
into the cell, it binds to the ligand-binding domain of the receptor; the complex of 
estradiol and ER then diffuses into the cell nucleus. This complex, in association 
with other coactivators or repressor proteins, can alter the subsequent expression 
of a variety of relevant target genes. In particular, the estradiol-ER complexes bind 
to specifi c sequences of DNA called estrogen-response elements (ERE) as homo- 
or heterodimers. These ERE DNA sequences function as enhancers, conferring 
estradiol-inducibility on the genes (fi gure 1). 
There are fi ve broad classes of human proteins relevant to estradiol produc-
tion and action. These include proteins involved in the neuroendocrine regulation 
of sex-hormone production (i.e., GnRH, LH and FSH); proteins involved in the 
synthesis of estradiol (i.e., the P450 enzymes); the estrogen receptors α and β; pro-
teins involved in the downstream pathways of estrogen action (i.e., COMT); and 
proteins involved in drug absorption, transport, and metabolism. In this thesis, we 
have chosen two candidate genes in this pathway to study in relation to disease risk; 
Figure 1. 
Estrogen receptor (ER) activation and estrogen-response (ERE) element binding
ER ER
ERE
CoActivator
 Gene expression
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the estrogen receptor α gene (ERα, also known as ESR1) and the gene encoding 
the P450 enzyme aromatase (CYP19).
Current generation of estradiol defi ciency models in mice with targeted disrup-
tion of the aromatase or the estrogen receptor (ER) gene provides insight into the 
role of estradiol in female and male reproductive and non-reproductive physiology. 
The majority of studies of estradiol defi ciency have focused on mice lacking the 
classical ERα, the ERα knockout mice (αERKO). Recently, a second estrogen 
receptor, ERβ, has been identifi ed.1,2 The importance of ERβ in humans is still 
largely unknown. The development of ERβ knockout mouse models (βERKO) is 
leading to a better understanding of the different effects these two receptors have 
in a number of tissues. Years of research using the ERKO mice as a research tool to 
investigate specifi c pathophysiological consequences of estradiol defi ciency has led 
to a large body of literature (for an extensive review see reference 3). 
The main fi ndings of the ERα and ERβ knockout mouse models are summa-
rized in table 1. It appears that ERα and ERβ are both very important in the central 
nervous system, bone, lung, urogenital tract, cardiovascular system, ovary, testis, 
kidney and colon. The physiological function of ERβ is under intense study but 
some results indicate that ERα and ERβ have different or even opposite biological 
actions.
Through an experiment of nature, medical science has discovered just how wide-
spread the effects of estradiol are in diverse human functions. In the last decade 
nine men and women have been reported with mutations in the aromatase (CYP19) 
gene leading to estradiol defi ciency and one man has been reported with complete 
estradiol resistance due to a recessive mutation in the ERα gene.4 These observa-
tions stimulated research ranging from integrative physiology to cell and molecular 
biology within and outside the reproductive system. Human and mouse estradiol 
defi ciency models have many similarities, indicating once again that mouse knock-
out models are an excellent tool to investigate the role of certain genes in human 
diseases. In young females, estradiol defi ciency gives rise to ambiguous genitalia 
and a failure of secondary sexual characteristics to develop, while in males a normal 
male sexual differentiation and pubertal development is seen. The involvement of 
estradiol in non-reproductive tissues such as bone and the cardiovascular system 
has led to the basis of this thesis. The absence of estradiol signaling in bone has 
striking consequences in both men and women, resulting in osteoporosis as well as 
continued linear bone growth due to non-closure of the epiphyses. Furthermore, 
estradiol defi ciency or resistance also leads to premature atherosclerotic coronary 
artery disease, endothelial dysfunction, and an abnormally low HDL/LDL cho-
lesterol ratio. Given the striking consequences of complete estradiol defi ciency or 
resistance on the human body, one can also envision more subtle and frequent 
mutations (i.e., polymorphisms) in genes involved in the estradiol signaling pathway 
potentially leading to increased risk of age-related diseases such as osteoporosis and 
cardiovascular disease in the general population. 
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Table 1. Summary of reported phenotypes in the αERKO and βERKO mouse 
models (Partially adapted from Couse et al.3)
References
General Neither αERKO nor βERKO is lethal. 8-10
Fertility
αERKO Both sexes are infertile. 9
βERKO Female is subfertile (reduced litter size); male is fertile. 8
Female reproductive tract
αERKO Tract undergoes normal pre- and neonatal development, 
but is insensitive to estradiol, DES, and hydroxy tamoxifen 
during adulthood.
9, 11, 12
Presence of non-ERα or -ERβ receptor-mediated estrogenic 
pathway for 4-OH-estradiol and methoxychlor.
13, 14
Loss of mitogenic actions of epidermal growth factor 
(EGF).
15
Responsive to mitogenic actions of androgens. 16
Responsive to progesterone and able to undergo artifi cially 
induced decidualization.
17
Ovaries undergo normal pre- and neonatal development, but 
are anovulatory during adulthood, exhibit multiple hemor-
rhagic cysts, and no corpora lutea.
9, 18
30–40% incidence of ovarian tumors by 18 months of age. 3
βERKO Tract undergoes normal pre- and neonatal development and 
appears sensitive to ovarian estrogen cycling during adult-
hood. 
8
Ovaries undergo normal pre- and neonatal development, but 
do not exhibit normal frequency of spontaneous ovulations 
during adulthood, exhibit a severely attenuated response to 
superovulation treatment with reduced numbers of oocytes, 
follicular arrest and anovulation.
8
Mammary gland
αERKO Undergoes normal prenatal development but is insensitive to 
E2-induced development during puberty and adulthood.
19
Responsive to exogenous progesterone and prolactin. 20
Susceptible to proto-oncogene (Wnt-1) induced ductal hyper-
plasia and lobuloalveolar adenocarcinoma but tumors exhibit 
a delayed growth rate compared to those in wild-type.
21
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Mammary gland cont.
βERKO Undergoes normal prenatal and pubertal development, virgin 
gland is grossly indistinguishable from that of age-matched 
wild-type.
8
Undergoes normal differentiation and lactation during 
pregnancy and motherhood.
8
Male reproductive tract
αERKO Tract undergoes normal pre- and neonatal development. 22, 23
Age-related phenotype of attenuated fl uid resorption in 
efferent ducts leads to dilation of rete testis, atrophy of the 
seminiferous epithelium, and decreasing sperm counts.
22, 24
Disrupted sperm function illustrated by an inability to fertil-
ize.
22
Age-related decrease in testis weight. 3
Age-related increase in seminal vesicle weight. 3
βERKO Undergoes normal pre- and neonatal development without 
apparent defects in spermatogenesis that impede fertility.
8
Neuroendocrine system: females
αERKO Anterior pituitary possesses all of the expected cell types, 
but exhibits elevated transcript levels for the gonadotropin 
subunits (gonadotropin α subunit, LH-β, FSH-β).
25
Elevated serum levels of estradiol, testosterone, and LH, but 
normal serum levels of progesterone and FSH.
11, 26
Normal lactotroph differentiation and number in the ante-
rior pituitary, but exhibits signifi cant defi cits in transcription 
of the PRL gene and serum PRL levels.
3, 25
Medial preoptic region of the hypothalamus exhibits elevated 
levels of PR transcripts which decreased after ovariectomy 
and return after estradiol treatment.
27, 28
Rapid actions of estradiol on hippocampal neurons are 
preserved.
29
βERKO Normal serum levels of estradiol. 3
Neuroendocrine system: males
αERKO Anterior pituitary possesses all the expected cell types, but 
exhibits elevated levels of LH-β transcripts.
25, 30
Elevated serum levels of estradiol, testosterone, and LH, but 
normal serum levels of progesterone and FSH.
3, 30
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Behavior: females
αERKO Exhibit a lack of estradiol and progesterone-induced sexual 
behavior, increased aggression, and infanticide.
31-33
βERKO Exhibit no defects in sexual behavior that impede fertility. 8
Behavior: males
αERKO Exhibit normal mounting and attraction toward wild-type 
females but a complete lack of intromission and ejaculation; 
display reduced aggression.
34-36
βERKO Exhibit no defects in sexual behavior that impede fertility. 8
Bone
αERKO Decrease in femoral bone length and diameter. 37
Decreased femur bone mineral density (BMD). 37-39
βERKO Males: no major bone abnormalities. 40
Females: slightly elevated BMD in adults. 40
Cognition
αERKO Impaired activity in cognitive function tests. 41
βERKO Normal cognition 41
Cardiovascular
αERKO Exhibit reduced estradiol-induced angiogenesis and reduced 
basal levels of vascular nitric oxide
42
Exhibit wild-type response to estradiol in the carotid artery 
injury model
43
Exhibit increased expression of L-type Ca2+ channels 44
Exhibit reduced response to estrogen-induced increases in 
serum apolipoprotein E
45
The protective actions of estradiol in preventing stroke are 
abolished in αERKO mice, but not in βERKO mice.
46
Adipose tissue
αERKO Signifi cant accumulation of white adipose tissue, which is 
characterized by an increase in adipocyte size and number.
47, 48
βERKO Normal body weight and adipose tissue 47
Other
αERKO Impaired glucose tolerance and insulin resistance 48, 49
No estradiol induced reduction of B lymphopoietic cells. 50
βERKO No estradiol induced reduction of B lymphopoietic cells. 50
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1.1 Dissection of Complex Traits
To fi nd disease-causing polymorphisms in genes involved in complex diseases a 
number of approaches can be used. Broadly defi ned these include genome searches 
by linkage analysis and candidate gene studies by association analysis. The fi rst 
method, the so-called “top-down” approach, uses linkage disequilibrium to identify 
areas of the genome that may carry a gene that infl uences a phenotype of interest. 
For such a genome search sibling pairs, a set of family pedigrees, or an isolated 
population are studied since areas of linkage disequilibrium in the genome are much 
larger in genetically more closely related individuals than in an out-bred population. 
This makes it easier to identify regions in the genome that are associated with the 
phenotype of interest. Once linkage studies, such as the one for height discussed 
in chapter 2.2 of this thesis, have identifi ed a region of potential linkage, the next 
step is fi ne-mapping of the region through the evaluation of candidate gene loci. 
Hundreds of genes may lie within the area identifi ed by linkage analysis. In associa-
tion analysis one or more candidate genes are chosen that are potentially the most 
interesting. Within the candidate gene, polymorphisms are tested for association 
with the phenotype of interest. 
The above described “top-down” method is time-consuming and often not 
feasible due to the high costs of such genome searches and the necessity of fi nding 
and testing sibling pairs, family pedigrees or an isolated population. Furthermore, 
genome searches often yield false-positive and false-negative results mainly due to 
the large amount of statistical power such a linkage study needs to identify subtle 
disease-causing loci. Therefore, the so-called “bottom-up” approach has become the 
preferred method of research in a growing number of studies of complex diseases. 
This method builds on known biology and entails choosing candidate genes based 
on the current knowledge about the pathophysiology of the disease or phenotype 
of interest. Given the phenotypes described in human and mouse estradiol knock-
out models, the genes within the estradiol endocrine pathway are potentially very 
interesting in bone and cardiovascular research and this thesis focuses on candidate 
genes within this pathway using the “bottom-up” approach.
1.2 Candidate Genes Approach
Within a candidate gene, potentially interesting polymorphisms are identifi ed 
and tested for association with the phenotype of interest, preferentially in a large 
population-based cohort study such as the Rotterdam Study.5 By sequencing the 
entire candidate gene, including promoters, introns and other untranslated regions 
in for example one-hundred individuals, a complete inventory can be made of the 
polymorphisms present in that gene. From direct sequencing of the vitamin D 
receptor (VDR) gene performed in our laboratory we have calculated that approxi-
mately one in 300 base pairs is polymorphic (Y. Fang, personal communication). 
That means that in a gene spanning almost 300 thousand base pairs (300 kb), such 
as the ERα gene, approximately 1000 polymorphisms will be present. From these 
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polymorphisms the most interesting ones are chosen based on their potential func-
tional signifi cance to the encoded protein. The most promising polymorphisms 
are those that lead to a change of an amino acid in the encoded protein, i.e., the 
non-synonymous polymorphisms. Other potentially interesting polymorphisms 
are located in the promoter regions and the 3-prime untranslated region (3’UTR), 
since these may modify mRNA expression or stability. In addition, polymorphisms 
that change potential transcription factor binding sites are also interesting since 
they may increase or decrease the rate of gene transcription. Although the list of 
polymorphisms identifi ed by sequencing of the entire gene usually leads to an 
exhaustive list of polymorphisms, the method is costly and very time-consuming. 
By consulting polymorphism databases such as Celera (www.celera.com) and NCBI 
(www.ncbi.nlm.nih.gov), and literature databases such as PubMed (www.ncbi.nlm.
nih.gov), an inventory of polymorphisms in a candidate gene can be made within a 
day. The latter method was used to identify polymorphisms in this thesis. 
1.3 Candidate Genes in the Estrogen Endocrine Pathway
The estrogen receptor is essential in de mediation of estradiol’s effects in di-
verse tissues. The ERα gene is the most well studied of the two estrogen receptors 
identifi ed. The ERα gene, located on chromosome 6q25, is the fi rst candidate gene 
discussed in this thesis. It is a large gene, spanning almost 300 kb of which only 
1791 base pairs are transcribed to the actual ERα protein. The rest of the gene is 
made up of an extensive promoter area of 150 kb, other regulatory regions such as 
the 3’ UTR (untranslated region) and introns (Figure 2). 
Using the above mentioned polymorphism and literature databases we were 
able to identify a large number of single nucleotide polymorphisms (SNPs) and 
variable number tandem repeats (VNTR) in the ERα gene (Figure 3). We preferen-
tially chose polymorphisms with frequency data available, either from the literature 
or from the polymorphism databases, and with a frequency of 5% or more in 
Caucasians. We focused on non-synonymous polymorphisms and polymorphisms 
located in the promoter regions and the 3’UTR. An exception was made for two 
intronic polymorphisms known from the osteoporosis literature.6 In total thirteen 
polymorphisms in the ERα gene were chosen to genotype for our studies (Figure 
4). Three polymorphisms were identifi ed via public literature databases and were 
Figure 2.
Estrogen receptor α (ERα) gene (6q25)
ACD
Coding Region 3’ UTRPromoter
1 2 3 5 6 7 84
BT1 T2E2 F            E1
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chosen based on previously reported associations in Caucasians. These were the 
TA-repeat VNTR at -1355 from the start of transcription and two intronic SNPs, 
identifi ed by the restriction enzymes PvuII and XbaI, located at -397 and -351 from 
the start of exon 2. Ten polymorphisms were chosen from the large number of 
polymorphisms identifi ed by consulting polymorphism databases. One of these 
polymorphisms was non-synonymous. None of the SNPs reported in the 3’UTR 
Figure 3.
Polymorphisms identifi ed in the ERα gene
Isoforms+478 Gly/Cys
Coding Region 3’ UTRPromoter
Non-
coding
-109
+2539 A/G 
+2821 T/C
+3007 A/C
+3662 C/T
+3862 -/T
+4018 C/T
+4651 A/G
+5113 C/G
31 2 4 5 7 86
ABC
3’ UTR
+30
+261 (B-variant)
Silent
+5269 A/G
+5315 A/G
+5597 A/T-10
PvuII & XbaI
-397/-351
+729   +975 +1275      +1782
D
-406
-417
-1612
-1355
-3246
-2991
-2224
-4907
-5154
Figure 4.
Polymorphisms chosen for analysis in the ERα gene
Isoforms+478 Gly/Cys
Coding Region 3’ UTRPromoter
Non-
coding
-109
ABC
3’ UTR
-4907
-5154
-3246
-2991
-2224
-406
-417
Silent
-10
PvuII & XbaI
-397/-351
+1782
-1612
-1355
D
32 4 5 7 81 6
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none had frequency data available. A synonymous polymorphism in exon 8 was 
proven polymorphic in Caucasians and since it is very likely that this polymor-
phism is in linkage disequilibrium with polymorphisms in the 3’UTR we chose to 
genotype this polymorphism instead. The remaining eight polymorphisms were 
chosen because of their location in the promoter regions or their ability to change 
a potential transcription factor binding site. Of the polymorphisms genotyped in 
a pilot sample of 300 participants, five polymorphisms had frequencies above 5%. 
These were the three previously known polymorphisms (TA-repeat, PvuII and 
XbaI), one of the promoter polymorphisms (-2224) and the exon 8 polymorphism 
(+1782). These five polymorphisms were genotyped in a set of 3000 randomly 
chosen individuals from the Rotterdam Study (38% of total cohort) and associa-
tion analyses were performed. If an association was observed in the random set of 
3000 that polymorphism was genotyped. Of the five polymorphisms genotyped 
in the random set, the promoter (-2224) and the exon 8 (+1782) SNPs were not 
associated with the phenotypes we studied. Therefore, the studies reported in this 
thesis are based on the TA-repeat (-1355), the PvuII (-397) and the XbaI (-351) 
polymorphisms.
The second candidate gene chosen for this thesis is the aromatase (CYP19) gene. 
Aromatase belongs to the cytochrome 450 enzyme super-family and is responsible 
for the conversion of androstenedione and testosterone to estrone and estradiol, 
respectively (Figure 5). This enzyme catalyzes the rate-limiting step in the periph-
eral conversion of estradiol and is therefore essential to circulating estradiol levels. 
The CYP19 gene is located on chromosome 15q21.1 and spans 123 kb including a 
coding region of 9 exons (exons II-X). Upstream of exon II, a number of alternative 
first exons are differentially spliced into distinct 5’UTRs (Figure 6). To date, nine 
different transcriptional start sites are known with individual promoters permitting 
tissue-specific regulation of expression. Even though each tissue expresses a unique 
5’UTR, the coding region and translated product (and therefore also the protein 
expressed) are identical. 
Figure 5.
Conversion of androstenedione and testosterone to estrone and estradiol by aro-
matase
Androstenedione Testosterone
Estrone (E1) Estradiol (E2)
Aromatase Aromatase
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Similar to our fi ndings for the ERα gene, using literature and polymorphism da-
tabases we were able to identify a large number of polymorphisms in the aromatase 
gene. Three polymorphisms were chosen to test in the random set of 3000 indi-
viduals from the Rotterdam Study: two non-synonymous SNPs in exons 1 (+115) 
and 7 (+792) and one SNP in the 3’UTR (+1531), see fi gure 6. The exon 1 variation 
was not found to be polymorphic in our population and we were unable to design 
primers to genotype the exon 7 SNP. The association with the CYP19 described in 
this thesis is based on the polymorphic 3’UTR SNP located at +1531.
1.4 Study Population
The results of the studies presented in this thesis were based on the Rotterdam 
Study, a prospective population-based cohort study, which was initiated to assess 
prevalence, incidence, and determinants of diseases in the elderly.5 The main focus 
of this study was on cardiovascular disease, neurogeriatric disease, ophthalmo-
logic disease, and locomotor disease. The Rotterdam Study was approved by the 
medical ethics committee of the Erasmus Medical Center and written informed 
consent was obtained from all participants. At baseline, between 1990 and 1993, 
all inhabitants aged 55 years and over (n=10,275) of the district of Ommoord in 
Rotterdam were invited to take part in the study. A total of 7,983 subjects (response 
rate 78%), 4878 of whom were women, entered the study. At baseline, and again at 
the fi rst, second and third follow-up visits (1994-1995, 1997-1999 and 2002-2004, 
respectively), information was gathered concerning amongst others lifestyle habits, 
socio-economic status, medical history and pharmacotherapeutic history. In addi-
tion to an interview, all subjects were invited to visit our research center for physical 
examination and blood drawing. 
For the entire cohort, information on vital status is obtained continuously 
from the municipal authorities in Rotterdam. For subjects who moved outside the 
research area, mortality data are obtained from general practitioners (GPs). GPs 
in the research area (covering 80% of the cohort) reported all relevant fatal and 
non-fatal events, such as fractures and myocardial infarctions, through a computer-
ized system. Research physicians verifi ed follow-up information by checking GPs’ 
patients’ records. This is possible because in The Netherlands the GP has a gate-
Figure 6.
CYP19 gene encoding aromatase (15q21.1-2) and the polymorphisms chosen for 
analysis
62 3 4 5 7 8 9 10
I.1     2a     I.4        I.5      I.f I.2     I.6    I.3   PII
3’UTR
115 Trp/Arg 792 Arg/Cys 1531 A/G
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keeper function, which means that the only way to access specialist and hospital 
care is by consulting a GP. The GP retains all medical information of his patients. 
For the remaining 20% of the cohort, research physicians regularly visited the GPs 
and collected data from their records. For hospitalized patients, discharge letters 
were additionally used for verifi cation. All events were coded independently by two 
research physicians according to the International Classifi cation of Diseases, 10th 
revision (ICD-10).7 If there was disagreement, consensus was reached in a separate 
session. A medical expert in the fi eld reviewed all coded events for fi nal classifi ca-
tion.
1.5 Aim and Description of Chapters
The objective of the studies described in this thesis was to determine the role 
of polymorphisms in candidate genes within the estrogen signaling pathway in 
common diseases of the elderly. Chapter 2 focuses on the consequences of ERα 
polymorphisms on bone pathophysiology. The fi rst article of chapter 2.1 discusses 
the incidence of fractures in the Rotterdam Study cohort. In chapter 2.2, the as-
sociation of ERα polymorphisms with BMD and vertebral fractures is discussed. 
The role of ERα polymorphisms in determining pre- and postmenopausal body 
height in women is reported in the last article of chapter 2. In chapter 3, the role of 
ERα polymorphisms in determining the risk of cardiovascular diseases, including 
myocardial infarction, stroke and cerebral white matter lesions, is reported. The role 
of ERα and CYP19 polymorphisms in determining circulating estradiol levels is 
explored in chapters 4.1 and 4.2. In chapter 5.1, the possible functional signifi cance 
of the ERα PvuII polymorphisms is reported. Finally, in the general discussion, 
chapter 6, the main fi ndings of this thesis are placed in perspective. 
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ABSTRACT
The incidence of all non-vertebral fractures, as well as the relation to bone min-
eral density (BMD), was quantifi ed in 7806 men and women from the Rotterdam 
Study, a prospective, population-based cohort study of men and women age 55 
years and older. In addition, the sensitivity of using a T-score at or below –2.5 for 
identifying subjects at risk for fractures was assessed. 
At baseline, between 1990 and 1993, femoral neck BMD was measurement by 
dual energy X-ray absorptiometry (DXA). Subsequently, gender-specifi c T-scores 
were calculated using the NHANES reference population. During a mean follow-
up of 6.8 years, information on incident non-vertebral fractures was gathered. 
In general, hip, wrist and upper humerus fractures are the most frequent 
fractures in both men and women. Femoral neck BMD appears to be an equally 
important risk factor in both genders, and is especially related to hip fractures. For 
all non-vertebral fractures, the age adjusted hazard ratio (95% confi dence interval) 
per standard deviation decrease in femoral neck BMD was 1.5 (1.4-1.6) for women 
and 1.4 (1.2-1.6) for men. For hip fractures the hazard ratios were 2.1 (1.7-2.5) for 
women and 2.3 (1.6-3.3) for men. 
Only 34% of all non-vertebral fractures occurred in women with a T-score be-
low -2.5, in men this percentage was even lower (21%). Thus, there is a clear need 
for the development of more sensitive risk assessment tools, using not only BMD, 
but also other clinical predictors of fractures. 
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INTRODUCTION
Osteoporosis is a condition characterized by low bone mineral density (BMD) 
and micro architectural deterioration of bone, resulting in a loss of bone strength 
and therefore increased fracture risk. Osteoporotic fractures, the clinical endpoint 
of osteoporosis, are associated with increased morbidity, mortality and high socio-
economic costs.1,2 Due to increased life expectancy the incidence of fractures is 
increasing over time, hereby increasing the population burden of fractures.2 
As early as 1842, Antley Cooper noticed that the incidence of fractures in-
creased with thinning of bone in the elderly.3 In the 20th century several studies 
have shown that, independent of age, the likelihood of a fracture increases with 
decreasing BMD.4 However, the majority of these studies focused on women only. 
Therefore, the relationship between BMD and fractures in men is largely unknown. 
Furthermore, due to limited power most studies focus on the most common osteo-
porotic fractures such as hip fractures. Therefore, information on the occurrence 
as well as the relationship to BMD of less common osteoporotic fractures in men 
and women is scarce. 
In clinical practice the defi nition of osteoporosis is based on the WHO-based 
T-score of BMD, which expresses BMD as the number of standard deviations (SD) 
below the average BMD in young adult men and women. In this defi nition subjects 
with a T-score at or below –2.5 are considered to have osteoporosis. Similarly, os-
teopenia is defi ned as a T-score between -1.0 and -2.5, whereas a T-score above -1.0 
is considered normal.5 These cut-off values were originally intended to assess the 
prevalence of osteoporosis, and not, as is common practice nowadays, to be used as 
a treatment threshold. Currently, there is ongoing debate about the strengths and 
limitations of bone densiometry in clinical practice. 
The aim of our study was to investigate the incidence of the common osteo-
porotic fractures as well as less common fractures in both men and women in 
the Rotterdam Study, a large population based study of diseases in the elderly. 
Furthermore, the association between femoral neck BMD and these fractures is 
compared between men and women. And fi nally, the sensitivity of using a T-score 
at or below -2.5 in order to identify subjects who will eventually sustain a fracture 
is studied.
METHODS
Study population
The Rotterdam Study is a prospective population-based cohort study of men 
and women aged 55 and over. The objective is to investigate the incidence of and 
risk factors for chronic disabling diseases. Both the rationale and the study design 
have been described previously.6 The focus of the Rotterdam Study is on neurologi-
cal, cardiovascular, ophthalmologic and locomotor diseases. The Medical Ethics 
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Committee of the Erasmus Medical Centre has approved the Rotterdam Study. All 
10,275 inhabitants of Ommoord, a district in Rotterdam, the Netherlands, were 
invited to participate. Of these, 7,983 (4,878 women) participated in the Rotterdam 
Study (resulting in a response rate of 78%). For various reasons informed consent 
for follow-up registration could not be obtained for 177 (2.2%) participants and 
these individuals were therefore excluded from the analyses, leaving 7806 men and 
women who were included in our analyses. For femoral neck BMD, analyses were 
restricted to the 5794 (74.2%) participants who were able to visit the study center 
for a BMD measurement at baseline. 
Clinical examination 
Between 1990 and 1993, participants were invited to come to the research centre 
for clinical examination. BMD measurement of the femoral neck was performed by 
dual energy X-ray absorptiometry (DXA) (Lunar DPX-L densitometer, Madison, 
Wisconsin, USA) as described previously.7 
Follow-up procedures
The present analysis is based on follow-up data collected from baseline (1990-
1993) until December 31st 1999. Follow-up time was calculated as time from baseline 
to fi rst fracture, death or end of the follow-up period, which ever occurred fi rst. 
The average follow-up time was 6.8 (SD 2.3) years. All events were reported either 
by general practitioners (GPs) in the research area by means of a computerized 
system (80% of the cohort) or through hospital records. Information from GPs 
outside the research area was obtained by regular checking of the patient records 
by research physicians. All reported events were verifi ed by research physicians 
who independently reviewed and coded the information. Subsequently, all coded 
events were reviewed by a medical expert for fi nal classifi cation. When studying 
the association between BMD and incident fractures, only non-vertebral fractures 
were considered.
Statistics
All analyses were performed for the total group and for men and women 
separately. Fracture incidence rates were calculated according to fracture site and 
subdivided in three main categories: upper extremity, lower extremity and other 
fractures. The incidence rates were expressed as numbers of fractures per 1,000 
person-years and the 95 percent confi dence intervals were calculated using the 
exact Poisson formula. The most frequent fractures were also studied in 5-year 
age groups. To determine which specifi c types of fracture were associated with 
low BMD, we estimated the relative risk for a fi rst fracture associated with one 
standard deviation (SD) decrease in femoral neck BMD using a Cox proportional 
hazards model. For these analyses we used separate femoral neck BMD standard 
deviation for men and women (0.134 and 0.132 g/cm2, respectively). Since multiple 
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fractures do not contribute to independent observations these analyses were based 
on the fi rst fracture in each individuals. To account for confounding by age, gen-
der-specifi c age adjustments were made by including age as a continuous variable 
in all models. 
Gender-specifi c T-scores were calculated from the femoral neck BMD using 
the NHANES reference population of Caucasian males and females aged 20 to 29 
years.8 Peak bone mass, as converted to the corresponding Lunar value, was 1.04 
g/cm2 (SD 0.14) for women and 1.13 g/cm2 (SD 0.16) for men. The absolute BMD 
cut-off values for osteoporosis (T-score below -2.5) and osteopenia (T-score be-
tween -1.0 and -2.5) were 0.69 g/cm2 and 0.90 g/cm2 in women and 0.72 g/cm2 and 
0.96 g/cm2 in men, respectively. Hazard ratios for the risk of incident non-vertebral 
fractures in subjects with osteoporosis and osteopenia were calculated using a Cox’ 
proportional hazards model. Subjects with a normal BMD (T-score ≥ -1.0) were 
defi ned as the reference group. 
SPSS 11.0 was used for all analyses.
RESULTS 
Follow-up was completed for 7806 individuals (3075 men) after a mean follow-
up time of 6.8 years (SD 2.3 years, range 1 day to 10.5 years). BMD measurements 
were available for 5794 individuals (2437 men). Women were on average 2.4 years 
older and had 0.07 g/cm2 lower mean femoral neck BMD. 
Incidence of non-vertebral fractures
During follow-up 939 (12.0%) participants sustained at least one incident non-
vertebral fracture. Table 1 shows the fracture incidence rates by site and gender. 
Overall, the incidence of non-vertebral fractures was 9.6 (95% confi dence interval 
8.3-11.0) per 1,000 person-years in men and 25.0 (95% confi dence interval 23.3-
26.9) per 1,000 person-years in women. For all fracture sites, women had a higher 
incidence rate and overall the age-adjusted incidence was 2.3 (95% confi dence 
interval 2.0-2.7) times higher in women than in men. In both men and women, the 
predominant fracture sites were the wrist, upper humerus and hip. 
Figure 1 shows the age-related incidence of all non-vertebral, wrist, upper hu-
merus and hip fractures in men and women. In both men and women, the incidence 
of hip fracture increased exponentially with age. In women, a moderate increase 
with age was observed for upper humerus fractures, whereas the incidence of wrist 
fractures increased markedly from the age of 55 years onward and stabilized after 
70 years of age. In men, upper humerus fractures appeared to show only a slight 
increase with age, while wrist fracture incidence showed the largest increase after 
75 years of age.
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Relation of bone mineral density with non-vertebral fractures
In the subgroup of subjects with BMD data available, 644 (11.1%) individu-
als suffered at least one non-vertebral fracture. Compared to the total population 
we observed a lower incidence of non-vertebral fractures (16.4 vs. 18.9 per 1,000 
person-years) and hip fractures (3.7 vs. 5.4 per 1,000 person-years) in these younger 
(mean age 67.9 vs. 70.3 years) individuals. 
The relative risk for site-specifi c non-vertebral fractures per standard deviation 
decrease in femoral neck BMD is shown in table 2. For all non-vertebral fractures 
combined, we observed a relative risk of 1.4 (95% confi dence interval 1.2-1.6) per 
gender-specifi c SD decrease in BMD in men and 1.5 (95% confi dence interval 1.4-
1.6) in women. The overall relation with BMD and fracture risk was similar in men 
and women. Specifi cally, fractures of the hip and wrist were strongly associated 
with low BMD, in both men and women, while for upper humerus fractures this 
was only signifi cant in women. 
Figure 2 shows the prevalence of gender-specifi c T-score defi ned osteoporosis 
and osteopenia for men and women. Overall, the age-adjusted prevalences of 
oteoporosis in the Rotterdam Study were 12.1% for men (mean age 67.5 years) and 
19.2% for women (mean age 68.3 years). The prevalence of osteoporosis increased 
with age, reaching 36.4% and 45.2% in men and women aged 85 years or over, 
respectively.
Figure 3 shows percentages of all non-vertebral and hip fractures that occurred 
in men and women with osteoporosis, osteopenia and normal bone. Only 34% of all 
non-vertebral fractures occurred in women with a T-score below -2.5, in men this 
percentage was even lower (21%). In women, approximately half (53%) of all hip 
fractures occurred in subjects with a T-score below -2.5. In men, only a little over a 
third (39%) of all hip fractures occurred in subjects with osteoporosis as defi ned by 
T-score. In addition, approximately one third of wrist and upper humerus fractures 
occurred in women with a T-score below –2.5 (30% and 36%, respectively), while 
for men this was 19% for wrist fractures and 36% for upper humerus fractures. 
In Table 3 numbers of non-vertebral fractures are shown for men and women 
in 10 year age strata for individuals with a T-score > -1, as well as for osteoporotic 
and osteopenic subjects. In addition, incidence rates and relative fracture risks as 
compared to subjects with a T-score above – 1.0 are shown. Importantly, even 
though osteoporotic subjects both have a higher incidence rate and a higher relative 
fracture risk as compared to “normal” subjects, the higher number of osteopenic 
subjects in the population results in an equal absolute number of fractures in par-
ticipants with osteopenia as compared to those with osteoporosis for women and a 
three times higher number for men. 
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Table 2. Age adjusted hazard ratios (95% CI) for the predictive value of femoral 
neck BMD (g/cm2) per gender-specifi c standard deviation (SD) decrease in The 
Rotterdam Study
Type of Fracture Men Women Total
Upper extremities
Upper humerus 11 1.7 (0.9-3.4) 59 1.5 (1.1-2.0) 70 1.7 (1.3-2.2)
Wrist 21 1.6 (1.0-2.6) 164 1.5 (1.3-1.8) 185 1.7 (1.5-2.0)
Hand 21 1.5 (0.9-2.4) 46 1.2 (0.9-1.6) 67 1.3 (1.0-1.7)
Other upper arm a 9 0.9 (0.5-1.7) 21 1.6 (1.0-2.6) 30 1.4 (0.9-2.0)
Other lower arm b 3 0.9 (0.5-1.7) 15 1.6 (1.0-2.6) 18 1.4 (0.9-2.0)
Lower extremities
Pelvis 7 1.3 (0.6-3.0) 17 1.4 (0.9-2.4) 24 1.4 (0.9-2.1)
Hip 36 2.3 (1.6-3.3) 116 2.1 (1.7-2.5) 152 2.1 (1.8-2.5)
Ankle 7 1.0 (0.5-2.2) 28 1.1 (0.7-1.6) 35 1.2 (0.8-1.7)
Metatarsal 7 1.4 (0.6-3.1) 28 1.2 (0.8-1.8) 35 1.4 (1.0-2.0)
Other foot c 8 2.0 (0.9-4.3) 30 1.2 (0.8-1.8) 38 1.5 (1.1.-2.1)
Other upper leg d 0 - 5 3.1 (1.2-7.8) 5 -
Other lower leg e 5 1.5 (0.6-3.8) 28 2.1 (1.4-3.1) 33 2.2 (1.5-3.1)
Other f 25 1.0 (0.7-1.4) 34 1.3 (0.9-1.9) 59 1.1 (0.9-1.4)
All non-vertebral 145 1.4 (1.2-1.6) 499 1.5 (1.4-1.6) 644 1.6 (1.4-1.7)
a Other upper arm fractures include fractures of the scapula, clavicle and non-proximal 
fractures of the humerus
b Other lower arm fractures include fractures of other parts of the radius and/or ulna
c Other foot fractures include non-metatarsal foot fractures
d Other upper leg fractures include non-hip fractures of the femur and patella fractures
e Other lower leg fractures include non-ankle fractures of the tibia and/or fi bula
f Other fractures include skull, rib and sternum
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Figure 3. Percentage of non-vertebral, hip, upper humerus and wrist fractures that 
occurred in men and women with osteoporosis, osteopenia or normal BMD using 
gender specifi c T-scores
Figure 2. Prevalence of osteoporosis and osteopenia in men and women by gender 
specifi c T-scores
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DISCUSSION
In this population-based prospective cohort study of fractures, the most fre-
quent non-vertebral fractures in elderly men and women are those of the wrist, 
upper humerus and hip. The risk of these fractures particularly increases with 
decreasing femoral neck BMD, an association that is similar in men and women. 
However, in absolute numbers, most non-vertebral fractures occur in individuals 
without osteoporosis (T-score above -2.5), suggesting that although low BMD is 
a strong risk factor for fractures, using only a T-score of BMD below –2.5 as a 
treatment threshold may not suffi ciently relieve the total burden of fractures in the 
whole population. 
Our study has a number of advantages. Only one other study has demonstrated 
a comparison of the relation between BMD and fractures in men and women 
from the same population. However, the prospective Hawaii Osteoporosis Study 
was limited to vertebral fractures only.9 To our knowledge, this study is the fi rst 
prospective study that includes all non-vertebral fractures in both men and women. 
Furthermore, we did not exclude fractures that resulted from high-energy trauma, 
thereby providing a more valid estimate of the incidence of both osteoporotic and 
non-osteoporotic fractures. In addition, in the Netherlands the only way to ac-
cess specialist and hospital care is consulting a general practitioner. Therefore by 
checking the general practitioners’ medical records of all participants should have 
resulted in a near complete follow-up. 
There are, however, disadvantages to this study design. Selective non-response 
of subjects with impaired mobility, or otherwise at an increased risk of fractures, 
may have occurred at baseline. Such non-response bias may have decreased the 
overall incidence rates. Furthermore, only about one third of all vertebral fractures 
spontaneously come to clinical attention.10 This leads to underestimation of the in-
cidence and the inability to accurately compare cohorts and associations. Therefore, 
when studying the association between BMD and incident fractures, only non-
vertebral fractures were considered. 
Our study found that the hip fracture incidence in men at any age approximates 
that of women who are on average 5 years younger. This confi rms the estimate 
from data based on national registration data previously reported by de Laet et 
al.11 In women in our study the incidence rate of wrist fractures increased until 
approximately 70 years of age and then leveled off. These results are confi rmed by 
a number of other population based studies.12-15 Impaired neuromuscular coordina-
tion and slower gait in elderly people predisposing them to fall on their side instead 
of their out-stretched hands may explain this phenomenon.16 This is supported by 
a strong increase in incidence of hip and upper humerus fractures in women over 
the age of 70. It is not clear why this pattern would apply only to women, although, 
in this study, the power for this comparison was low due to the limited number 
of wrist fracture in men. However, debate about this explanation is still ongoing 
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given that other recent European studies have not shown this pattern for wrist 
fractures.17-20 In these studies in women the incidence of wrist fractures increased 
progressively with age also including the older age ranges studied.
Only few previous population-based studies have assessed incidence rates 
of fractures at all skeletal sites in both genders.12,15,21 With regard to the overall 
incidence of fractures we confi rm the estimates observed by Singer et al. and 
Donaldson et al., whereas we observed a lower incidence compared to Melton et al. 
Although comparison of absolute incidence rates of fractures is complicated due to 
differences in age, gender, general health and fracture ascertainment, the observed 
age related incidence rates of the most common types of non-vertebral fractures, 
i.e. hip, upper humerus and wrist fractures approximated those observed in both 
studies mentioned.22-25 Overall the incidence rates for mainly trauma-related frac-
tures, such as fractures of the hand, ankle, foot, rib and pelvis, were lower in our 
study as compared to the North American study.15 
The fi nding that the incidence of all non-vertebral fractures is inversely related 
to femoral neck BMD is concordant with previous studies.4,26-32 For women, we 
showed that fractures of the upper humerus, wrist and hip, as separate groups, 
have the strongest association with BMD, again in agreement with data reported 
previously.27 The fact that we observed the highest risk estimates for hip fractures is 
probably due to the site (femoral neck) where BMD was measured. Cummings et al. 
previously suggested that site-specifi c BMD best predicts the fracture risk for that 
specifi c site.26 Our data show that in men as well as in women, the risk of hip, upper 
humerus and wrist fractures increases with decreasing BMD in a similar way. 
Since osteoporosis is a common condition amongst the elderly and the associ-
ated (socio-economic) costs are high, there is a strong need for adequate fracture 
prevention. However, the results of this study show that if a BMD screening 
program would be introduced with T-score of -2.5 as treatment threshold, the 
majority of individuals who will fracture would not be offered treatment. In fact, in 
women, two thirds of all non-vertebral fractures and approximately half of all hip 
fractures during the next seven years would be missed. In men these percentages 
are even larger. However, simply lowering the T-score threshold is not the answer 
either since treatment may not be cost-effective in the lower risk population. The 
numbers needed to treat with an intervention are directly infl uenced by the fracture 
incidence in those in whom an intervention is undertaken. If a lower T-score cut-off 
value were chosen more individuals would reach the required fracture risk thresh-
old for intervention and the fracture incidence in this group would also be lower. 
Therefore, when lowering the T-score threshold the numbers needed to treat will 
also increase thereby decreasing the cost-effectiveness of the intervention. Thus, 
from a public health point of view, a screening strategy based on BMD alone is 
unlikely to be suffi cient for prevention of fractures in the population. This problem 
is not unique for bone disease. Rose previously spoke about the prevention paradox: 
a large number of people at a small risk may give rise to more cases than the small 
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number of people who are at high risk.33 Using other clinical predictors of fractures, 
such as age, weight, prevalent fractures, medication use and co-morbidity, along 
side BMD screening, we may be able to more accurately identify those subjects who 
are at increased risk for fractures.34 Nevertheless, this prevention paradox does not 
diminish the value of the T-score in identifying subjects at high risk for fractures. 
This ‘case fi nding’ approach offers these individuals the opportunity to reduce 
their fracture risk substantially. However, as the high-risk group of individuals with 
osteoporosis constitutes only approximately 16% of the population over 55 years, 
reducing the incidence of fractures in that group alone will not be suffi cient to 
adequately relieve the public health burden of fractures. 
In conclusion, of all non-vertebral fractures, wrist, upper humerus and hip 
fractures are the most frequent fractures in elderly men and women. In addition, 
BMD is an equally important risk factor in men and women. Finally, this study 
shows that using only a T-score at or below -2.5 SD as a criterion for interventions 
will not resolve the population burden of fractures. There is a clear need for the 
development of more sensitive risk assessment tools, using not only BMD, but also 
other clinical predictors of fractures. Using such an approach, we may be able to 
more accurately identify those subjects who are at increased risk for fractures.
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ABSTRACT
This study investigates the infl uence of genetic variation of the estrogen recep-
tor alpha (ERα) gene locus on several bone parameters in 2042 individuals of The 
Rotterdam Study, a prospective population-based cohort study of elderly subjects. 
We analyzed three polymorphic sites in the 5’ region of the ERα gene; a (TA)n-
repeat in the promoter region, and molecular haplotypes of the PvuII and XbaI 
RFLPs in intron 1, and inferred long-range haplotypes (LRH) thereof. 
We observed only three of the possible four PvuII–XbaI haplotypes in our popu-
lation. A comparison with other Caucasian populations showed similar haplotype 
frequencies, while in Asian and African populations these were different. Linkage 
disequilibrium (LD) analysis between the PvuII–XbaI haplotype and the (TA)n 
repeat showed strong LD between the two sites. Reconstruction of long range 
haplotypes over the entire 5’ region, revealed six frequent LRH. 
In men, we did not observe an association between the ERα polymorphisms 
studied and bone parameters. In women, we demonstrated an allele dose effect 
of haplotype ‘px’ (P=0.003) and a low number of (TA)n repeats (P=0.008) with 
decreased lumbar spine bone mineral density (BMD) (4.8% lower BMD in women 
homozygous for haplotype ‘px’, representing 28% of the population, compared 
with homozygous non-carriers) and decreased vertebral bone area (2.3% difference 
between extreme genotypes; P=0.016). Most importantly, we found an increased 
vertebral fracture risk with evidence for an allele dose effect with an odds ratio of 
2.2 (95% CI 1.3–3.5) for haplotype ‘px’, and 2.0 (1.5–3.2) for a low number of (TA)n 
repeats. The ERα genotype dependent fracture risk is largely independent of BMD 
and bone area. Combination of risk alleles at both loci by long-range haplotyping 
improved the associations slightly, but because of the strong LD between the two 
polymorphic sites, we were unable to determine if any particular polymorphic site 
is driving the associations found. We conclude that ERα polymorphism in the 5’ 
(promoter) region is associated with vertebral fracture risk, lumbar spine BMD 
and vertebral bone area in postmenopausal women, but not in men. The molecular 
mechanism underlying this association needs further study.
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INTRODUCTION
Osteoporosis is characterized by low bone mineral density (BMD) and an in-
creased risk of fractures.1 Osteoporosis is considered to be a multifactorial syndrome 
with environmental and genetic factors interacting. Twin studies have suggested 
that up to 75% of the variance in BMD is genetically determined.2,3 Genetic varia-
tions in several genes are thought to be responsible for this genetic component and 
one of the potential candidates is the estrogen receptor alpha (ERα) gene. 
Several lines of evidence show the important role of the estrogen endocrine 
system in the regulation of BMD and the occurrence of osteoporosis. Exposure 
to low estrogen levels occurring after menopause in women is associated with in-
creased risk for osteoporosis. The serum level of estradiol has been shown to be an 
important predictor of subsequent bone mass and risk for osteoporotic fractures.4-6 
In line with this, estrogen replacement treatment in early postmenopausal women 
decreases the risk of osteoporotic fractures.7-9 Estrogens exerts its effect primarily 
via the ERα and the pivotal role of ERα in the regulation of bone mass was sug-
gested by a report of a young adult male with a loss-of-function mutation of the 
ERα gene resulting in a phenotype with low BMD.10 Consistent with this, an ERα 
knockout mouse model showed that both female and male mice had decreased 
bone mass.11
Several genetic variations in the ERα gene have been described and associa-
tions of these polymorphisms with BMD have been reported, but results have been 
inconsistent.12-21 In part, this is due to the limited sample size of most studies where 
lack of power can lead to spurious results. In addition, differences between popula-
tions can play a role, such as ethnicity, age, environment and genetic make-up. Most 
studies focused on women and have not analyzed fractures, the clinically most 
relevant endpoint of osteoporosis. 
We analyzed three polymorphic sites in the 5’ end of the ERα gene. These were 
a (TA)n VNTR located approximately 1 kb upstream of the fi rst exon, and the PvuII 
and XbaI restriction fragment length polymorphisms (RFLPs) in intron 1, about 
400 bp upstream of exon 2.22 Since no functional effect of these sequence varia-
tions on expression or function of the ERα protein has been established so far, they 
were treated essentially as anonymous polymorphisms. In association studies they 
are therefore considered as markers and association can be explained by linkage of 
marker alleles with a truly functional allele elsewhere in the gene. We hypothesize 
that genetic variation in the ERα gene could lead to differences in mRNA ex-
pression, which might result in different responsiveness to circulating levels of its 
ligand estrogen, which in turn results in genotype-dependent differences in bone 
mass, bone metabolism and fracture risk. Therefore, we investigated, in a large and 
homogeneous population-based sample of Caucasian elderly men and women, the 
infl uence of the ERα polymorphism on BMD, vertebral bone area and fractures 
and compared our results with those obtained in other association studies.
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MATERIAL AND METHODS
Study population
Subjects were participants of the Rotterdam Study, a prospective population 
based cohort study of individuals aged 55 years and over. The study was designed 
to investigate the incidence of, and determinants of, chronic disabling diseases. 
Rationale and design have been described previously.23 The Rotterdam Study was 
approved by the Medical Ethics Committee of Erasmus University Medical School 
and written informed consent was obtained from each subject. All 10 275 inhabit-
ants aged 55 years and over of a district in Rotterdam, The Netherlands, were 
invited for baseline examination between August 1990 and June 1993. Of those, 
7983 participated. Baseline measurements of bone mineral density were available for 
5931 independently living subjects from the study, but 1453 of these were excluded 
on the basis of age (>80 years), use of a walking aid, known diabetes mellitus or use 
of diuretic, estrogen, thyroid hormone or cytostatistic drug therapy. From the 4478 
remaining subjects, we studied a random sample of 2042 subjects. 
In addition, we determined allele frequencies in a panel of subjects of African 
origin from the Coriell Institute (Camden, NJ, USA), which consists of 10 African-
American subjects (HD04) and nine African subjects from south of the Sahara 
(HD12). 
Clinical examination
At baseline, BMD (expressed in g/cm2) was measured at the femoral neck and 
BMD and average vertebral bone area (cm2) was measured over the L2–L4 of the 
lumbar spine by dual energy X-ray absorptiometry (DEXA, Lunar DPX-L densi-
tometer, Lunar Corp., Madison, WI, USA) as described previously.24 Height and 
weight were measured in standing position in indoor clothing without shoes. BMI 
was computed as weight in kilograms divided by height in meters squared (kg/m2). 
Menopause status and age at menarche was assessed and validated as described 
previously.25 
Vertebral fracture assessment
Both at baseline and at a follow-up visit, between 1997 and 1999, thoracolumbar 
radiographs of the spine were obtained. The follow-up radiographs were available 
for 1184 individuals, who survived after an average 7.4 years after baseline center 
visit and who were still able to come to our research center. All follow-up radio-
graphs were scored for the presence of vertebral fracture by the McCloskey/Kanis 
method, as described previously.26,27 If a vertebral fracture was detected, the base-
line radiograph was evaluated as well. If the vertebral fracture was already present 
at baseline, it was considered a baseline prevalent fracture. If it was not present at 
baseline, the fracture was defi ned to be incident. 
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Assessment of incident non-vertebral fracture
Follow-up started either at 1 January 1991 or, when later, at the time of inclu-
sion into the study. For this analysis follow-up ended either at December 1999 or, 
when earlier, at the participant’s death. The general practitioners of the participants 
provided data on morbidity including non-vertebral fractures and mortality. For 
approximately 80% of the study population, medical events were reported through 
computerized general practitioner diagnosis registers. For the remaining 20%, 
research physicians collected data from the general practitioners’ medical records of 
the study participants. All collected fractures were verifi ed by reviewing discharge 
reports and letters from medical specialists. Fracture events were coded indepen-
dently by two research physicians according to the International Classifi cation of 
Diseases, 10th revision (ICD-10). In case of discrepancy, consensus was attained in 
a separate session. A medical expert in the fi eld reviewed all coded events for fi nal 
classifi cation. 
Genotyping
Genomic DNA was isolated from peripheral leucocytes by standard procedures. 
The molecular haplotyping of the PvuII and XbaI RFLPs was performed as shown 
in Figure 1. A 346 bp PCR fragment was generated by a forward primer (ER-F: 
5’-GATATCCAGGGTTATGTGGCA-3’) and a reverse primer (ER-R: 5’-AGGT
GTTGCCTATTATATTAACCTTGA-3’) in a reaction mixture of 10 µl containing 
10 ng of genomic DNA, 50 mM KCl, 10 mM Tris–HCl (pH 8.3), 1.5 mM MgCl2, 
0.2 mM deoxy-NTP, 2 pM of each primer, and 0.2 U Super Taq polymerase (HT 
Biotechnology Ltd, Cambridge, UK). The reactions were performed in 384-well 
format in a thermocycler (MJ-tetrad) with a cycling protocol of 94, 60 and 72°C for 
45 s each for 30 cycles. Ten microliters of PCR product were digested by addition of 
5 µl of digestion mixture containing 5 U PvuII, 7 U XbaI restriction enzyme (MBI 
Fermentas) and 1.5 µl of ReactBuffer 2 (Life Technologies Inc.) and incubating for 
90 min at 37°C. The digestion products were analyzed by electrophoresis in a 3% 
agarose gel in 0.5xTBE (1x TBE=89 mM Tris, 89 mM boric acid, 2 mM Na2EDTA) 
for 80 min. at 125 V. Separation patterns were documented with a digital camera 
(DC120, Kodak Company, Rochester, NY, USA) under UV illumination (302 nm). 
Genotypes were defi ned as haplotype numbers 1, 2, etc. by decreasing frequency 
in the population. The correspondence between haplotype numbers, RFLP alleles 
and nucleotides at positions -397int1 and -351int1 is shown in Figure 1. 
A 160–194 bp PCR fragment was generated containing the (TA)n VNTR us-
ing a FAM-labeled forward primer (5’-GACGCATGATATACTTCACC-3’) and 
reverse primer (5’-GCAGAATCAAATATCCAGATG-3’) in a reaction mixture 
of 10 µl containing 10 ng of genomic DNA, 50 mM KCl, 10 mM Tris–HCl (pH 
8.3), 1.5 mM MgCl2, 0.2 mM deoxy-NTP, 5 pM of each primer, and 0.2 U Super 
Taq polymerase (HT Biotechnology Ltd, Cambridge, UK). The reactions were per-
formed in 384-well format in a thermocycler (MJ-Tetrad) with a cycling protocol 
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of 94, 59 and 72°C for 30 s each for 28 cycles. The labeled PCR products were 
analyzed on an ABI 3100 automated capillary DNA sequencer using Genescan 
software (Applied Biosystems, Perkin Elmer, Capelle a/d IJssel, The Netherlands). 
The length of alleles was determined using internal size standards and genotypes 
were expressed as size-allele combinations. 
Statistical analysis
Estimation of PvuII–XbaI haplotype frequency. In our own study, the 
PvuII–XbaI haplotypes were derived from direct molecular haplotyping, as de-
scribed above. Assessment of the PvuII–XbaI haplotypes in other study popula-
tions, described in previous manuscripts was possible when the combined genotype 
per individual was known.12-15,17 We used these data to infer the frequency of the 
haplotypes present in the population using the program 3LOCUS.pas.28 
Linkage disequilibrium analysis. The linkage disequilibrium coeffi cient (D’) 
between each pair of alleles at both polymorphic loci was calculated. The coeffi cient 
is positive when the alleles co-occur and is negative when alleles exclude each other. 
D’ is calculated from the disequilibrium measure D=h-pq, where h is the frequency 
of the haplotype present in the population and p and q are frequencies of the alleles 
under investigation where p<q. In order to compare the degree of disequilibrium 
between pairs of alleles with different allele frequencies, the allele frequency-in-
dependent D’ was calculated, where D’=D/Dmax. If D<0 then Dmax=pq, and 
if D>0 then Dmax=p(1-q). We used the program PHASE for determining the 
frequencies of the TA–PvuII–XbaI haplotypes in different subpopulations.29
Association analysis. Subjects were grouped according to genotype. We 
grouped subjects by allele copy number (0, 1, 2) for the PvuII–XbaI RFLP haplo-
types 1 (px), 2 (PX) and 3 (Px). For the (TA)n VNTR, subjects were fi rst grouped 
according to carrier status of each allele separately. In a second analysis, the (TA)n 
VNTR alleles were grouped according to the number of TA-repeats: group ‘H’ 
includes alleles with a high number of TA repeats [(TA)n≥18] and group ‘L’ includes 
alleles with a low number of TA repeats [(TA)n<18]. The cut-off point was based 
on the bimodal allele frequency distribution (Fig. 2). Subjects were genotyped as 
‘LL’, ‘LH’ or ‘HH’. 
We allowed for three possible genetic models to explain differences between 
groups, i.e. an allele dose effect, a dominant effect or a recessive effect. Allele dose 
was defi ned as the number of copies of a certain allele in the genotype. In case of a 
consistent trend refl ected as an allele-dose effect we performed a linear regression 
analysis to quantify the association. In case of a dominant or a recessive effect of the 
test allele, analysis of (co)variance [AN(C)OVA] was performed to test for differ-
ences between two genotype groups. For dominant alleles we compared test-allele 
carriers versus non-carriers, while for recessive effects homozygous subjects for the 
test allele were compared to heterozygous carriers combined with non-carriers. 
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HWE was calculated according to standard procedures using the chi-square 
analysis. To estimate non-vertebral fracture risk we used Cox proportional hazard 
models, thereby taking potential differences in follow-up time into account. P-val-
ues were two-sided and 0.05 or less was considered signifi cant. To estimate the risk 
of vertebral fractures, odds ratios with 95% confi dence intervals (95% CI) were 
calculated using logistic regression models. We were not able to use Cox propor-
tional hazard models since the exact time of event was not known. We performed 
all vertebral fracture analysis separately for both prevalent and incident fractures, 
and always found the same trends. Therefore, for reasons of power, all vertebral 
fracture analysis presented were done with combined prevalent and incident ver-
tebral fractures. To calculate risk estimates and 95% CI for incremental classes 
of haplotypes (allele–dose effects), the genetic variable was used as a continuous 
measure in the model. All statistical analysis was performed using SPSS version 
10.1.0 (SPSS Inc., Chicago, IL, USA). 
RESULTS 
Baseline characteristics 
Table 1 shows the baseline characteristics of the total study population and also 
for the subgroup for whom vertebral fracture data were available. The individuals 
in the vertebral fracture study were on average 2 years younger, but none of the 
other baseline characteristics were signifi cantly different. 
Genotype and allele frequencies
Table 2 shows the genotype distribution according to PvuII–XbaI RFLP 
haplotypes in men and women. Genotypes were found to be in Hardy–Weinberg 
equilibrium (HWE; P=0.96 and 0.99, respectively, for men and women). Table 3 
shows the frequencies of the haplotypes found in our cohort of women, compared 
with those in other populations of women. The frequencies of the haplotypes were 
similar in other Caucasian populations, but in two Asian populations haplotype 3 
(Px) was more frequent, while the haplotype 2 (PX) allele was less frequent. In the 
small African population tested (Coriell panel), haplotype 1 was less frequent than 
in Caucasian and Asian women, and haplotype 2 was more frequently present. In all 
populations the haplotype 4 (pX) was rare or not present at all.
The frequencies of the (TA)n VNTR alleles in our total population are shown 
in Figure 1. The bimodal distribution of VNTR alleles is similar to that found 
in earlier studies of Caucasians. The (TA)n genotype data were not available for 
other ethnic groups or could not be determined because of low power due to small 
sample size and the large number of alleles.
Chapter 2.2
44
Table 1. Baseline characteristics of the total study population and the subgroup 
for whom vertebral fracture data are available 
Study 
population
Study population 
vertebral fractures p-value
Women
Number 1100 657
Age (yrs) 67.0 ± 6.9 65.7 ± 6.4 <0.001
Height (cm) 162 ± 6 162 ± 7 0.09
Weight (kg) 68.5 ± 10.3 68.7 ± 10.0 0.75
BMI (kg/m2) 26.2 ± 3.7 26.0 ± 3.7 0.55
FN-BMD 0.80 ± 0.12 0.81 ± 0.12 0.13
LS-BMD 1.01 ± 0.17 1.02 ± 0.17 0.73
Age of menopause (yrs) 48.7 ± 4.9 48.7 ± 5.0 0.97
Age at menarche (yrs) 13.7 ±1.7 13.7 ± 1.8 0.67
Men
Number 942 527
Age (yrs) 67.3 ± 7.1 65.4 ± 6.5 <0.001
Height (cm) 175 ± 7 176 ± 6 0.03
Weight (kg) 78.2 ± 10.6 79.2 ± 10.0 0.09
BMI (kg/m2) 25.5 ± 2.9 25.6 ± 2.8 0.50
FN-BMD 0.87 ± 0.13 0.88 ± 0.13 0.20
LS-BMD 1.15 ± 0.20 1.15 ± 0.19 0.81
Values are means ± Standard Deviation
Table 2. Genotype distribution according to PvuII–XbaI haplotypes. 1=px; 
2=PX; 3=Px.
Men Women 
Genotype number (frequency) number (frequency)
11 275 (29.2) 311 (28.3)
12 350 (37.2) 421 (38.3)
13 122 (13.0) 127 (11.5)
22 105 (11.1) 142 (12.9)
23 76 (8.1) 86 (7.8)
33 14 (1.5) 13 (1.2)
Total 942 (100) 1100 (100)
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Figure 1. 
Allele frequencies of (TA)n VNTR polymorphism in the total study population. 
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Table 3. PvuII–XbaI haplotype frequencies in women with several ethnic back-
grounds
Ethnic
origin 
Number 
of 
subjects Country (reference) 
Haplotype
1 (px) 2 (PX) 3 (Px) 4 (pX)
Caucasian 1100 The Netherlands 
(this study) 
53.0 36.1 10.9 0
Caucasian 610 Italy (14) 52.1 40.9 5.7 1.3
Caucasian 454 Denmark (16) 53.0 33.7 13.3 0
Caucasian 206 United Kingdom (13) 56.1 33.5 9.2 1.2
Asian 238 Japan (15) 54.5 18.7 26.5 0.3
Asian 598 Korea (18) 57.7 18.5 21.5 2.3
African 19 Coriell panel 36.8 50.0 13.6 0
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LD and haplotype analysis PvuII–XbaI and the (TA)
n
 VNTR 
LD-analysis showed strong LD between the (TA)n-repeat and PvuII–XbaI hap-
lotype. In order to get more insight into the pattern of linkage disequilibrium 
between the two polymorphic loci, pairwise disequilibria measures (D’) between 
the three different PvuII–XbaI haplotypes and all the different (TA)n-repeat al-
leles were calculated. Figure 2 shows that haplotype 1 is in strong (although not 
complete) LD with a low number of (TA)n-repeat, while haplotype 2 is linked to a 
longer (TA)n repeat and haplotype 3 is not in LD with the (TA)n VNTR.
We went on to reconstruct long range haplotypes (LRH) of PvuII–XbaI RFLP 
haplotypes and the (TA)n-VNTR alleles. The (TA)n VNTR is located at a distance 
of 35 kb from the two RFLPs so molecular haplotypes of all three polymorphisms 
cannot easily be determined. Instead, haplotypes frequencies were inferred based on 
genotype frequencies of individual polymorphisms using a Markov chain–Monte 
Carlo algorithm for haplotype reconstruction of each individual (Table 4).29 
Owing to the strong LD, we observed two frequent LRHs (L-1 and H-2) among 
the six possible haplotypes. While 88% of the L (TA)n VNTR alleles are linked 
to the PvuII–XbaI haplotype 1, only 69% of H (TA)n alleles are in LD with the 
PvuII–XbaI haplotype 2. This refl ects the differences in D’ as shown in Figure 2. 
We then analyzed association of ERα polymorphism with bone characteristics for 
the PvuII–XbaI haplotypes and the (TA)n VNTR separately and for the combined 
LRHs.
Table 4. Estimated frequencies of long range haplotypes from PvuII–XbaI hap-
lotype alleles and (TA)n alleles in 1100 women. The (TA)n alleles are defi ned as L 
(n<18) and H (n≥18).
LRH haplotype (TA)n PvuII–XbaI Number of alleles (%)
A L 1 1065 (48.4)
B L 2 59 (2.7)
C L 3 54 (2.5)
D H 1 105 (4.8)
E H 2 732 (33.3)
F H 3 185 (8.4)
Total 2200 (100)
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PvuII–XbaI haplotype and bone characteristics
We investigated the relation between each of the three PvuII–XbaI haplotypes and 
BMD, using linear regression analysis. For each haplotype, subjects were grouped 
according to the number of copies of the haplotype under investigation. Haplotype 
1 (px) showed a signifi cant association with decreased BMD at the lumbar spine 
(LS-BMD) in women (Table 5), while haplotype 2 was associated with increased 
LS-BMD and haplotype 3 did not show an association. Baseline characteristics 
according to the haplotype 1 carrier status showed that, in both genders, age and 
body mass index (BMI) did not differ signifi cantly between the genotypes (results 
not shown), while, as was previously found in women, age at menopause differed 
signifi cantly.25 The mean age at menopause was 0.6 years higher for every copy 
of haplotype 1 (P=0.005, linear regression). No signifi cant difference was found 
for age at menarche. Table 5 shows also vertebral bone area measures according 
to haplotype 1 genotype, which was signifi cantly different between the different 
genotypes in women. In men, no association was found between the haplotype 1 
genotype and BMD or bone area measures. In all analyses, additional adjustment 
for baseline age, BMI and age at menopause did not essentially change the associa-
tions. 
Figure 2. 
Pairwise disequilibrium coeffi cients (D’) between the three PvuII-XbaI halpotype 
alleles and the 13 most common (TA)n repeat alleles. The coeffi cient is positive 
when the alleles are linked, and is negative when the alleles exclude each other. 
When D’ is 1, the two alleles are completely linked, when D’ is –1, the two alleles 
exclude each other completely.
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Table 6 shows the number of fractures and odds ratios according to haplotype 1 
carrier status. We found no association of the haplotype 1 with risk for non-verte-
bral fracture, neither in men nor in women. We did additional analyses for different 
types of non-vertebral fracture, like hip, upper humerus and wrist, but we could not 
fi nd a signifi cant association of the haplotype 1 for any of these different types of 
fractures. For women we found a signifi cantly increased risk for vertebral fractures 
in haplotype 1 carriers. We found evidence for an allele dose effect in which the risk 
Table 5. Bone measures (mean±SD) according to ER genotype for PvuII–XbaI haplo-
type 1
Bone measures 
Number of copies of PvuII–XbaI hap-
lotype 1
P-value c0 1 2 
Women n=240 n=548 n=311 
Femoral neck BMD (g/cm2) 
 Crude 0.81±0.12 0.81±0.12 0.80±0.13 0.36
Adjusted a 0.81±0.11 0.81±0.12 0.80±0.10 0.22
Lumbar spine BMD (g/cm2) 
Crude 1.03±0.17 1.02±0.17 0.99±0.16 0.006
Adjusted a 1.04±0.15 1.02±0.16 0.99±0.15 0.001
Lumbar spine bone area (cm2) 
Crude 43.3±4.3 42.5±4.6 42.3±4.4 0.01
Adjusted a 43.3±4.5 42.6±4.5 42.3±4.5 0.02
Men n=472 n=274 
Femoral neck (g/cm2) 
Crude 0.87±0.14 0.87±0.13 0.86±0.13 0.26
Adjusted b 0.88±0.13 0.87±0.13 0.86±0.13 0.08
Lumbar spine (g/cm2) 
Crude 1.15±0.19 1.16±0.20 1.15±0.20 0.68
Adjusted b 1.16±0.19 1.16±0.18 1.15±0.18 0.41
Lumbar spine bone area (cm2) 
Crude 51.8±5.2 51.5±5.3 52.2±5.6 0.28
Adjusted b 51.9±5.3 51.5±5.2 52.2±5.3 0.45
a Values are adjusted for age, BMI and age at menopause.
b Values are adjusted for age and BMI.
c P-values were calculated using linear regression analysis.
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increased 2.0 (1.4–2.9) times per copy of the haplotype 1. In view of the possible 
confounding effect of vertebral fractures on vertebral bone area, we adjusted the 
associations of vertebral bone area for presence or absence of vertebral fractures 
and found no effect of this adjustment on the association. In an additional analysis, 
we have excluded the fracture cases and found that the association between bone 
area and ERα polymorphism was still present (data not shown). This strongly sug-
gests that the effect of ERα variation on bone area is independent of fractures. 
In view of these results and the strong LD between the PvuII–XbaI haplotype 
and the (TA)n VNTR, we went on to analyze the (TA)n VNTR associations to bone 
characteristics, in women only and only for lumbar spine BMD, vertebral bone 
area and only for vertebral fracture risk. In view of these results and the strong LD 
between the PvuII-XbaI haplotype and the (TA)n VNTR, we went on to analyze 
the (TA)n VNTR associations to bone characteristics, in women only and only for 
lumbar spine BMD, vertebral bone area and only for vertebral fracture risk. 
Table 6. 
Fracture risk according to PvuII–XbaI haplotype 1 carrier status
Womena number of copies of
 PvuII–XbaI haplotype 1
Menb number of copies of
PvuII–XbaI haplotype 1 2
0 1 2 0 1 2
Non-vertebral 
No. fractures/
total no. (%) 
31/241
(12.9) 
84/548
(15.3) 
35/311
(11.3) 
13/195
(6.7) 
29/472
(6.1) 
16/275 
(5.8)
 OR crude 1 1.2 
(0.8–1.8) 
0.9 
(0.5–1.4) 
1 0.9 
(0.5–1.8) 
0.9 
(0.4–1.8)
 OR adjusted 1 1.2
(0.8–1.9) 
0.8
(0.5–1.4) 
1 0.9 
(0.5–1.8) 
0.8 
(0.4–1.7)
Vertebral 
No. fractures/
total no. (%) 
9/146
 (6.2) 
37/318
(11.6) 
41/193
(21.2) 
13/104 
(12.4) 
23/254
(9.1) 
29/169 
(17.2)
 OR crude 1 2.0 
(0.9–4.3) 
4.1
(1.9–8.8) 
1 0.7
(0.3–1.4) 
1.5 
(0.7–2.9)
 OR adjusted 1 2.0
(0.9–4.3) 
4.0 
(1.9–8.7) 
1 0.6 
(0.3–1.4) 
1.3 
(0.6–2.8)
OR=odds ratios; OR are presented with 95% confi dence intervals.
a Values are adjusted for age, BMI, age at menopause and BMD (non-vertebral type of fractures were ad-
justed for femoral neck BMD, vertebral fractures for lumbar spine BMD and lumbar spine bone area).
b Values are adjusted for age, BMI and BMD (non-vertebral type of fractures were adjusted for femoral 
neck BMD, vertebral fractures for lumbar spine BMD and lumbar spine bone area).
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The (TA)
n
 VNTR and bone characteristics
We investigated the relation between each (TA)n VNTR allele and bone charac-
teristics by grouping the women according to carrier status of the individual (TA)n 
VNTR allele under investigation. Table 7 shows that all carriers of alleles with a 
low number of (TA)n repeats (n<18) have a higher percentage of vertebral fractures 
rather than one or two individual (TA)n alleles. The same was observed for the as-
sociation with lumbar spine BMD. However, for the vertebral bone area we did not 
observe such a clear pattern of association. Based on the results described above, 
and the clear bimodular distribution of the (TA)n VNTR alleles, the (TA)n alleles 
were grouped into a high number of repeats (n≥18, allele H) and a low number 
of repeats (n<18, allele L) and association analysis between genotype and bone 
characteristics was repeated. Similar results were found with the L-allele of the TA-
VNTR when compared with the haplotype 1 associations. The short (TA)n VNTR 
was associated with decreased BMD at the lumbar spine and decreased lumbar 
spine bone area in women. Differences were 4.8 and 2.2%, respectively, between 
the extreme genotype groups LL and HH. Similar to the haplotype 1, we found 
a signifi cant association with vertebral fractures in women, and we did not fi nd 
an association with non-vertebral fractures (results not shown). Again we found 
evidence for an allele dose effect with vertebral fracture risk increasing 2.2 (95% CI 
1.5–3.1) per copy of the L-allele of the (TA)n VNTR, and this risk was independent 
of the possible confounding factors age, BMI, lumbar spine BMD, lumbar spine 
bone area and age at menopause (data not shown). 
Long-range haplotypes of PvuII–XbaI haplotypes and the (TA)
n
-VNTR and 
bone characteristics
In order to determine which of the polymorphic sites at the 5’ region of the ER 
gene is driving the associations with bone end-points, we repeated the association 
analysis with the six observed LRHs. Table 8 shows the difference between carriers 
and non-carriers of the particular LRH with respect to percentage of vertebral 
fractures, mean lumbar spine BMD and mean vertebral bone area.
For vertebral fractures, all LRHs with a low number of TA repeats show a 
higher percentage of vertebral fractures in carriers compared to non-carriers. This 
pattern was not seen for BMD and bone area measures. However, the largest ef-
fect was always observed for the LRH allele A, which is the combination of a low 
number of TA repeats and PvuII–XbaI haplotype 1. This is also refl ected in Table 
9, where the three different risk alleles (PvuII–XbaI haplotype 1, TA-L and LHR-A) 
are compared for their strength of association. The long-range haplotype A (the 
combination of the haplotype px and VNTR allele L) shows a small improvement 
of the associations compared with the individual risk alleles.
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Table 7. Differences in mean BMD of the lumbar spine and percentage of ver-
tebral fractures between women carrying the test (TA)n allele and women not 
carrying the test allele
Number of
(TA)n 
Number of
carriers
∆ percentage 
vertebral 
fracturesa ∆ LS BMDb ∆ LS bone areac
13 153 +9.6 -0.02 -0.50
14 543 +4.7 -0.015 +0.29
15 194 +2.8 -0.002 -0.93
16 54 +6.2 -0.014 -0.76
17 63 +7.8 +0.008 +0.32
18 25 -5.0 +0.018 -1.09
19 78 -5.4 +0.012 -0.27
20 59 -8.1 -0.036 +0.82
21 187 -7.1 +0.02 +0.75
22 170 -2.2 +0.011 -0.10
23 237 -3.6 +0.009 +0.39
24 144 -5.1 +0.025 +0.62
25 37 -3.9 -0.033 -0.66
a Percentage of vertebral fractures in allele-carriers minus that of non-carriers.
b Mean BMD of allele-carriers minus mean BMD of non-carriers.
c Mean vertebral bone area of allele-carriers minus that of non-carriers.
Table 8. Association of the six PvuII–XbaI (TA)n repeat LRH alleles in 1100 
women with BMD and bone area of the spine
LRH 
allele 
Haplotype 
alleles (TA)n,
PvuII–XbaI 
Number 
of carriers 
∆ percentage
vertebral
fracturesa 
∆ LS BMD
(g/cm2)b
∆ LS bone 
area (cm2)c
A L, 1 797 +9.3 -0.028 -0.78
B L, 2 57 +5.1 +0.026 +0.20
C L, 3 51 +3.0 -0.005 +0.16
D H, 1 100 -3.4 +0.009 +0.41
E H, 2 604 -8.2 +0.019 +0.55
F H, 3 174 -3.8 +0.010 +0.06
L=low number of (TA)n repeats (n<18); H=high number of (TA)n repeats (n≥18).
a Percentage of vertebral fractures in allele-carriers minus that of non-carriers
b Mean BMD of allele-carriers minus mean BMD of non-carriers
c Mean vertebral bone area of allele-carriers minus that of non-carriers
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DISCUSSION
This study shows an association between the PvuII–XbaI haplotype and the 
(TA)n repeat in the ERα gene with lumbar spine BMD, vertebral bone area and 
vertebral fracture risk in postmenopausal women. No association was found with 
femoral neck BMD and non-vertebral fractures. In men, no signifi cant association 
with bone characteristics was found. We demonstrated that in our population the 
PvuII–XbaI haplotype and the (TA)n VNTR are in strong LD, which makes it very 
diffi cult to determine which one of the two polymorphic sites is driving the as-
sociations with these bone characteristics. 
Several studies in women have reported inconsistent associations between 
polymorphism of the ERα gene and BMD.12-21 The existence of ethnic differences 
between the populations, the case–control designs and a health-based selection bias 
in several studies could explain the discordant fi ndings. The present study confi rms 
data of a number of previous studies.12,14,20,30 In contrast, two other studies found 
the PvuII–XbaI haplotype 3 (Px) to be associated with decreased BMD,13,15 whereas 
others showed no association.16,18,31 Statistical reasons (such as lack of power and 
study design) could contribute to the contradictory results published so far. In ad-
dition, our fi ndings together with those of others suggest that there could be allelic 
heterogeneity at the ERα locus among different populations. This should be accom-
Table 9. Associations in 1100 women with vertebral fracture risk, lumbar spine 
BMD and vertebral bone area by ERA genotype as defi ned by the PvuII–XbaI 
haplotype, the (TA)n VNTR, and the combination thereof (the LRH)
Odds 
ratiosa 
per copy 
of the 
allele P valueb
∆ LS BMDc 
(g/cm2)
per copy 
of the 
allele P valueb
∆ LS bone 
aread (cm2)
per copy 
of the 
allele P valueb
PvuII–XbaI 
haplotype 1 
2.0 
(1.4–2.9)
<0.001 -0.0208 0.003 -0.465 0.016
(TA)n 
VNTR L 
2.2 
(1.5–3.1)
<0.001 -0.0183 0.008 -0.474 0.013
LRH 
allele A 
2.2 
(1.5–3.1)
<0.001 -0.0220 0.002 -0.540 0.005
a Odds ratios are presented with 95% confi dence intervals; odds ratios are adjusted for age, BMI 
and lumbar spine BMD.
b P-values are calculated using linear regression.
c BMD values are adjusted for age and BMI. 
d Vertebral bone area values are adjusted for age and BMI.
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panied with differences in genotype distributions, which we indeed found when we 
studied the allelic frequencies among different ethnic populations. The two Asian 
populations studied showed different frequencies of the haplotypes 3 (Px) and 2 
(PX) compared with the Caucasian populations, while in the small African study 
sample the haplotype 1 (px) was present at lower frequency.15,18 A different degree 
of LD between the polymorphism studied and the true functional polymorphism 
in the different populations might be another reason for the inconsistent results 
concerning association studies between ERα variations and bone characteristics. 
Our fi ndings of the association with vertebral fractures are in line with those of 
Langdahl et al.and Becherini et al.12,14 These case–control studies reported results 
using the TA-VNTR in the promoter region and found a lower mean number of TA 
repeats present in individuals with osteoporotic fractures. Interestingly, the increase 
in fracture risk we found in the present population-based study was not explained 
by the relatively modest 0.2 SD difference in BMD between the genotypes. We 
observed the ERα genotype association with vertebral fractures to be independent 
of lumbar spine BMD and of age at menopause. Whereas the assessment of BMD 
is to some extent ERα-dependent, and as such indirectly infl uences the risk of frac-
tures, the BMD-independent relation of ERα genotype with fractures suggests that 
other underlying biological mechanisms than those refl ected in BMD explain the 
increased fracture risk. This same phenomenon was also observed for the relation 
between the collagen-type I alpha 1 Sp1 polymorphism, BMD and fracture risk, 
and for VDR polymorphisms.32,33 This suggests that BMD might not be the most 
suitable endpoint in genetic association studies for osteoporosis, at least for these 
candidate genes. In addition, it indicates that these genetic markers might be used to 
predict fracture risk independently or in combination with BMD measurements. 
We also found an association of ERα polymorphism with a parameter of bone 
geometry, total vertebral bone area. This association was independent of the as-
sociation with vertebral fractures and suggests a relation between ERα polymor-
phism and bone size. Therefore, we hypothesize that ERα polymorphisms leads to 
a difference in bone growth, which might be explained by a genotype-dependent 
estrogen sensitivity locally at the site of bone growth. In support of this hypothesis, 
we recently found an association of ERα polymorphism with stature.34 Together 
with our previous observation of the genetic effect of ERα polymorphism on 
menopausal status, and associations with cardiovascular disease and cancer, this 
illustrates the pleiotropic nature of the ERα protein.25,35,36 The estrogen endocrine 
system can be simultaneously involved in several different metabolic pathways, 
such as the reproductive system, bone and cardiovascular function. 
Our study has some potential limitations. Vertebral fracture data were only 
collected in individuals that survived the follow-up period of approximately 
7 years. Although this results in a healthy responder bias this is not likely to be 
genotype-dependent, since we did not fi nd an infl uence of the ERα polymorphisms 
we studied on survival (data not shown) and, therefore, we do not expect this to 
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infl uence our results. Genetic association studies can be infl uenced by population 
heterogeneity. In this cohort study, all subjects were Dutch Caucasians; to our 
knowledge no systematic differences were present with respect to the part of The 
Netherlands in which this study was performed. Therefore our study population 
might be considered as an ethnically homogeneous and representative sample of 
the Dutch subjects. 
The results from this study clearly show strong linkage disequilibrium between 
the (TA)n VNTR in the promoter and the PvuII–XbaI haplotypes in the fi rst intron 
of the gene. Previous studies also showed a strong relationship between the two 
polymorphic sites, however we determined the pattern of linkage disequilibrium 
between the two polymorphic sites in detail and tried to assess which one of the 
polymorphisms is driving the associations. Although some earlier studies suggested 
one of the polymorphisms to have stronger effects than the others, we were unable 
to distinguish the different effects of the two polymorphic sites because of the 
strong linkage between them despite the large population we had available to study. 
However, the association studies with the long range haplotypes tend to suggest 
that both sites are contributing, since a particular long range haplotype shows the 
strongest effects on the different bone parameters and fracture risk. 
The PvuII and XbaI polymorphic sites are located in an intron, and so far it is not 
known whether they have functional consequences. However, polymorphisms in 
introns could affect mRNA production, since introns have been recognized to con-
tain regulatory sequences. A well-known example is the Sp1 polymorphism located 
in the fi rst intron of the collagen-type I alpha 1 gene, which is known to change 
the mRNA production of the gene which eventually leads to decreased BMD an 
increased fracture risk.32,37 The PvuII–XbaI polymorphic site in the fi rst intron of 
the ERα gene could infl uence gene expression in a similar manner. Recently, a 
report showed that the PvuII polymorphism is located within a potential B-myb 
binding site, which was able to regulate transcription effi cacy of a reporter gene.38 
Alternatively, the location of a variable length of the (TA)n VNTR in the pro-
moter of the ERα gene could also affect gene transcription. Previous studies have 
shown that a VNTR in proximity to a promoter can have a signifi cant infl uence 
on transcriptional regulation.39-41 However, it is still possible that yet another third 
polymorphic site linked to the ones studied here is the true functional sequence 
variation. The only way to clarify this issue is to identify all polymorphisms in this 
region of the gene and perform functional studies on these polymorphisms. 
A loss of function mutation in ERα leading to low BMD was initially reported in 
a young adult male. However, in the present study we showed that the associations 
observed were present in women but not in men. For fractures, this might simply 
be explained by lack of statistical power due to the lower number of fractures ob-
served in men. In that respect one should keep in mind that, although the present 
population study includes a large number of individuals, exact estimation of the 
fracture risks and the size-effect of the BMD-association can only be determined 
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by meta-analysis of all data. The difference between men and women with respect 
to the associations found can be explained by the higher circulating estrogen levels 
in elderly men compared with postmenopausal women, which may mask the differ-
ences between genotypes. 
The associations were strongest at the spine (i.e. with lumbar spine BMD 
and with vertebral fractures). This is in line with previous data showing a higher 
response to estrogen replacement therapy at the lumbar spine in contrast to the 
femoral neck.19,42-44 Probably, the effect of the ERα is more pronounced in the 
vertebral body, which is rich in trabecular bone, due to a higher bone turnover 
rate. Trabecular bone has a higher rate of bone turnover than cortical bone because 
trabecular bone presents relatively more surface per unit of bone volume. 
We conclude that the PvuII–XbaI RFLP-haplotype and the (TA)n-VNTR in the 
ER gene are associated with lumbar spine BMD, vertebral bone area, and verte-
bral fracture risk in postmenopausal women. This risk is independent of BMD 
differences or other confounding factors. Combination of risk alleles at both loci 
by long-range haplotyping improved the associations slightly, but because of the 
strong linkage disequilibrium between the two polymorphic sites, we were unable 
to determine if any particular site is driving the associations. Further studies are 
needed to elucidate the exact molecular mechanism underlying this association. 
Chapter 2.2
56
REFERENCES
1. Anonymous. Paper presented at: Consensus Development Conference on 
Osteoporosis; 1993; Hong Kong.
2. Evans RA, Marel GM, Lancaster EK, Kos S, Evans M, Wong SY. Bone mass is 
low in relatives of osteoporotic patients. Ann Intern Med. 1988;109(11):870-873.
3. Pocock NA, Eisman JA, Hopper JL, Yeates MG, Sambrook PN, Eberl S. Genetic 
determinants of bone mass in adults. A twin study. J Clin Invest. 1987;80(3):706-710.
4. Khosla S, Melton LJ, 3rd, Atkinson EJ, O’Fallon WM, Klee GG, Riggs BL. 
Relationship of serum sex steroid levels and bone turnover markers with bone mineral 
density in men and women: a key role for bioavailable estrogen. J Clin Endocrinol Metab. 
1998;83(7):2266-2274.
5. Cummings SR, Browner WS, Bauer D, Stone K, Ensrud K, Jamal S, Ettinger B. 
Endogenous hormones and the risk of hip and vertebral fractures among older women: 
Study of Osteoporotic Fractures Research Group. N Engl J Med. 1998;339(11):733-
738.
6. Ettinger B, Pressman A, Sklarin P, Bauer DC, Cauley JA, Cummings SR. 
Associations between low levels of serum estradiol, bone density, and fractures 
among elderly women: the study of osteoporotic fractures. J Clin Endocrinol Metab. 
1998;83(7):2239-2243.
7. Cauley JA, Seeley DG, Ensrud K, Ettinger B, Black D, Cummings SR. Estrogen 
replacement therapy and fractures in older women: Study of Osteoporotic Fractures 
Research Group. Ann Intern Med. 1995;122(1):9-16.
8. Torgerson DJ, Bell-Syer SE. Hormone replacement therapy and prevention of non-
vertebral fractures: a meta-analysis of randomized trials. JAMA. 2001;285(22):2891-
2897.
9. Rossouw JE, Anderson GL, Prentice RL, LaCroix AZ, Kooperberg C, Stefanick 
ML, Jackson RD, Beresford SA, Howard BV, Johnson KC, Kotchen JM, Ockene 
J. Risks and benefi ts of estrogen plus progestin in healthy postmenopausal women: 
principal results From the Women’s Health Initiative randomized controlled trial. 
JAMA. 2002;288(3):321-333.
10. Smith EP, Boyd J, Frank GR, Takahashi H, Cohen RM, Specker B, Williams 
TC, Lubahn DB, Korach KS. Estrogen resistance caused by a mutation in the 
estrogen-receptor gene in a man. N Engl J Med. 1994;331(16):1056-1061.
11. Korach KS. Insights from the study of animals lacking functional estrogen receptor. 
Science. 1994;266(5190):1524-1527.
12. Langdahl BL, Lokke E, Carstens M, Stenkjaer LL, Eriksen EF. A TA re-
peat polymorphism in the estrogen receptor gene is associated with osteoporotic 
fractures but polymorphisms in the fi rst exon and intron are not. J Bone Miner Res. 
2000;15(11):2222-2230.
ERα polymorphisms and osteoporosis
57
13. Albagha OM, McGuigan FE, Reid DM, Ralston SH. Estrogen receptor alpha 
gene polymorphisms and bone mineral density: haplotype analysis in women from the 
United Kingdom. J Bone Miner Res. 2001;16(1):128-134.
14. Becherini L, Gennari L, Masi L, Mansani R, Massart F, Morelli A, Falchetti 
A, Gonnelli S, Fiorelli G, Tanini A, Brandi ML. Evidence of a linkage disequilib-
rium between polymorphisms in the human estrogen receptor alpha gene and their 
relationship to bone mass variation in postmenopausal Italian women. Hum Mol Genet. 
2000;9(13):2043-2050.
15. Kobayashi S, Inoue S, Hosoi T, Ouchi Y, Shiraki M, Orimo H. Association of 
bone mineral density with polymorphism of the estrogen receptor gene. J Bone Miner 
Res. 1996;11(3):306-311.
16. Bagger YZ, Jorgensen HL, Heegaard AM, Bayer L, Hansen L, Hassager C. 
No major effect of estrogen receptor gene polymorphisms on bone mineral density or 
bone loss in postmenopausal Danish women. Bone. 2000;26(2):111-116.
17. Mizunuma H, Hosoi T, Okano H, Soda M, Tokizawa T, Kagami I, Miyamoto 
S, Ibuki Y, Inoue S, Shiraki M, Ouchi Y. Estrogen receptor gene polymorphism 
and bone mineral density at the lumbar spine of pre- and postmenopausal women. 
Bone. 1997;21(5):379-383.
18. Han K, Choi J, Moon I, Yoon H, Han I, Min H, Kim Y, Choi Y. Non-associa-
tion of estrogen receptor genotypes with bone mineral density and bone turnover in 
Korean pre-, peri-, and postmenopausal women. Osteoporos Int. 1999;9(4):290-295.
19. Deng HW, Li J, Li JL, Johnson M, Gong G, Davis KM, Recker RR. Change of 
bone mass in postmenopausal Caucasian women with and without hormone replace-
ment therapy is associated with vitamin D receptor and estrogen receptor genotypes. 
Hum Genet. 1998;103(5):576-585.
20. Willing M, Sowers M, Aron D, Clark MK, Burns T, Bunten C, Crutchfi eld M, 
D’Agostino D, Jannausch M. Bone mineral density and its change in white women: 
estrogen and vitamin D receptor genotypes and their interaction. J Bone Miner Res. 
1998;13(4):695-705.
21. Aerssens J, Dequeker J, Peeters J, Breemans S, Boonen S. Lack of association 
between osteoarthritis of the hip and gene polymorphisms of VDR, COL1A1, and 
COL2A1 in postmenopausal women. Arthritis Rheum. 1998;41(11):1946-1950.
22. Yaich L, Dupont WD, Cavener DR, Parl FF. Analysis of the PvuII restriction 
fragment-length polymorphism and exon structure of the estrogen receptor gene in 
breast cancer and peripheral blood. Cancer Res. 1992;52(1):77-83.
23. Hofman A, Grobbee DE, de Jong PTVM, van den Ouweland FA. Determinants 
of disease in the elderly: the Rotterdam Elderly Study. Eur J Epidemiol. 1991;7:403-
422.
24. Burger H, van Daele PL, Algra D, van den Ouweland FA, Grobbee DE, 
Hofman A, van Kuijk C, Schutte HE, Birkenhager JC, Pols HA. The association 
between age and bone mineral density in men and women aged 55 years and over: the 
Rotterdam Study. Bone Miner. 1994;25(1):1-13.
Chapter 2.2
58
25. Weel AE, Uitterlinden AG, Westendorp IC, Burger H, Schuit SC, Hofman 
A, Helmerhorst TJ, van Leeuwen JP, Pols HA. Estrogen receptor polymor-
phism predicts the onset of natural and surgical menopause. J Clin Endocrinol Metab. 
1999;84(9):3146-3150.
26. McCloskey EV, Spector TD, Eyres KS, Fern ED, O’Rourke N, Vasikaran S, 
Kanis JA. The assessment of vertebral deformity: a method for use in population 
studies and clinical trials. Osteoporos Int. 1993;3(3):138-147.
27. Van der Klift M, De Laet CE, McCloskey EV, Hofman A, Pols HA. The inci-
dence of vertebral fractures in men and women: the Rotterdam Study. J Bone Miner Res. 
2002;17(6):1051-1056.
28. Long JC, Williams RC, Urbanek M. An E-M algorithm and testing strategy for 
multiple-locus haplotypes. Am J Hum Genet. 1995;56(3):799-810.
29. Stephens M, Smith NJ, Donnelly P. A new statistical method for haplotype recon-
struction from population data. Am J Hum Genet. 2001;68(4):978-989.
30. Ho AY, Yeung SS, Kung AW. PvuII polymorphisms of the estrogen receptor al-
pha and bone mineral density in healthy southern Chinese women. Calcif Tissue Int. 
2000;66(6):405-408.
31. Vandevyver C, Vanhoof J, Declerck K, Stinissen P, Vandervorst C, Michiels L, 
Cassiman JJ, Boonen S, Raus J, Geusens P. Lack of association between estrogen 
receptor genotypes and bone mineral density, fracture history, or muscle strength in 
elderly women. J Bone Miner Res. 1999;14(9):1576-1582.
32. Uitterlinden AG, Burger H, Huang Q, Yue F, McGuigan FE, Grant SF, Hofman 
A, van Leeuwen JP, Pols HA, Ralston SH. Relation of alleles of the collagen type 
Ialpha1 gene to bone density and the risk of osteoporotic fractures in postmenopausal 
women. N Engl J Med. 1998;338(15):1016-1021.
33. Uitterlinden AG, Weel AE, Burger H, Fang Y, van Duijn CM, Hofman A, van 
Leeuwen JP, Pols HA. Interaction between the vitamin D receptor gene and collagen 
type Ialpha1 gene in susceptibility for fracture. J Bone Miner Res. 2001;16(2):379-385.
34. Schuit SC, Van Meurs JB, Bergink AP, Van Der Klift M, Fang Y, Leusink 
G, Hofman A, Van Leeuwen JP, Uitterlinden AG, Pols HA. Height in Pre- 
and Postmenopausal Women Is Infl uenced by Estrogen Receptor alpha Gene 
Polymorphisms. J Clin Endocrinol Metab. 2004;89(1):303-309.
35. Lu H, Higashikata T, Inazu A, Nohara A, Yu W, Shimizu M, Mabuchi H. 
Association of estrogen receptor-alpha gene polymorphisms with coronary artery 
disease in patients with familial hypercholesterolemia. Arterioscler Thromb Vasc Biol. 
2002;22(5):817-823.
36. Weiderpass E, Persson I, Melhus H, Wedren S, Kindmark A, Baron JA. Estrogen 
receptor alpha gene polymorphisms and endometrial cancer risk. Carcinogenesis. 
2000;21(4):623-627.
ERα polymorphisms and osteoporosis
59
37. Frosst P, Blom HJ, Milos R, Goyette P, Sheppard CA, Matthews RG, Boers 
GJ, den Heijer M, Kluijtmans LA, van den Heuvel LP, et al. A candidate genetic 
risk factor for vascular disease: a common mutation in methylenetetrahydrofolate 
reductase. Nat Genet. 1995;10(1):111-113.
38. Herrington DM, Howard TD, Brosnihan KB, McDonnell DP, Li X, Hawkins 
GA, Reboussin DM, Xu J, Zheng SL, Meyers DA, Bleecker ER. Common 
estrogen receptor polymorphism augments effects of hormone replacement therapy 
on E-selectin but not C-reactive protein. Circulation. 2002;105(16):1879-1882.
39. Bennett ST, Wilson AJ, Esposito L, Bouzekri N, Undlien DE, Cucca F, Nistico 
L, Buzzetti R, Bosi E, Pociot F, Nerup J, Cambon-Thomsen A, Pugliese A, 
Shield JP, McKinney PA, Bain SC, Polychronakos C, Todd JA. Insulin VNTR 
allele-specifi c effect in type 1 diabetes depends on identity of untransmitted paternal 
allele, The IMDIAB Group. Nat Genet. 1997;17(3):350-352.
40. Iwashita S, Koyama K, Nakamura Y. VNTR sequence on human chromosome 
11p15 that affects transcriptional activity. J Hum Genet. 2001;46(12):717-721.
41. Chevalier D, Cauffi ez C, Bernard C, Lo-Guidice JM, Allorge D, Fazio F, Ferrari 
N, Libersa C, Lhermitte M, D’Halluin JC, Broly F. Characterization of new muta-
tions in the coding sequence and 5’-untranslated region of the human prostacylcin 
synthase gene (CYP8A1). Hum Genet. 2001;108(2):148-155.
42. Moore M, Bracker M, Sartoris D, Saltman P, Strause L. Long-term estrogen re-
placement therapy in postmenopausal women sustains vertebral bone mineral density. 
J Bone Miner Res. 1990;5(6):659-664.
43. Grey AB, Cundy TF, Reid IR. Continuous combined oestrogen/progestin therapy 
is well tolerated and increases bone density at the hip and spine in post-menopausal 
osteoporosis. Clin Endocrinol (Oxf). 1994;40(5):671-677.
44. Duan Y, Tabensky A, DeLuca V, Seeman E. The benefi t of hormone replacement 
therapy on bone mass is greater at the vertebral body than posterior processes or 
proximal femur. Bone. 1997;21(5):447-451.
 

Chapter 2.3
Height in Pre- and Postmenopausal Women is 
Infl uenced by Estrogen Receptor Alpha Gene 
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ABSTRACT
The estrogen receptor alpha gene (ERα) is known to be involved in metabolic 
pathways infl uencing growth. We have performed two population-based asso-
ciation studies using three common polymorphisms within this candidate gene to 
determine whether these are associated with variation in adult stature. 
In 607 women, aged 55 to 80 years from the Rotterdam Study, the ERα PvuII-
XbaI haplotype 1 (px) and the L-allele of the TA-repeat polymorphism (< 18 
TA-repeats) were signifi cantly associated with an allele dose dependent decrease 
in height. Per allele copy of ERα PvuII-XbaI haplotype 1 height was 0.9 cm shorter 
(p-trend = 0.02) and 1.0 cm per allele copy of the TA-repeat L-allele (p-trend = 
0.003,). These results were independent of age, age at menarche and menopause 
and lumbar spine BMD, and remained signifi cant after participants with vertebral 
fractures were excluded. In 483 men from the Rotterdam Study we found no asso-
ciation with height. In 1500 pre- and perimenopausal women from the Eindhoven 
Study a similar association was observed; women were 0.5 cm shorter per allele 
copy of the ERα haplotype 1 (p-trend = 0.03). 
In conclusion, we demonstrate a role for genetic variations in the estrogen 
receptor alpha gene in determining adult stature in women.
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INTRODUCTION
Adult stature has been a topic of genetic research since the beginning of the 
20th century. Early studies considered the racial differences in stature proof of 
heritability.1 Later, studies of twins and families quantifi ed this heritability, which is 
generally believed to be over 80%.2-4 Today, adult stature is commonly recognized 
as a complex trait that is regulated by multiple genetic and environmental factors. 
The importance of genetic research of height lies not only in unraveling the 
physiological processes involved in growth. In clinical practice, short stature is fre-
quently treated in pediatric endocrine departments. In addition, aspects of skeletal 
size have been implicated in the risk of many diverse diseases including osteoporotic 
fractures,5 cancer,6 and cardiovascular disease.7 These associations emphasize the 
heterogeneity of factors that determine stature; that is variations in genes affect-
ing skeletal size may also determine the risk for certain diseases through direct or 
indirect pathways (pleiotropy). Thus, unraveling the genetic origins of stature will 
not only give important information about the physiology of growth, but may also 
provide new insights into the mechanisms of diseases such as osteoporosis, cancer, 
and cardiovascular disease.
To identify the individual genetic factors underlying differences in height sev-
eral approaches can be pursued, including genome searches by linkage analysis 
followed by candidate gene studies by association analysis. Recently, the fi rst four 
genome wide linkage studies of stature were published, leading to the identifi cation 
of several potential regions of linkage.8-11 The region on chromosome 6 (6q24-25) 
is of special interest not only because the results were independently replicated, 
but also because it is centered on a gene which is known to be involved in meta-
bolic pathways infl uencing growth, the estrogen receptor alpha gene (ERα).8,11 The 
estrogen resistant male described in 1994 illustrates the importance of the ERα 
gene in bone development and growth.12 A disruptive mutation in the ERα gene, 
producing a non-functional estrogen receptor in this man, led to absence of the 
pubertal growth spurt, delayed bone maturation, unfused epiphyses, and continued 
growth into adulthood. Given the striking effects of complete estrogen resistance 
on stature, it is conceivable that subtler and more frequent variations (polymor-
phisms) in the ERα gene, may affect skeletal size in healthy individuals. 
The aim of this study was to determine whether polymorphisms in the ERα 
gene are associated with variation in height in an adult population. We addressed 
this question in two Dutch population-based studies.
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METHODS
The Rotterdam Study
Study population
The Rotterdam Study is a population-based, prospective cohort study of men 
and women aged 55 years and over. Rationale and design have been described 
previously.13 All 10,275 inhabitants, age 55 or older, of Ommoord, a district of 
Rotterdam, The Netherlands, were invited to participate. Base-line examinations, 
including a home interview and an extensive physical examination, took place 
between 1990 and 1993. The overall response rate was 77% for the home interview 
and 6451 participants (71%) were also able to visit the research center, where an-
thropometrics were measured and blood samples were taken. 
Subjects
For the present study we included independently living subjects, age 55 to 80 
years and of Northern European decent who were initially part of a large epide-
miological study of bone mineral density. Baseline measurements of bone mineral 
density were available for 5931 independently living subjects from the initial 7983 
participants of the Rotterdam Study, 1453 of these were excluded on the basis of 
age (>80 years), use of a walking aid, known diabetes mellitus or use of diuretic, 
estrogen, thyroid hormone or cytostatistic drug therapy. From the 4478 remaining 
individuals, we studied a random sample of 2042 subjects. Information on vertebral 
fractures was available for 1184 participants of the study. Subjects with one or more 
prevalent vertebral fractures at baseline (n = 94) were excluded. In the remaining 
sample of 1090 subjects (607 women and 483 men) the following polymorphisms 
were determined: the PvuII and XbaI RFLP haplotype and the TA-repeat VNTR 
polymorphism in the ERα gene.
Clinical examination
During the home interview female participants were asked to recall their age at 
menarche and menopause and responses were validated as described previously.14 
At the research center, height and weight were measured in standing position in 
indoor clothing without shoes. All height measurements were attained by a research 
assistant using a standard wall-mounted statiometer. Body mass index (BMI) was 
computed as weight in kilograms divided by height in meters squared (kg/m2). At 
baseline, average bone mineral density (BMD expressed in g/cm2) was measured 
over L2 to L4 of the lumbar spine by dual energy X-ray absorptiometry (DEXA, 
Lunar DPX-L densitometer, Lunar Corp., Madison, WI, USA) as described previ-
ously (41). Spine radiographs were assessed for the presence of vertebral fractures 
at baseline by the McCloskey-Kanis method.15,16 Vertebral body area (cm2) was 
measured over the second through fourth lumbar vertebra by postero-anterior 
scanning using dual energy X-ray absorptiometry (DEXA; Lunar DPX-L, Lunar 
Corp., Madison, WI, U.S.A.). 
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The Eindhoven Perimenopausal Osteoporosis Study
Study population
The Eindhoven Study is a population-based cohort study of women born be-
tween 1941 and 1947, living in the city of Eindhoven, The Netherlands. Rationale 
and design have been described previously.17 Of the eligible 8503 women, 6700 
(79%) participated. Base-line examinations, including an interview by a trained 
research assistant and an extensive physical examination, took place between 1994 
and 1995. All participants gave their written informed consent and two medical 
ethical committees approved the study. 
Subjects
For the present study we included a random sample of 1500 pre- and perimeno-
pausal women of Northern European decent. Pre- and perimenopausal status was 
defi ned as last menses less than one year ago. This cohort was initially part of a large 
epidemiological study of cholesterol in which subjects were excluded according to 
the following criteria: use of hormone replacement therapy, oral contraceptives, and 
cholesterol-lowering therapy.
Clinical examination
During the interview participants were asked about age of menarche and meno-
pause. Height and weight were measured in indoor clothing without shoes at either 
of two research centers: Diagnostic Center Eindhoven and St. Joseph Hospital in 
Veldhoven, a suburb of Eindhoven. All height measurements were attained by a 
research assistant using a standard wall-mounted statiometer. Body mass index 
(BMI) was computed as weight in kilograms divided by height in meters squared 
(kg/m2). 
Genotyping
Genomic DNA was isolated from peripheral leukocytes by standard procedures. 
The PvuII (C to T substitution) and XbaI (G to A substitution) restriction frag-
ment length polymorphisms (RFLP) are located in intron 1 of the ERα gene, 397 
bp and 351 bp, respectively, upstream of exon 2. To increase genetic resolution, 
we constructed haplotypes in this area of the ERα gene.18 As the two RFLPs are 
separated by only 46 bp, we identifi ed haplotypes by a direct molecular haplotyping 
method. A 346 bp PCR fragment was generated by a forward primer (ER-F: 5’-
GATATCCAGGGTTATGTGGCA-3’) and a reverse primer (ER-R:5’-AGGTG
TTGCCTATTATATTAACCTTGA-3’) in a reaction mixture of 10 μL containing 
20 ng of genomic DNA, 50 mM KCl, 10 mM Tris-HCl (pH 8.3), 1.5 mM MgCl2, 
0.2 mM deoxy-NTP, 2 pM of each primer, and 0.2 U Super Taq polymerase (HT 
Biotechnology Ltd., Cambridge, UK). The reactions were performed in 384-well 
format in a thermocycler (MJ-tetrad) with a cycling protocol of 94, 60, and 72ºC for 
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45 sec. each for 30 cycles. Ten microliters of PCR product were digested by addition 
of 5 μL of digestion mixture containing 5 U PvuII, 7 U XbaI restriction enzyme 
(MBI Fermentas) and 1.5 μL of ReactBuffer 2 (Life Technologies Inc.) and incubat-
ing for 90 min. at 37ºC. The digestion products were analyzed by electrophoresis 
in a 3% agarose gel in 0.5xTBE (1xTBE = 89 mM Tris, 89 mM boric acid, 2 mM 
Na2EDTA) for 80 minutes at 125 Volts. Separation patterns were documented with 
a digital camera (DC120, Kodak Company, Rochester, NY) under UV illumination 
(302 nm). 
The alleles were defi ned as haplotypes such as “Px”, capitals denoting absence 
and lower cases letters denoting presence of the restriction site for the PvuII (P/p) 
and XbaI (X/x) enzymes on each of the alleles. The haplotype alleles were coded as 
haplotype numbers 1 through 4 in order of decreasing frequency in the population 
(1 = px, 2 = PX, 3 = Px, and 4 = pX). Genotypes are analyzed as combinations of 
two alleles. 
The (TA)n Variable Number of Tandem Repeat (VNTR) polymorphism 
is located 1 kb upstream of the fi rst exon at –1118 bp from the transcription 
start site and –1351 bp from the translation start site. A 160-194 bp PCR frag-
ment containing the TA-repeat VNTR was generated using a FAM-labeled 
forward primer (5’-GACGCATGATATACTTCACC-3’) and reverse primer (5’-
GCAGAATCAAATATCCAGATG-3’) in a reaction mixture of 10 μL containing 
10 ng of genomic DNA, 50 mM KCl, 10 mM Tris-HCl (pH 8.3), 1.5 mM MgCl2, 
0.2 mM deoxy-NTP, 5 pM of each primer, and 0.2 U Super Taq polymerase (HT 
Biotechnology Ltd., Cambridge, UK). The reactions were performed in 384-well 
format in a thermocycler (MJ-tetrad) with a cycling protocol of 94, 59, and 72ºC 
for 30 sec. each for 28 cycles. The labeled PCR products were analyzed on an 
ABI 3100 automated capillary DNA sequencer using Genescan software (Applied 
Biosystems, Perkin Elmer, Capelle a/d IJssel, The Netherlands). The allele length 
was determined using internal size standards. 
Statistical analysis
One-way analysis of variance (ANOVA) and Pearson’s chi-square were used to 
compare age, gender, and age at menarche, in our study population to the entire 
Rotterdam Study cohort. To account for the possible confounding effects of age 
and gender, all other baseline characteristics were compared by adjusted analysis of 
covariance (ANCOVA). 
To analyze the relationship between the ERα genotypes, height and poten-
tial confounders, we stratifi ed subjects by allele copy number (0,1 or 2) for the 
PvuII-XbaI haplotype in the ERα gene. In view of the large number of individual 
genotypes, the ERα TA-repeat alleles were grouped according to the number of 
TA-repeats: group H including alleles with a high number of TA-repeats (TA ≥ 
18) and group L including alleles with a low number of TA-repeats (TA < 18). 
Individuals were then genotyped and analyzed as "LL", "LH" or "HH". The cut off 
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value of 18 TA-repeats is based on previous fi ndings which indicate that 18 or more 
TA-repeats are associated with osteoporosis in our population.18
We allowed for three possible models to explain differences between genotype 
groups, i.e., an allele dose effect, a dominant effect, or a recessive effect. Allele dose 
was defi ned as the number of copies of a certain allele in the genotype. In case of a 
consistent trend, refl ected as an allele dose effect, we performed a (multiple) linear 
regression analysis to quantify the association. In case of a dominant or recessive 
effect of the test-allele, ANOVA and ANCOVA tests were performed. For domi-
nant effects we compared test-allele carriers versus non-carriers while for recessive 
effects, subjects homozygous for the test allele were compared to heterozygous 
carriers and non-carriers. First, the crude differences between genotype groups 
were calculated stratifi ed by gender. Subsequently, the analysis was adjusted for the 
potential confounding effects of age and age at menarche in women.
We searched for possible intergenic interactions within the ERα gene. We used 
the genotype data for each of the polymorphisms to infer frequency of the long 
range haplotype alleles within each gene using the PHASE program.19
All statistical analyses were performed using SPSS version 11.0.1 (SPSS Inc., 
Chicago, USA).
RESULTS
The baseline characteristics of the subjects selected from the Rotterdam Study 
differ from the total cohort. More men have been included in our study (44% 
versus 39%) and the participants of our study were on average 5.2 years younger 
as compared to the entire Rotterdam Study population. There were no signifi cant 
differences in age at menarche or menopause. After adjustment for age, women in 
our study population weighed less (68.1 vs. 69.4 kg, p<0.01) and had a signifi cantly 
lower BMI (26.2 vs. 26.7 kg/m2, p<0.01) as compared to the entire Rotterdam Study 
cohort. In both men and women, after adjustment for age, there no were signifi cant 
differences in height as compared to the entire Rotterdam Study population.
To study the effects of the ERα PvuII-XbaI haplotypes on height in women prior 
to menopause, we analyzed a random set of 1500 pre- and perimenopausal women 
from the Eindhoven Perimenopausal Osteoporosis Study. The participants selected 
for our study were on average 0.8 years younger then the entire Eindhoven Study 
cohort. There was no signifi cant difference in age at menarche and after adjustment 
for age and there were no signifi cant differences in any of the anthropometric 
parameters between our study population and the total cohort. 
Table 1 shows the location, number of subjects analyzed and allele frequencies 
for all polymorphisms. All genotypes and haplotypes were in Hardy-Weinberg 
equilibrium and frequencies were similar to other studies of Caucasian subjects.20-
22
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In the 607 female subjects remaining after exclusion of participants with preva-
lent vertebral fractures at baseline (n=94), an association was seen between height 
and ERα PvuII-XbaI haplotypes. In women, a signifi cant allele dose effect was 
observed for the ERα haplotype 1 (the most frequent allele), corresponding to a 
0.9 cm decrease in height per allele copy (p-trend 0.02, Table 2), extreme genotypes 
varied 1.8 cm. We observed a trend for association of ERα haplotype 1 with age 
at menopause (p-trend 0.06), in that homozygous carriers of the ERα haplotype 1 
had a 1.1 year later age at menopause. However, age at menarche was not associated 
with ERα haplotype 1. Lumbar spine BMD and lumbar vertebral area were both 
signifi cantly associated with ERα haplotype 1 (p-trend 0.05 and 0.01, respectively). 
A signifi cant variation in weight was also observed, however investigation of the 
relationship with BMI revealed this association to be driven by height differences. 
Adjustment for age, age at menarche, age at menopause and lumbar spine BMD did 
not signifi cantly change the observed association between ERα haplotype 1 and 
height. In women, the ERα haplotype 2 showed a similar, but opposite allele dose 
effect on height corresponding to a 0.7 cm increase in height per haplotype 2-allele 
copy (p-trend = 0.06), extreme genotypes differed 1.6 cm (results not shown). No 
association with height was observed for the ERα haplotype 3 (results not shown). 
When these same analyses were performed on the 483 male subjects (mean age 
65.2 standard deviation 6.6), no relationship with height was seen; non-carriers of 
haplotype 1 were 176.5 cm, heterozygous carriers 175.7 cm and homozygous carri-
ers 176.0 cm (p-value 0.6, Table 2). We also analyzed ERα haplotype 1 dependent 
Table 1. Polymorphisms analyzed in this study
Polymorphism Alleles
No. subjects
analyzed
Allele frequency
(%)
The Rotterdam Study
PvuII/XbaI RFLP
(intron 1 -397 C/T
 and -351 G/A)
Haplotype 1 - px - T-A 1090 /1176/2180 (54)
Haplotype 2 - PX - C-G 1090 / 754/2180 (35)
Haplotype 3 - Px - C-A 1090 / 250/2180 (11)
Haplotype 4 - pX - T-G 1090      -/2180 (0)
(TA)n (-1351 from
translation start site)
“L”-allele (< 18 repeats) 1090 /1173/2180 (54)
The Eindhoven Study
PvuII/XbaI RFLP
(intron 1 -397 C/T
 and -351 G/A)
Haplotype 1 - px - T-A 1500  1620/3000 (54)
Haplotype 2 - PX - C-G 1500 1077/3000 (36)
Haplotype 3 - Px - C-A 1500 / 303/3000 (10)
Haplotype 4 - pX - T-G 1500    -/3000 (0)
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height differences in men in age categories, above and below the median age of 65 
years. However, in both age categories no association was observed; the p-value for 
trend was 0.4 in youngest age category and 0.7 in the oldest age category.
We analyzed the association between the ERα TA-repeat VNTR polymorphism, 
located in the promoter region, and height in The Rotterdam Study. Nineteen dif-
ferent alleles were identifi ed. The bimodal distribution pattern of the TA-repeat 
alleles in our population (Figure 1) shows two peaks at 13-15 and 21-23 TA-repeats. 
A low frequency was seen for the intermediate 16-20 TA-repeats and the extremes 
of the spectrum (9-12 and 24-33 TA-repeats). 
In women, the L-allele (fewer than 18 TA-repeats) of the TA-repeat VNTR 
polymorphism showed a similar signifi cant association with decreased height as the 
ERα haplotype 1. A 1.1 cm decrease in height per allele copy of the L-allele (p-trend 
< 0.01), independent of age, age at menarche and age at menopause was observed 
(results not shown); extreme genotypes differed 2.2 cm in mean height. Apparent 
lumbar vertebral area was also signifi cantly associated with the L-allele, extreme 
genotypes differed 0.4 cm2 (p-trend 0.02). While in men, as for the PvuII-XbaI 
haplotypes, no association with height or apparent lumbar vertebral area was seen.
We observed strong linkage disequilibrium between the polymorphic sites at the 
5’ region of the ERα gene. In order to determine which of the polymorphic sites 
is driving the association with height and vertebral bone area, we constructed long 
range haplotypes (LRH) using the PHASE program.19 Table 3 shows frequencies 
Figure 1. 
Frequency distribution of the ERα dinucleotide (TA) repeat polymorphism in 1090 
subjects (2180 chromosomes). Group “H” includes alleles with a high number of 
TA-repeats (TA ≥ 18) and group “L” includes alleles with a low number of TA-
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of each of the 6 observed haplotypes. Due to the strong linkage disequilibrium 
between the PvuII-XbaI haplotype and the TA-repeat VNTR, we observed two 
frequent LRH alleles (allele A and E) among the 6 possible haplotypes. Table 3 
also shows the difference in mean height between carriers and non-carriers of each 
particular LRH allele. The largest effect on height was observed for the LRH al-
lele A, which is the combination of a low number of TA repeats and PvuII-XbaI 
haplotype 1. 
To study the effects of the ERα PvuII-XbaI haplotype 1 on height in women prior 
to menopause, we analyzed a random set of 1500 pre- and perimenopausal women 
from the Eindhoven Perimenopausal Osteoporosis Study. The ERα haplotypes were 
also associated with variation in height in these pre- and perimenopausal women. A 
signifi cant allele dose effect was observed for ERα haplotype 1, corresponding to a 
0.5 cm decrease in height per allele copy (p-trend = 0.03, Table 4). 
DISCUSSION
The fi rst genome wide linkage studies of stature identifi ed a region of potential 
linkage to adult stature on chromosome 6 (6q24-25).8-11 This region is centered on a 
gene, which is known to be involved in metabolic pathways infl uencing growth, the 
estrogen receptor alpha gene (ERα). Following these results three polymorphic sites 
in the estrogen receptor alpha gene were investigated for associations with height. 
We found these common polymorphisms in the 5’ region of the ERα gene to be 
signifi cantly associated with height in postmenopausal women, as well as pre- and 
perimenopausal women. Difference in height between extreme genotypes between 
1.0 and 2.2 cm were observed, dependent upon the group of women studied and 
Table 3. Association of the 6 ERα PvuII-XbaI-TA-repeat long range haplotype 
(LRH) alleles in women (n=607), The Rotterdam Study
LRH allele
Haplotype alleles
Nr. of carriers Δ height (cm)TA-repeat 
PvuII-XbaI 
haplotype
A L 1 441 - 1.30
B L 2 30 - 1.28
C L 3 28 + 0.90
D H 1 54 + 0.75
E H 2 339 + 0.77
F H 3 101 + 1.10
L = Low number of TA-repeats (< 18), H = High number of TA-repeats (≥ 18)
Δ height = mean height of allele carriers minus mean height of non-carriers
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the polymorphism analyzed. 
In the Rotterdam Study, a population-based study of adults aged 55 years and 
older, the ERα PvuII-XbaI haplotype 1 (-397 T and -351 A) and the L-allele of 
the TA-repeat VNTR polymorphism (fewer than 18 TA-repeats) were signifi cantly 
associated with a decrease in height per allele copy (0.9 cm and 1.0 cm per allele 
copy, respectively). Homozygous carriers of PvuII-XbaI haplotype 1 were 1.8 cm 
shorter than subjects who did not carry this haplotype; homozygous carriers of 
the TA-repeat L-allele were 2.2 cm shorter than non-carriers. Furthermore, these 
polymorphisms were also associated with a smaller apparent lumbar vertebral area 
(0.4 cm2). These associations were not found in the male participants of our study. 
We considered that the postmenopausal drop in estrogen levels may be instru-
mental in the association we found for the ERα gene with height. This would indicate 
that it is not attained adult height that is infl uenced by ERα gene polymorphisms, 
but the age-related decrease in stature. To address this hypothesis we excluded par-
ticipants with radiologically confi rmed vertebral fractures at baseline and adjusted 
for age at menopause and found that each did not change our results. However, 
vertebral fractures that do not meet the McCloskey-Kanis criteria, that is vertebral 
deformities with a reduction in vertebral height that do not meet the cut-off level, 
may still be present in the Rotterdam population. We have tried to address this by 
adjusting for lumbar spine BMD. Women most susceptible to these less severe verte-
bral fractures will on average have a lower lumbar spine BMD. Furthermore, as has 
been reported previously, ERα haplotype 1 is associated with lumbar spine BMD.18 
Therefore, by adjusting our analysis for lumbar spine BMD we have adjusted for 
Table 4. Characteristics of Women by ERα PvuII-XbaI haplotype 1 (n=1500), 
The Eindhoven Study
Copy number of ERα haplotype 1 allele P-
value0 1 2
Number (%) a 331 (22.13) 718 (47.9) 451 (30.1) 0.2 a
Age ± SE (years) 49.8 ± 0.1 50.1 ± 0.1 50.0 ± 0.1 0.3 b
Age at menarche ± SE (yrs) 14.0 ± 0.4 14.2 ± 0.3 14.2 ± 0.4 0.7 b
Weight ± SE (kg) c 68.8 ± 0.7 69.3 ± 0.4 68.7 ± 0.6 0.8 b
BMI ± SE (kg/m2) c 25.2 ± 0.3 25.7 ± 0.2 25.5 ± 0.2 0.5 b
Height ± SE (cm) 165.3 ± 0.4 164.7 ± 0.2 164.3 ± 0.3 0.03 b
Height ± SE (cm) d 165.3 ± 0.4 164.7 ± 0.2 164.3 ± 0.3 0.04 b
a P-value for Hardy-Weinberg equilibrium
b Linear regression
c Adjusted for age and age at menarche
d Adjusted for age
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a surrogate for vertebral fractures and have shown that these fractures most likely 
do not play an essential role in the observed association. Furthermore, we analyzed 
the association between the ERα PvuII-XbaI haplotypes and height in 1500 pre-and 
perimenopausal women from The Eindhoven Study, a population-based cohort 
of women aged 46 to 57 years. In this study the PvuII-XbaI haplotype 1 was also 
signifi cantly associated with decreased height, where haplotype 1 was associated 
with a 0.5 cm shorter stature per allele copy. Thus, in pre- and perimenopausal 
women, where vertebral fractures are not likely to be an important confounder, 
the results were similar to the association found in postmenopausal women. Given 
these fi ndings we expect the confounding by less severe vertebral fractures that do 
not meet the McCloskey-Kanis cut-off level will not have infl uenced our results. 
Furthermore, we hypothesize that ERα polymorphisms infl uence attained height 
earlier in life, rather than after menopause. However, the effect does seem to be 
greater in postmenopausal women than in pre- and perimenopausal women (1.8 cm 
vs. 1.0 cm). Yet, we can not be sure whether this is a signifi cant difference or falls 
within the 95% confi dence intervals for both populations. 
As seen in other populations, in The Rotterdam Study strong linkage disequi-
librium exists between the intron 1 PvuII and XbaI polymorphic sites and the TA-
repeat VNTR located approximately 21 kb upstream of these polymorphisms.18,21,23 
It is still unclear which of these polymorphisms is driving the association we 
observed with stature. It is diffi cult to distinguish the different effects of the two 
polymorphic sites by association analyses because of the strong linkage between 
them. However, the association studies with the long range haplotypes suggest that 
both sites are contributing since the long range haplotype defi ned by carrier status 
for both the PvuII-XbaI as well as the TA-repeat VNTR risk alleles (LRH A) shows 
the strongest effects on stature, especially when we compare LRH alleles A and B 
versus C and D and E versus F. However, larger studies are necessary to prove this 
hypothesis.
In this study we observed that the genetic associations between ERα polymor-
phisms and height were found only in women. This is unexpected because the only 
known clinical example of the consequences of a non-functional estrogen receptor 
alpha on height was observed in a male. Two explanations arise. First, the physiol-
ogy of pubertal growth in males differs from females in that it begins and fi nishes 
later in life and has a higher peak velocity. Furthermore, men are taller than women 
mostly as a result of longer legs rather than longer torsos.24 In addition, there are 
structural and physiological differences between vertebral and long shafted bone 
growth. This raises the possibility that the ERα gene polymorphisms particularly 
infl uence mechanisms controlling vertebral bone growth. To investigate this theory 
we measured average vertebral area from lumbar spine DEXA scans. Indeed, ERα 
polymorphisms were signifi cantly associated with apparent vertebral body area 
which supports the hypothesis that ERα gene polymorphisms infl uence vertebral 
bone growth.
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Another explanation for the fact that the association with stature was only seen 
in women relates to the predominant role of androgens in males. Perhaps, while 
in the predominantly estrogenic puberty of females, polymorphisms in the ERα 
gene lead to height differences, in males variances in androgenic response (perhaps 
through polymorphisms) may override these variances. 
The ERα PvuII and XbaI polymorphisms have been an important area of re-
search in diseases such as osteoporosis, cardiovascular disease, and cancer.21,25,26 
Until recently neither of the PvuII or XbaI RFLPs was known to have functional 
consequences. It was thought that the PvuII and XbaI polymorphisms acted as a 
marker through linkage disequilibrium for a truly functional sequence variation 
elsewhere in the gene. Therefore, to increase genetic resolution, we combined 
the PvuII and XbaI polymorphisms in multi-allelic haplotype makers. However, 
recently Herrington et al. have shown that the C-allele of the PvuII RFLP produces 
a functional binding site for the transcription factor B-myb, suggesting that pres-
ence of this allele may result in augmented estrogen receptor alpha transcription or 
produce estrogen receptor alpha isoforms that have different properties than the 
full-length gene product.27 
The TA-repeat VNTR polymorphism is located in the promoter region of the 
ERα gene. The location of the TA-repeat VNTR polymorphism in the promoter 
region, 700 bp upstream of promoter “B” and 600 bp downstream of promoter 
“C”, indicates it may have functional signifi cance.28 Studies have shown that vari-
able number of tandem repeats (VNTR) polymorphisms in proximity to gene 
promoters, such as the TA-repeat, can have a signifi cant infl uence on transcrip-
tional regulation.29 It is, therefore, plausible that the number of TA repeats could be 
important for ERα gene transcription, but molecular biological functional studies 
are necessary to address this issue.
How do these possibly functional polymorphisms in the ERα gene infl uence 
attained height in women? Perhaps early age at menarche leads to premature clo-
sure of the epiphyseal growth plates and subsequent shorter stature.30 Stavrou et al. 
have shown that age at menarche is infl uenced by ERα polymorphisms.31 However, 
adjustment for age at menarche did not change the association, making this a less 
likely mechanism. Therefore, we hypothesize that the ERα polymorphisms lead 
to genotype-dependent differences in ERα expression and consequently variable 
estrogen “sensitivity” directly at the site of linear bone growth, the epiphyseal 
growth plates. A prerequisite for a direct estrogen action at the level of the growth 
plate is the presence of ERα on chondrocytes in the growth plate. Indeed, the ERα 
has been localized in all zones of the growth plate, i.e. resting, proliferating, and 
hypertrophic chondrocytes.32 
Two previous studies have shown an association between ERα polymorphisms 
and adult stature. Lehrer et al. showed that a rare synonymous polymorphism in 
codon 87 in exon 2 of the ERα gene (“B-variant”) was associated with height in 
American women of multiracial descent.33 However, given the synonymous nature 
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of this polymorphism it is unlikely that the “B-variant” allele will lead to a function-
ally different estrogen receptor alpha. This “B-variant” polymorphism has previ-
ously been shown to be in strong linkage disequilibrium with the PvuII and XbaI 
polymorphisms,34 raising the possibility that it is the PvuII or XbaI polymorphism 
which is driving this observed association. In a study of adolescent boys Lorentzon 
et al. found an association between shorter stature and the PvuII T-allele and the 
XbaI A-allele, which corresponds to the ERα haplotype 1.35 Although this study 
was in young boys, it is in line with our fi ndings in adult women. 
Our study has limitations. Within the Rotterdam Study vertebral fracture 
data was only collected in individuals who survived the follow-up period of ap-
proximately 7 years. This resulted in a healthy responder bias (as illustrated by 
differences in mean age with the entire Rotterdam Study cohort). However, this 
bias is not likely to be genotype-dependent, since we did not fi nd an infl uence 
of the ERα polymorphisms we studied on survival (data not shown). Genetic as-
sociation studies can be infl uenced by population heterogeneity. This is especially 
true for case-control studies in a population of mixed racial origin. However, our 
study groups are drawn from two population based cohort studies and all subjects 
were Dutch Caucasians and have similar social background. Therefore, our study 
populations may be considered ethnically homogeneous and representative of the 
Dutch population. 
In conclusion, in the present population-based association studies of stature, 
we have confi rmed the role of the estrogen receptor alpha gene in determining 
adult stature. The effects were present in pre-, peri- and postmenopausal women, 
but not seen in males. However, confi rmation of the role of this candidate gene 
in determining height does not exclude that other genes also located in the region 
defi ned by recently published genome scans do not also play a role in between-
person variation in height.
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ABSTRACT
Context: The role of estrogens in ischemic heart disease (IHD) is uncertain. 
Evidence suggests that genetic variations in the estrogen receptor alpha (ERα) gene 
may infl uence IHD risk, but the role of common sequence variations in the ERα 
gene is unclear.
Objective: To determine if the ERα haplotype created by the PvuII (c.454-
397T>C) and XbaI (c.454-351A>G) polymorphisms is associated with myocardial 
infarction and IHD risk.
Design, Setting, and Participants: In 6408 men and postmenopausal women 
from The Rotterdam Study, a population-based, prospective cohort study of par-
ticipants aged 55 years and over, ERα PvuII-XbaI haplotypes were determined. The 
average follow-up was 7.0 years. 
Main Outcome Measures: The primary outcome was incident myocardial in-
farction and IHD defi ned as myocardial infarctions, revascularization procedures 
and IHD mortality. Detailed interviews, physical examinations, and blood samples 
were taken, including assessment of cardiovascular risk factors. 
Results: In women, the ERα haplotype 1 (PvuII T and XbaI A) allele was as-
sociated with an increased myocardial infarction risk in an allele-dose dependent 
manner. Approximately 29% of women were homozygous carriers of haplotype 
1, 49% were heterozygous carriers and 22% were non-carriers. After adjusting 
for known cardiovascular risk factors such as age, previous myocardial infarction, 
BMI, age at menopause, use of HRT, blood pressure, smoking, diabetes mellitus 
and cholesterol, heterozygous carriers of haplotype 1 were at a 2.23 times increased 
risk of myocardial infarction (95% confi dence interval (CI) 1.13-4.43) as compared 
to non-carriers, while homozygous carriers were at 2.48 times increased risk 
(95% CI 1.22-5.03). Myocardial infarction event rates for homozygous carriers, 
heterozygous carriers and non-carriers of haplotype 1 were 3.2%, 2.8% and 1.3%, 
respectively. For IHD events we observed a similar association. In women, the 
effect of haplotype 1 on fatal IHD was larger than on non-fatal IHD. Although the 
association was not signifi cant, we observed that carriers of haplotype 1 died more 
often as a result of IHD. In men, the ERα haplotypes were not associated with 
myocardial infarctions or IHD. 
Conclusions: This population-based, prospective cohort study shows a signifi -
cant two-fold increased risk of incident myocardial infarction and IHD, in post-
menopausal women who carry ERα haplotype 1 (PvuII T-allele and XbaI A-allele). 
This association is independent of known cardiovascular risk factors. 
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INTRODUCTION
Ischemic heart disease (IHD) has a strong genetic component, but the identity 
of the genetic risk factors is unknown. There is a large ongoing effort to fi nd genes 
involved in cardiovascular disease. Recently, a large case-control study was pub-
lished in which 112 polymorphisms in 71 candidate genes for myocardial infarction 
were examined and three associated gene variants were identifi ed.1 However, genes 
involved in the pathways of sex steroids were not considered. Several lines of evi-
dence implicate sex hormones in cardiovascular disease risk, such as the difference 
in disease risk between men and women. The risk of IHD in women between pu-
berty and menopause is lower than that in age-matched men. However, this gender 
difference diminishes when postmenopausal women and men of similar age are 
compared.2,3 These observations have led to the suggestion that it is the lowering 
of endogenous estrogen following menopause that may be the critical factor in 
removing the relative protection against IHD women have in their pre-menopausal 
years.
Estrogen exerts its effects by binding to the estrogen receptors alpha and beta 
that, once activated, regulate the expression of multiple genes. A large body of 
data implicates the estrogen receptor alpha gene (ERα, also known as ESR1) in 
cardiovascular disease. First, in 1994 Smith et al. described a man with a null 
mutation in the ERα leading to unresponsiveness to estrogen. This 31-year-old 
man was reported to have premature atherosclerotic coronary artery disease and 
endothelial dysfunction despite the presence of high levels of circulating estrogen.4 
Furthermore, ERα has been identifi ed in most cardiovascular tissues such as the 
coronary arterial wall in smooth muscle cells,5,6 endothelial cells7 and myocardial 
cells.8 In addition, in premenopausal women, fewer estrogen receptors were found 
in women with atherosclerotic coronary arteries than in those with normal coro-
nary arteries.5 Finally, variant ERα transcripts are extensively expressed in human 
vascular tissues.9 
It is conceivable that common sequence variations (polymorphisms) in the ERα 
gene may affect cardiovascular disease risk in the general population. Several single 
nucleotide polymorphisms (SNP) and variable number tandem repeats (VNTR) 
polymorphisms have been identifi ed in the ERα gene (http://www.ncbi.nlm.nih.
gov). Cross-sectional studies have reported associations between a number of these 
polymorphisms in the ERα gene and cardiovascular risk factors and phenotypes, 
including body mass index,10 hypertension,11 coronary fl ow reserve12 and coronary 
atherosclerosis.13,14 Of the polymorphisms identifi ed in the ERα gene, the PvuII (also 
known as c.454-397T>C, IVS1-397 T/C and rs2234693) and XbaI (also known as 
c.454-351A>G, IVS1-351 A/G and rs9340799) SNPs are the most widely studied 
so far. These polymorphisms are located in the fi rst intron of the ERα gene, 397 
and 351 basepairs upstream of exon 2. Herrington and colleagues have recently 
shown a potential functional signifi cance for the PvuII polymorphism.15 Therefore, 
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the aim of this study was to determine whether these polymorphisms in the ERα 
gene are associated with incident IHD and myocardial infarction in particular in a 
population of men and postmenopausal women aged 55 years and older. We have 
addressed this in a prospective study design by analyzing 6408 subjects from a 
population-based cohort study including the assessment of IHD and its clinically 
most relevant manifestation, myocardial infarction. 
METHODS
Study population
The Rotterdam Study is a population-based, prospective cohort study of men 
and women aged 55 years and over. The study was initiated to assess prevalence, 
incidence, and determinants of diseases in the elderly.16 The main focus of the 
Rotterdam Study was on cardiovascular disease, neurogeriatric disease, ophthalmo-
logic disease, and locomotor disease. Between July 1st, 1989 and May 17th, 1993 all 
residents age 55 or older of Ommoord, a district of Rotterdam, The Netherlands, 
were invited to participate. A total of 7983 men and women (78% of those eligible) 
entered the study and 7085 participants were able to visit the research center. Base-
line examinations took place between July 5th, 1989 and September 21st, 1993 and 
included an initial home visit and interview by a trained research assistant and an 
extensive physical examination at the research center. The Rotterdam Study was 
approved by the medical ethics committee of the Erasmus Medical Center. Each 
eligible person received written and oral information about the goals and research 
methodology of the study together with a description of the examinations involved. 
Written informed consent was obtained from all participants. 
Our study population of 6408 participants (3791 women) included men and 
postmenopausal women of Caucasian origin who were able to visit the research 
center and who completed all parts of the baseline examination including a blood 
sample.
Cardiovascular risk factors
Cardiovascular risk factors were obtained by interview and physical examination 
at baseline. Interview information, including smoking habits, age at menopause and 
use of hormone replacement therapy (HRT), was obtained by a trained research 
assistant. HRT was defi ned as current or former user and never user. Smoking was 
categorized as current, past or never smoker. Anthropometric measurements were 
obtained at the research center. Body mass index (BMI) was calculated as weight in 
kilograms divided by height in meters squared. Two standardized blood pressure 
measurements were taken with the subject in sitting position using a random zero 
sphygmomanometer and averaged. Hypertension was defi ned as a systolic pressure 
≥ 160 mmHg and/or a diastolic pressure ≥ 100 mmHg and/or use of antihyper-
tensive medication, encompassing grade 2 and grade 3 hypertension according to 
the World Health Organization (WHO) criteria.17 After an overnight fast, blood 
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samples were obtained. Serum total cholesterol was determined by an enzymatic 
procedure.18 High-density lipoprotein (HDL) was measured similarly, after pre-
cipitation of the non-HDL fraction. Diabetes mellitus was considered present with 
current use of antidiabetic medication or a non-fasting or postload glucose level 
above 11 mmol/L according to the WHO.19 A history of myocardial infarction 
was based on self-reported information checked with the general practitioner’s or 
hospital records which included written information on diagnosis and treatment 
and/or ECG evidence. Infarctions detected by the Modular ECG analysis system 
(MEANS) without evidence of symptoms (silent myocardial infarctions), were 
verifi ed by an experienced cardiologist.20,21
Incident Ischemic Heart Disease 
Follow-up started at the time of inclusion into the study and ended either on 
the 1st of January 2000 or, when earlier, at the participant’s death. Research as-
sistants collected follow-up data on cardiovascular disease morbidity and mortality 
data from the general practitioners and in case of treatment by a specialist hospital 
records were retrieved. With respect to vital status of the participants, information 
was also obtained regularly from the municipal health authorities in Rotterdam. 
All collected events were verifi ed by reviewing hospital discharge reports and 
letters from medical specialists. Two research physicians independently coded 
events according to the International Classifi cation of Diseases, 10th revision 
(ICD-10).22 In case of discrepancy, consensus was attained in a separate session. 
Finally, a medical expert in cardiovascular disease reviewed all coded events for 
fi nal classifi cation. In the analyses we used the following outcome measurements: 
incident myocardial infarction (I21) and IHD (defi ned as myocardial infarction 
(I21), percutaneous transluminal coronary angioplasty (PTCA; Z95.5), coronary 
artery bypass graft (CABG; Z95.1) and death from IHD (I20-I25)). In identifying 
myocardial infarctions, general practitioner and hospital records were consulted and 
all available information, which included ECG, cardiac enzymes and the clinical 
judgment of the treating specialist, were used to code the events. Silent myocardial 
infarctions were not included in the analysis. Revascularization procedures were 
identifi ed by consulting hospital discharge letters from the medical specialist. For 
further analyses myocardial infarction and IHD were also classifi ed as fatal and 
non-fatal. In addition, mortality due to all causes was also documented during fol-
low up.
Genotyping
All participants were genotyped for the PvuII and XbaI polymorphisms. The 
variations were 397 and 351 nucleotides upstream in the intron. These polymor-
phisms have also been described at http://www.ncbi.nlm.nih.gov/SNP under iden-
tifi cation numbers rs2234693 (c.454-397T>C) and rs9340799 (c.454-351A>G). 
DNA was extracted using proteinase K and sodium-dodecyl-sulphate digestion 
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at 37°C overnight and purifi ed using phenol–chloroform extractions. The extracted 
DNA was then precipitated using 4 mol/l NaCl and two volumes of cold absolute 
ethanol. DNA was solubilized in double-distilled water and stored at -20°C until 
used for DNA amplifi cation. Genotypes were determined in 5 ng genomic DNA 
using the Taqman allelic discrimination assay. Primer and probe sequences were 
optimized using the SNP assay-by-design service of Applied Biosystems. For 
details see http://store.appliedbiosystems.com. Reactions were performed on the 
Taqman Prism 7900HT 384 wells format. We used the genotype data for each 
of the two polymorphisms to infer the haplotype alleles present in the popula-
tion using the program PHASE which implements a Bayesian statistical method 
for reconstructing haplotypes from population genotype data.23 The alleles were 
defi ned as haplotypes such as “T-A” representing a thymidine (T) nucleotide at the 
PvuII polymorphic site and an adenosine (A) nucleotide at the XbaI polymorphic 
site. Haplotype alleles were coded as haplotype numbers 1 through 4 in order of 
decreasing frequency in the population (1=T-A, 2=C-G, 3=C-A, and 4=T-G).24,25 
Statistical analysis
To compare possible confounders between subjects grouped by the ERα hap-
lotype of interest one-way analysis of variance (ANOVA) was used for continuous 
variables and Pearson’s chi-square for dichotomous. 
The association between the ERα haplotypes and fi rst incident IHD events 
was evaluated by stratifying subjects by gender and allele copy number (0,1 or 2) 
for the haplotype of interest and using a standard age-adjusted Cox proportional 
hazards model (Model 1). The proportional hazards assumption was tested and 
met for the Cox proportional hazards models. Based on previous analyses we chose 
haplotype 1 as the risk allele.24-27 Hazard ratios of events were computed as esti-
mates of relative risk. To account for possible confounding we excluded all subjects 
with previous myocardial infarctions at baseline (Model 2) and computed relative 
risks in a multivariate model containing the following predictors of coronary heart 
disease: age, BMI, age at menopause, use of HRT, systolic blood pressure, smoking, 
diabetes mellitus, total and HDL-cholesterol (Model 3).28 For the analysis of fatal 
and non-fatal IHD, participants who did not have an IHD event during follow-up 
were categorized as the reference group. To study the risk of suffering a fatal IHD 
event between carriers and non-carriers of the ERα haplotypes a logistic regression 
model was used with the above mentioned cardiovascular risk factors as covari-
ates. 
For missing data on categorical covariates, we used a missing value indicator, 
whereas for missing data on continuous covariates, we used the median value of 
the respective value as calculated from the total sample. Missing values did not 
exceed 3.5% for any covariate. For all statistical analysis p-values below 0.05 were 
considered statistically signifi cant. All statistical analyses were performed using 
SPSS version 11.0.1 (SPSS Inc., Chicago, USA).
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RESULTS
We observed the four possible PvuII-XbaI haplotype alleles in the following 
frequencies: haplotype 1 (T-A) 53.5%, haplotype 2 (C-G) 34.7%, haplotype 3 (C-
A) 11.8% and haplotype 4 (T-G) was present in 1 allele in 12,816 chromosomes. 
Genotype distributions were in Hardy-Weinberg equilibrium (HWE).
The baseline characteristics of the study population are shown in Table 1. ERα 
haplotype 1 (PvuII T-allele and XbaI A-allele) was associated with diastolic blood 
pressure in women (p = 0.03). 
Follow-up started at the time of inclusion into the study (between July 5th, 
1989 and September 21st, 1993) and ended either on the 1st of January 2000 or, 
when earlier, at the participant’s death. The mean follow-up duration was 7.0 years 
(standard deviation 2.0 years; range 18 days to 10.5 years). Of the 6408 participants, 
1474 (23.0%) died of various causes during follow-up and 167 were lost to follow-up 
(2.6%). Two-hundred and eighty-fi ve (4.4%) participants had an incident myocar-
dial infarction during follow up, of which 53 (18.6%) were fatal and 232 (81.4%) 
non-fatal. Four-hundred and forty (6.9%) participants had an incident IHD event, 
of which 97 (22.0%) were fatal and 343 (78.0%) non-fatal. 
In the 3791 postmenopausal women in our study, ERα haplotype 1 was sig-
nifi cantly associated with increased risk of myocardial infarction as well as IHD 
(Table 2, Model 1). Exclusion of 303 women with prevalent myocardial infarctions 
at baseline and adjustment for age (Table 2, Model 2) and subsequently for BMI, 
age at menopause, use of HRT, diastolic blood pressure, smoking, diabetes mel-
litus, and total and HDL-cholesterol did not essentially change the results (Table 2, 
Model 3). As compared to non-carriers, heterozygous carriers of haplotype 1 were 
at a 2.23 times increased risk of myocardial infarction (95% confi dence interval 
(CI) 1.13-4.43), while homozygous carriers were at 2.48 times increased risk (95% 
CI 1.22-5.03). For IHD the risk for heterozygous carriers was 2.04 times increased 
(95% CI 1.16-3.58), for homozygous carriers the risk was 2.41 times higher (95% 
CI 1.35-4.31). Adjustment for current use of HRT, as opposed to any prior HRT 
use, did not infl uence the estimates. In women, ERα haplotype 2 showed an op-
posite, but non-signifi cant effect on IHD risk compared to haplotype 1: for incident 
myocardial infarctions the hazard ratio was 0.76 (95% CI 0.55-1.05) per copy of the 
“C-G” allele and 0.78 (95% CI 0.59-1.01) per allele copy for IHD. No association 
with myocardial infarction or IHD was observed for the ERα haplotype 3 (S.C.E. 
Schuit, unpublished data, November 2003). 
The two polymorphisms were also analyzed separately. Given the strong link-
age disequilibrium between the PvuII and XbaI polymorphisms and the virtual 
non-existence of haplotype 4, haplotype 1 fully represents the PvuII polymorphism. 
Therefore, the results for haplotype 1 presented here are exactly the same as for the 
PvuII polymorphism alone. The TT-genotype group is represented by the absence 
of haplotype 1, and the TC- and CC-genotypes by the presence of one or two copies 
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of haplotype 1, respectively. The XbaI A-allele was non-signifi cantly associated with 
myocardial infarction risk (hazard ratio 1.31 (95% CI 0.96-1.80) per copy of the 
A-allele) and IHD (hazard ratio 1.29 (95% CI 0.99-1.68) per copy of the A-allele).
In the 2617 men in our study the ERα haplotypes were not signifi cantly associ-
ated with incident myocardial infarctions or IHD (Table 2 for haplotype 1). 
Figure 1 shows the association between ERα haplotype 1 and the cumulative 
proportional hazard of incident myocardial infarction during follow-up in women, 
after exclusion of participants with a prevalent myocardial infarction at baseline and 
adjustment for cardiovascular risk factors. Table 3 shows that, for postmenopausal 
women, the effect of haplotype 1 on fatal IHD was larger than on non-fatal IHD; 
the hazard ratio for fatal IHD was 6.13 (95% CI 1.41-26.68) for extreme genotypes 
and 1.86 (95% CI 0.97-3.56) for non-fatal IHD. For the effect of haplotype 1 on fa-
tal and non-fatal myocardial infarctions results were similar. In women who do not 
carry haplotype 1, 13.3% of IHD events were fatal, for heterozygous carriers this 
was 26.9% and 34.0% for homozygous carriers. This resulted in cardiovascular risk 
factor adjusted odds ratios of 3.66 (95% CI 0.56-23.80) for heterozygous and 4.39 
Figure 1. 
Myocardial infarction hazard curve for women according to ERα haplotype 1 (T-A) 
in 3488 women.
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(95% CI 0.69-28.06) for homozygous carriers versus non-carriers. For myocardial 
infarctions the odds ratios were similar. 
In addition, we analyzed the fi rst year cumulative mortality in the 168 women 
who had an IHD event during follow up. Although these results did not reach 
statistical signifi cance, Figure 2 shows that the fi rst year mortality due to all causes 
in female homozygous carriers of haplotype 1 is approximately twice that of non-
carriers. 
DISCUSSION
In this prospective population-based study, we show an increased risk of myo-
cardial infarctions in postmenopausal women who carry of ERα haplotype 1 (PvuII 
T-allele and XbaI A-allele), while in men no association was seen. The risk estimates 
did not change after adjusting for clinically relevant cardiovascular risk factors, in-
dicating that ERα haplotype 1 is an independent risk factor. Heterozygous carriers 
of haplotype 1 had a 2.23 times increased risk of myocardial infarction as compared 
Figure 2. 
First year cumulative mortality in 168 women with an IHD event.
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to non-carriers, while homozygous carriers had a 2.48 times increased risk. We 
also analyzed the risk of IHD events by taking together myocardial infarctions as 
well as revascularization procedures (PTCA and CABG) and IHD mortality. Using 
this approach, we included approximately 50% more events and observed a similar 
increased risk in female carriers of haplotype 1. In men no association between the 
ERα haplotypes and myocardial infarction or IHD risk was observed.
In women, the effect of haplotype 1 on fatal IHD was larger than on non-fatal 
IHD and carriers of haplotype 1 died more often as a result of IHD. Furthermore 
the fi rst year cumulative mortality after IHD was two times higher in women 
homozygous for haplotype 1 as compared to non-carriers. This is mainly due to 
genotype-dependent differences in mortality within the fi rst month after an IHD 
event. Although the latter two analyses did not reach statistical signifi cance, these 
results suggest that postmenopausal women who carry ERα haplotype 1 are not 
only twice as likely to have an IHD event, they are also more likely to die from it.
A number of possible indirect as well as direct ERα-dependent mechanisms via 
which estrogens may exert their cardioprotective effects have been presented in 
the literature.29,30 Some of the protective effects of estrogens could potentially be 
mediated through systemic effects such as changes in lipid profi le, coagulation and 
fi brinolytic systems.29 However, in our study the ERα PvuII and XbaI genotypes 
were not associated with differences in a number of cardiovascular risk factors at 
baseline such as hypertension, hypercholesterolemia and diabetes mellitus. This is 
in accordance with two previous studies that have shown that the PvuII and XbaI 
genotypes were not associated with baseline cholesterol levels in healthy men and 
postmenopausal women, as well as in men and women with pre-existing coronary 
artery disease.31,32 Furthermore, when our analyses were adjusted for the presence 
of these and other common cardiovascular risk factors, the observed hazard ratio 
did not fundamentally change. This suggests that it is not through these patho-
physiological pathways that ERα gene polymorphisms infl uence IHD disease, but 
that this haplotype is an independent risk factor. 
Direct actions of estrogen on blood vessels could contribute substantially to the 
cardioprotective effects of estrogen.29,33,34 One of these direct actions on the blood 
vessel wall that may be essential in IHD pathology is the infl uence of estrogen on 
nitric oxide (NO) production. Endothelial cell-derived NO plays a critical role in 
cardiovascular disease pathology. NO, a primary vascular target of estrogens, not 
only causes the relaxation of the vascular smooth muscle cells, but also inhibits 
platelet activation.35 Estrogen increases NO production in vessels such as the aorta 
by increasing the expression and enzymatic activity of the enzyme responsible 
for NO synthesis, endothelial NO synthase (eNOS), as well as by inducing the 
release of NO. Several studies have shown that ERα is essential to all three of these 
estrogen effects on vascular NO production.36-39 This is further supported by the 
observation that basal production of endothelium-derived NO was signifi cantly 
lower in the aorta of ERα knock-out mice compared to wild-type mice.40 Studies 
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have shown that ERα also mediates two other effects of estrogen in the vessel 
wall: acceleration of re-endothelialization and inhibition of the vascular injury 
response.41,42 Particularly the latter two mechanisms may explain why the ERα 
polymorphisms are most strongly associated with fatal IHD.
How could these specifi c polymorphisms in the ERα gene infl uence myocardial 
infarction risk in postmenopausal women? The PvuII and XbaI polymorphisms 
have been an important area of research in diseases such as osteoporosis,24,43,44 
cardiovascular disease,31 and cancer.45 A number of hypotheses for the functional 
signifi cance of these polymorphisms have been reported in the literature. Given 
their location, 397 and 351 basepairs upstream from the start of exon 2, possible 
functional mechanisms include altering ERα expression via altered binding of tran-
scription factors and infl uencing alternative splicing of the ERα gene. Both these 
mechanisms can be a direct result of either of these polymorphisms or through 
linkage disequilibrium with a truly functional, but so far unknown, sequence 
variation elsewhere in the ERα gene. The fi rst mechanism was recently supported 
by fi ndings of Herrington et al.15 which were confi rmed in our own laboratory 
(S.C.E. Schuit, unpublished data, November 2003). Herrington et al. showed that 
the PvuII T-allele eliminates a functional binding site for the transcription factor 
B-myb. This suggests that presence of this allele may result in lower ERα transcrip-
tion. In the presence of a decreased number of alpha estrogen receptors, estrogen 
signaling may be less effective and, therefore, estrogen actions may be decreased. 
These fi ndings are further supported by the observation in our study population, 
as well as in others, that this PvuII T-allele has previously been associated with a 
number of phenotypes that are known to be related to low estradiol levels and 
therefore low estrogen activity, such as increased risk of osteoporosis, decreased 
risk of osteoarthritis, and hysterectomy, lower BMI, shorter stature, and later age 
at menopause.10,24-27 In our study, we have found the T-allele to be associated with 
increased risk of myocardial infarction and IHD events in postmenopausal women. 
This suggests that the potentially lower ERα expression caused by the presence 
of the T-allele at the -397 polymorphic site may lead to a higher susceptibility to 
IHD. The fact that the XbaI A-allele is also associated with IHD may be due to 
linkage disequilibrium with the PvuII SNP or to functional signifi cance of the XbaI 
polymorphism itself. 
An intriguing aspect of this study is that ERα haplotype 1 is signifi cantly 
associated with an increased risk of IHD in women, but not in men. Recently, 
Shearman et al. also reported an association between the PvuII polymorphism and 
cardiovascular disease in the Framingham Heart Study.46 This study found that 
the PvuII T-allele prevented IHD in men. This is seemingly in contrast to our 
fi ndings that the T-allele prevents IHD in women in our study. However, there 
is not a clear confl ict with the seemingly opposite results reported by Shearman 
et al. since the men in our study showed a non-statistical trend opposite to the 
women. Furthermore, the men in the Rotterdam Study were much older than the 
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men from Framingham Heart Study and we know that effects of risk factors often 
change in older cohorts. Furthermore, the Framingham Heart Study had very few 
cardiovascular events in women, for example only 3 cases of myocardial infarction 
were documented in the female participants of that study. 
An explanation for these opposing results in men and women is not immediately 
apparent. The most obvious difference between men and postmenopausal women 
is the cessation of gonadal function in women. Perhaps the presence of an intact 
hypothalamic-pituitary-gonadal (HPG) axis in men leads to protection of the ERα 
PvuII T-allele on cardiovascular disease, while in postmenopausal women, who are 
completely dependent on peripheral conversion to estradiol, an opposing effect oc-
curs. In men, compared to postmenopausal women of the same age, estradiol levels 
are approximately three times higher (S.C.E. Schuit, unpublished data, November 
2003). Apparently in the presence of suffi ciently high estradiol levels, differences in 
ERα expression do not have clinical consequences. However, estrogen defi ciency 
after menopause in combination with lower ERα expression caused by the PvuII 
T-allele may lead to a higher susceptibility to IHD. This could explain why we did 
not see an association between ERα gene polymorphisms and IHD in men. 
There are limitations to genetic association studies. They can be infl uenced by 
population stratifi cation or heterogeneity. This is especially true for case-control 
studies in a population of mixed racial origin. However, for our study a popula-
tion-based prospective cohort study-design was chosen and all subjects were of 
Dutch Caucasian origin. Furthermore, the PvuII and XbaI genotypes were in 
Hardy-Weinberg equilibrium and haplotype frequencies were similar to those 
found in other studies of Caucasian subjects.47 Therefore, our study population may 
be considered ethnically homogeneous and representative of the Dutch popula-
tion. Another limitation of association studies is the defi nition of the phenotype 
of interest and the occurrence of phenotype heterogeneity. We diagnosed incident 
myocardial infarctions and IHD in strict adherence to the ICD-10 guidelines and 
consulted hospital discharge letters and reports from treating specialists to identify 
cardiovascular disease events. Therefore, we feel that phenotype heterogeneity will 
not have infl uenced our results. Furthermore, in the Netherlands the only way to 
access specialist and hospital care is by consulting a general practitioner. Therefore, 
checking the general practitioners’ medical records for all participants should have 
resulted in a near complete follow-up. As can be said for all association studies, the 
validity of genetic association studies is greatly strengthened by confi rmation of the 
results. The fi ndings reported in this study are supported by not only functional 
studies, but also by associations with other phenotypes (pleiotropy) in women such 
as osteoporosis, osteoarthritis, hysterectomy, BMI, stature and age at menopause. 
The presented body of data supports the theory that in women the presence of the 
PvuII T-allele leads to lower estrogen action. 
Selective non-response of subjects with impaired health, or otherwise at an 
increased risk of cardiovascular disease, may have occurred. However, such a 
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non-response bias will presumably not be genotype dependent and will not lead to 
overestimation of the hazard ratios. 
In interpreting the clinical implications of these results we must take in account 
that 78% of the population is carrier of the ERα haplotype 1 risk allele and that 
heterozygous and homozygous carriers of haplotype 1 have a two-fold increased 
risk of IHD. Perhaps we should view this not as a “risk” allele, but consider the 
non-carriers as having a protective allele. This implies that non-carriers (22% of 
the population) have a 50% reduced risk. 
In conclusion, this population-based prospective cohort study shows a signifi -
cant two-fold increased risk of incident myocardial infarction, as well IHD events, 
in postmenopausal women who carry ERα haplotype 1 (PvuII T-allele and XbaI 
A-allele). The association was not explained by known cardiovascular risk factors 
such as age, previous myocardial infarction, BMI, age at menopause, use of HRT, 
blood pressure, smoking, diabetes mellitus and cholesterol. Therefore, haplotype 
1 is an independent risk factor for IHD. Furthermore, our results also suggest that 
postmenopausal women who carry ERα haplotype 1 are not only twice as likely to 
have an IHD event, they are also more likely to die from it.
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ABSTRACT
Lacunar brain infarcts and cerebral white matter lesions are frequently seen 
on MRI scans in elderly people. These lesions probably result from cerebral small 
vessel disease. Since the risk of cerebrovascular disease is different between men 
and women, estrogens and estrogen receptor genes may play a role. We studied the 
role of common sequence variations in the ERα gene in relation to infarcts and 
white matter lesions.
From the Rotterdam Scan Study, a population-based, prospective cohort study 
of participants aged 60 years and over, 522 non-demented men and postmenopausal 
women underwent cerebral MRI scanning and ERα PvuII-XbaI haplotypes were 
determined. 
In postmenopausal women ERα PvuII-XbaI haplotype 1 (allele frequency 
54.6%) was associated with a two to three times increased risk of brain infarcts 
on MRI and increased severity of subcortical white matter lesions, both in an al-
lele-dose dependent manner. In men, opposite effects were observed, male carriers 
of haplotype 1 had signifi cantly less severe periventricular as well as subcortical 
white matter lesions. Furthermore, although the association was not signifi cant, 
male carriers of haplotype 1 tended to have brain infarcts on MRI less frequently. 
These associations were independent of known cardiovascular risk factors such as 
age, BMI, smoking, systolic blood pressure, diabetes mellitus, total and HDL-cho-
lesterol, age at menopause and ever use of HRT. The fi ndings in women are in line 
with a previous report by the Rotterdam Study that ERα haplotype 1 was associated 
with a two-fold increased risk of ischemic heart disease in postmenopausal women, 
but not in men.
In conclusion, in postmenopausal women, the ERα PvuII-XbaI haplotype 1 al-
lele increases the risk of cerebral small vessel disease related lesions on MRI, while 
in men an opposite effect is seen. 
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INTRODUCTION
Brain infarcts and cerebral white matter lesions are frequently observed on 
magnetic resonance imaging (MRI) scans in elderly people.1,2 These lesions are 
associated with an increased risk of stroke and dementia.3-5 They are considered 
to be caused by ischemic small vessel disease and have a multifactorial etiology. 
However, the exact pathogenesis is not fully understood.
 Epidemiological and animal-based studies provide strong evidence that genetic 
factors are important in the pathogenesis of cerebrovascular disease.6 A number of 
monogenetic disorders responsible for cerebrovascular disease have been identifi ed, 
but the prevalence of each is quite low.6 Therefore, the population-attributable risk 
of cerebrovascular disease due to these disorders is also very limited. The majority 
of cases of cerebrovascular disease in the general population are multifactorial in 
etiology and here genetic factors are expected to play an important role. As in other 
complex traits, classical patterns of inheritance can not be demonstrated and the 
genetic etiology is polygenic.
The risk of stroke in women between puberty and menopause is almost half 
the risk in age-matched men.7,8 However, this gender difference diminishes within 
ten years after menopause.9,10 This observation has led to the suggestion that it 
is the lowering of endogenous estrogen following menopause that may be the 
critical factor in removing the relative protection against stroke women have in 
their pre-menopausal years. Furthermore, lacunar brain infarcts and white matter 
lesions seem to be more frequent in elderly women than men,4,11 indicating a role 
for estrogen in cerebral small vessel disease pathology.
Common variations in the gene encoding estrogen receptor α (ERα, also 
known as ESR1) that alter its expression or function may account for some of 
the genetic variability in the general population, especially in postmenopausal 
women. ERα, the most well studied of the two estrogen receptors (the other being 
ERβ), regulates gene expression resulting in transcription activation of numerous 
genes. ERα gene expression has been identifi ed in a number of human vascular 
tissues such as endothelial cells and vascular smooth muscle cells.12,13 Several single 
nucleotide polymorphisms (SNP) and variable number tandem repeats (VNTR) 
polymorphisms have been identifi ed in the ERα gene (http://www.ncbi.nlm.nih.
gov). Of the polymorphisms identifi ed, the PvuII and XbaI SNPs, located in the 
fi rst intron 397 and 351 basepairs upstream of exon 2, are the most widely studied 
so far. The haplotype created by these two SNPs has recently been associated with 
cardiovascular disease risk in women in our study population.14 
The aim of this study was to determine whether polymorphisms in the ERα 
gene are associated with prevalent brain infarcts and the extent of white matter 
lesions on MRI in men and postmenopausal women aged 60 years and older. 
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METHODS
Study population
This study is based on the Rotterdam Study, a large prospective population-
based study in 7983 elderly aged 55 years or older that aims to assess determinants 
of diseases in later life.15 The Medical Ethics Committee of Erasmus Medical 
Center approved the study protocol and participants gave written informed 
consent. Baseline examinations took place from 1990 to 1993. In 1995 to 1996, a 
random selection was made of 965 living members of the cohort in strata of age 
(5-years strata from 60 to 90) and sex for participation in the Rotterdam Scan 
Study. As part of the eligibility criteria, we excluded persons who had dementia at 
the time of selection (n=17) and persons who had contraindications to undergo 
MRI (n=116). This left 832 participants eligible. MRI images were obtained for 563 
(68%) of these eligible subjects in 1995 and 1996. Participants of non-Caucasian 
decent (n=7) were excluded from analyses and all women were postmenopausal. 
Data on cardiovascular risk factors was not available for 41 individuals leaving 522 
participants (258 women). 
Cardiovascular risk factors
Cardiovascular risk factors were obtained by interview and physical examination 
from 1995 to 1996. Interview information, including smoking habits (never, current, 
former smoker), age at menopause and use of hormone replacement therapy (HRT, 
ever versus never use), was obtained by a trained research assistant. Participants were 
asked to bring all prescribed medication to the research center, where a physician 
checked the indication for use. Body mass index (BMI) was calculated as weight in 
kilograms divided by height in meters squared. Blood pressure was measured twice 
using a random zero sphygmomanometer with the subject in sitting position and 
the results were averaged. Hypertension was defi ned as a systolic pressure ≥ 140 
mmHg or a diastolic pressure ≥ 90 mmHg, or use of antihypertensive medication. 
Diabetes mellitus was defi ned as the use of oral anti-diabetics, insulin or a random 
or post-load glucose level of 11.1 mmol/l or higher. Serum total cholesterol and 
HDL-cholester were determined by an enzymatic procedure.16 
Cerebral Infarcts and White Matter Lesions
Axial T1-, T2- and proton density-weighted scans were made on a 1.5-T MRI 
scanner (MRVISION, Siemens, Germany) as described previously.5 Slices were 5 
mm tick with an interslice distance of 1 mm. Infarcts were defi ned as ≥ 3 mm focal 
hyperintensities on T2-weighted images. Lesions in the white matter also had to 
have corresponding prominent hypointensities on T1-weighted images to distin-
guish infarcts from cerebral white matter lesions. Lacunar infarcts were defi ned 
as infarcts 3 to 20 mm in size and located in the subcortical white matter or basal 
ganglia. 
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White matter lesions were considered present if visible as hyperintense on 
proton density and T2 weighted images, without prominent hypointensity on T1 
weighted scans. We summed three region specifi c semiquantitative grades (lesions 
adjacent to the frontal horns, the lateral walls, and the occipital horns of the lateral 
ventricle) to get a total periventricular white matter lesions grade (range 0-9). We 
counted subcortical white matter lesions in three size categories based on their 
maximal diameter (< 3 mm, 3-10 mm, >10 mm). A total volume was approximated 
by assuming that these subcortical lesions were spherical with a fi xed diameter 
(volume range 0-29.5 ml). Both intra-rater and inter-rater studies (n=100) showed a 
good to excellent agreement (κ = 0.79-0.90, r = 0.88-0.95).17
Genotyping
Genomic DNA was isolated from peripheral leucocytes by standard procedures. 
Genotypes were determined using the Taqman allelic discrimination assay. Primer 
and probe sequences were optimized using the SNP assay-by-design service of 
Applied Biosystems (Nieuwerkerk aan den IJssel, The Netherlands). For details 
see http://store.appliedbiosystems.com. Reactions were performed on the Taqman 
Prism 7900HT 384 wells format. We used the genotype data for each of the two 
polymorphisms to infer frequency of the haplotype alleles present in the popula-
tion using the program PHASE.18 The alleles were defi ned as haplotypes such as 
“C-G” representing the C-allele for the PvuII SNP and the G-allele for the XbaI 
SNP. Haplotype alleles were coded as haplotype numbers 1 through 4 in order of 
decreasing frequency in the population (1=T-A, 2=C-G, 3=C-A, and 4=T-G). 
Statistical analysis
One-way analysis of variance (ANOVA), linear regression and Pearson’s chi-
square were used to compare baseline characteristics between subjects grouped by 
the PvuII-XbaI haplotype of interest. 
The association between PvuII-XbaI haplotypes and mean values for size and 
grade of periventricular and subcortical white matter lesions was evaluated by 
stratifying subjects by gender and allele copy number (0,1 or 2) for the haplotype of 
interest and using a multivariate linear regression model. Based on previous analy-
ses we chose haplotype 1 as the risk allele.14,19-22 To evaluate the association with 
cerebral infarcts a multivariate logistic regression model was used. In the analyses 
with lacunar infarcts, people with non-lacunar infarcts were excluded. Since con-
founding may have infl uenced the observed associations, the analyses were adjusted 
for predictors of cerebrovascular disease: age, BMI, age at menopause, use of HRT, 
systolic blood pressure, smoking, diabetes mellitus, total and HDL-cholesterol.
We allowed for three possible models to explain differences between genotype 
groups, i.e., an allele dose effect, a dominant effect, or a recessive effect. Allele dose 
was defi ned as the number of copies of the haplotype. 
All statistical analyses were performed using SPSS version 11.0.1 (SPSS Inc., 
Chicago, USA).
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RESULTS
We observed the four possible ERα PvuII-XbaI haplotype alleles in the follow-
ing frequencies: haplotype 1 (T-A) 54.6%, haplotype 2 (C-G) 35.6%, haplotype 3 
(C-A) 9.8% and haplotype 4 (T-G) was not present in our population. Genotype 
distributions were in Hardy-Weinberg equilibrium (HWE) and similar between 
genders and across age categories.
The baseline characteristics of the 522 participants in our study population are 
shown in Table 1. ERα PvuII-XbaI haplotype 1 (“T-A”) was not associated with any 
of the baseline characteristics. 
MRI diagnosed cerebral infarcts were found in 138 (26.4%) participants. Of 
these 115 (83.3%) were lacunar infarcts. In the 258 postmenopausal women in our 
study, PvuII-XbaI haplotype 1 was signifi cantly associated with brain infarcts in an 
allele-dose dependent manner (Table 2). After adjustment for the cardiovascular 
risk factors age, BMI, systolic blood pressure, smoking, diabetes mellitus, total and 
HDL-cholesterol, age at menopause and ever use of HRT, homozygous carriers of 
haplotype 1 were at a 2.95 (95% confi dence interval (CI) 1.09-8.04) times increased 
risk of having one or more brain infarcts visible by MRI as compared to non-
carriers, while heterozygotes were at a 2.34 (95% CI 0.91-6.02) times increased 
risk. In looking specifi cally at lacunar brain infarcts a similar allele-dose dependent 
association with ERα haplotype 1 was observed. In women, ERα haplotype 2 
showed a signifi cant, opposite allele-dose effect on brain infarcts: the odds ratio 
for homozygous carriers versus non-carriers was 0.21 (95% CI 0.06-0.81; results 
not shown). No association between ERα haplotype 3 and brain infarcts was found 
(results not shown). 
Although no signifi cant association was found between ERα haplotypes and 
brain infarcts in the 264 male participants of our study, brain infarcts on MRI were 
seen less often in male carriers of haplotype 1 than in non-carriers (Table 2). 
The overall mean subcortical white matter lesion volume was 1.8 ml (SD 3.4 
ml) and the mean periventricular WML grade was 2.8 (SD 2.2). In both men 
and women, white matter lesions were associated with ERα haplotype 1 (Table 
3). In postmenopausal women, ERα haplotype 1 was associated with an almost 
two times greater severity of subcortical white matter lesions (p-trend = 0.04). For 
periventricular white matter lesions similar results were seen, however, statistical 
signifi cance was not reached. In men, ERα haplotype 1 was signifi cantly associ-
ated with a two times lower volume of subcortical (p-trend = 0.05) white matter 
lesions. For periventricular white matter lesions similar signifi cant results were seen 
(p-trend = 0.03). Adjustment for cardiovascular risk factors did not change these 
associations. 
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DISCUSSION
The present population-based study demonstrates that in postmenopausal 
women ERα PvuII-XbaI haplotype 1 is associated with increased risk of cerebral 
infarcts on MRI and increased severity of white matter lesions. In men, opposite 
effects were observed, haplotype 1 was signifi cantly associated with decreased 
white matter lesion severity. Although statistical signifi cance was not reached, brain 
infarcts were seen less often in male carriers of haplotype 1 than in non-carriers. 
These associations were independent of known cardiovascular risk factors such 
as age, BMI, smoking, systolic blood pressure, diabetes mellitus, total and HDL-
cholesterol age at menopause and ever use of HRT. 
Brain infarcts and white matter lesions were frequent in our population and are 
associated with an increased risk of stroke and dementia.3-5 Several lines of evidence 
support the idea that estrogen and the ERα are important in the pathogenesis in 
cerebrovascular disease. Schmidt et al. reported a lower incidence and less extensive 
white matter hyperintensities, and smaller total white matter hyperintensity areas 
on MRI scans in women on hormone replacement therapy.23 This was interpreted 
as refl ecting less silent ischemic brain damage in estrogen users. In addition, the 
total volume of white matter hyperintensity areas was inversely related to the dura-
tion of estrogen therapy. Evidence supporting a mediatory role for ERα in estrogen 
related neuroprotection has been reported by Dubal et al. They demonstrated 
that following middle cerebral artery occlusion in rats, ERα expression was highly 
upregulated in the injured cerebral cortex.24 Furthermore, they also established that 
ERα is a critical mechanistic link in mediating the protective effects of estradiol 
in brain injury.25 Finally, Sawada et al. reported that administration of a potent 
ER antagonist dramatically increased infarct size in female rats following middle 
cerebral artery occlusion.26
A number of possible indirect as well as direct ERα-dependent mechanisms 
via which estrogens may exert their cardioprotective effects have been presented 
in the literature.27,28 Some of the protective effects of estrogens could potentially 
be mediated through systemic effects such as changes in lipid profi le, coagulation 
and fi brinolytic systems.27 In our study, ERα PvuII-XbaI genotypes were not associ-
ated with differences in a number of cardiovascular risk factors at baseline such 
as hypertension, hypercholesterolemia and diabetes mellitus. Furthermore, when 
our analyses were adjusted for the presence of these and other common cardiovas-
cular risk factors, the observed hazard ratio did not fundamentally change. These 
fi ndings suggest that it is not through these known risk factors that ERα gene 
polymorphisms infl uence cerebrovascular disease. However, we can not exclude a 
role for the coagulation and fi brinolytic systems.
Direct actions of estrogen on blood vessels could contribute substantially to 
the vascular protective effects of estrogen.27,29,30 One of these direct actions on 
the blood vessel wall that may be essential in ischemic cerebrovascular disease 
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pathology, is the infl uence of estrogen on nitric oxide (NO) production. NO, a 
primary vascular target of estrogens, not only causes the relaxation of the vascular 
smooth muscle cells; it also inhibits platelet activation.31 Estrogen increases NO 
production in vessels such as the cerebral microvessels by increasing the expression 
and activity of the enzyme responsible for endothelial NO synthesis (eNOS), as 
well as by inducing the release of NO. Several studies have shown that ERα is 
essential to all three of these effects of estrogen on vascular NO production.32-35 
This hypothesis is further supported by the observation that basal production of 
endothelium-derived NO was signifi cantly lower in the aortas of ERα knock-out 
mice compared to wild-type mice.36
The large majority (84%) of strokes detected by MRI are silent, that is there are 
no clinical manifestations, and most silent strokes (89%) are lacunar infarcts.4,37 
Cerebral brain infarcts, in particular lacunar brain infarcts, and white matter lesions 
are considered to be caused by ischemic small vessel disease.38 Perhaps augmented 
auto-regulation in small cerebral arteries due to changed NO action causes to the 
genotype-dependent differences in the prevalence of infarcts and white matter le-
sions.
How do these specifi c polymorphisms in the ERα gene infl uence cerebral infarc-
tion risk in postmenopausal women? The PvuII and XbaI polymorphisms have been 
an important area of research in diseases such as osteoporosis,22,39,40 cardiovascular 
disease,41 and cancer.42 A number of hypotheses for the functional signifi cance of 
these polymorphisms have been reported in the literature. Given their location, 397 
and 351 basepairs upstream from the start of exon 2, possible functional mechanisms 
include changed ERα expression via altered binding of transcription factors and 
infl uence on alternative splicing of the ERα gene. Both these mechanisms can be 
a direct result of either of these polymorphisms or through linkage disequilibrium 
with a truly functional, but so far unknown, sequence variation elsewhere in the 
ERα gene. The fi rst mechanism was recently supported by fi ndings of Herrington 
et al.43 and which were confi rmed in our own laboratory (chapter 5.1). Herrington 
et al. showed that the T-allele of the PvuII RFLP eliminates a functional binding 
site for the transcription factor B-myb. This implies that the presence of this allele 
may result in lower ERα transcription. This fi nding is supported by the observa-
tion in our study population, as well as in others, that the T-allele of the PvuII 
polymorphism is associated with increased risk of phenotypes that are known to be 
related to decreased estradiol-effectiveness such as osteoporosis,22 decreased risk of 
osteoarthritis and hysterectomy,21,44 shorter stature,19 and later age at menopause.21 
In our study, we have found the T-allele to be associated with increased risk of 
cerebral infarcts and white matter lesions in women in an allele dose-dependent 
manner. Lower ERα expression caused by the PvuII T-allele may be the functional 
mechanism behind this fi nding in females. In line with this hypothesis the fact that 
the XbaI polymorphism A-allele is also associated with estradiol levels may be due 
to linkage disequilibrium with the PvuII SNP or another functional polymorphism, 
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or due to functional signifi cance of the XbaI polymorphism itself. 
An intriguing aspect of this study as that opposing effects are observed in men 
and women. This is not the fi rst time opposite effects of ERα polymorphism have 
been reported in men and women. Recently, two studies have reported associations 
between these SNPs and cardiovascular disease risk: the Rotterdam Study and the 
Framingham Study.14,45 In the Rotterdam Study, ERα PvuII-XbaI haplotype 1 is 
an independent risk factor for myocardial infarction and other forms of ischemic 
heart disease in postmenopausal women.14 In men, no signifi cant association was 
observed with ischemic heart disease. In the Framingham study, Schearman et 
al. reported that the T-allele of the PvuII polymorphism prevented cardiovascular 
disease, including stroke in men.45 The association in women could not be exam-
ined due to lack of power. These fi ndings may be compared to our fi ndings for 
haplotype 1 since the PvuII polymorphism is fully represented by haplotype 1 given 
the strong linkage disequilibrium between the PvuII and XbaI SNPs,. Rather than 
concluding the results of Rotterdam and Framingham studies are contradictory, 
one may venture to theorize that ERα polymorphisms have opposing effects in 
men and women. Especially in light of the fi ndings of the present study where 
opposite effects of ERα haplotype 1were also seen in men and women. 
A paradoxical relationship seems to exist between ERα gene polymorphisms 
and gender. The Rotterdam Study recently reported an association between haplo-
type 1 and lower estradiol levels in postmenopausal women, a fi nding which may be 
inline with the increased risk cerebral infarcts and white matter lesions in women 
reported here.20 This study also reported a non-signifi cant trend in the opposite 
direction in men, male carriers of haplotype 1 tended to have higher estradiol levels 
then their non-carrier counterparts. It is hypothesized that the reason for such an 
opposite effect was that elderly men, in contrast to postmenopausal women, still 
have a largely intact hypothalamic-pituitary-gonadal (HPG) axis and estradiol still 
plays an important role in the regulation of gonadotropin release. These fi ndings 
fi t with our observation that these polymorphisms seem to play a protective role 
against cerebrovascular disease in men, but are a risk factor in women.
The overall picture presented by our results for the role of ERα gene polymor-
phisms in cerebral small vessel disease is that in women haplotype 1 is an inde-
pendent risk factor, while in men haplotype 1 is an independent protective factor. 
However, not all the associations were signifi cant in men and women. In women, 
cerebral infarcts and subcortical white matter lesions were signifi cantly increased. 
For periventricular lesions the same trend was observed in women, however sta-
tistical signifi cance was not reached. In men, both subcortical and periventricular 
lesions were signifi cantly decreased. Although a similar reduction of cerebral 
infarcts was observed in men, statistical signifi cance not reached. From our results 
we can not determine whether the non-signifi cant results for periventricular white 
matter lesions in women and cerebral infarcts in men are false-negative results 
or that different pathophysiological mechanisms are the basis. Differences in the 
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vascularization and susceptibility to hypoperfusion of the different brain regions 
might underlie the differences in associations.46 Further studies will be necessary to 
answer this question in the future.
The strengths of this study are the population-based design and the large num-
ber of elderly non-demented participants in whom both brain imaging and ERα 
genotyping are available. However, the possibility of population stratifi cation and 
related limitations, as cautioned for in all genetic association studies, can not be 
excluded. For the present study a population-based cohort study-design was chosen 
and all subjects were of Dutch Caucasian origin. Furthermore, the PvuII-XbaI 
genotypes were in Hardy-Weinberg equilibrium and haplotype frequencies were 
similar to those found in other studies of Caucasian subjects.47 Therefore, our study 
population may be considered ethnically homogeneous and representative of the 
Dutch population. We can not exclude that selection bias played a role in our fi nd-
ings since the response rate in our study was 54%. However, such a non-response 
bias will presumably not be genotype dependent and will not lead to overestimation 
of the hazard ratios. 
In conclusion, this population-based study showed an increased risk of cere-
brovascular disease in postmenopausal women who carry the ERα PvuII-XbaI hap-
lotype 1 allele. In men, this same allele protected against cerebrovascular disease. 
These associations were not explained or infl uenced by known cardiovascular risk 
factors such as age, previous myocardial infarction, BMI, age at menopause, use of 
HRT, blood pressure, smoking, diabetes mellitus and total and HDL-cholesterol. 
These fi ndings are in line with a previous report by the Rotterdam Study that ERα 
haplotype 1 is associated with a two-fold increased risk of ischemic heart disease in 
postmenopausal women14 and a report from the Framingham Study that haplotype 
1 is a protective factor against cardiovascular disease in men.45 
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ABSTRACT
Individual variation in postmenopausal estradiol (E2) level is an important de-
terminant of diseases such as osteoporosis. It has been suggested that the estrogen 
receptor alpha (ERα) gene may infl uence serum E2 levels, but the role of common 
sequence variations in the ERα gene is unclear. 
In 631 postmenopausal women and 528 men from the Rotterdam Study, a 
population-based, prospective cohort study of individuals aged 55 years and over, 
ERα PvuII-XbaI haplotypes were determined. In women, haplotype 1 (T-A) was 
signifi cantly associated with an allele-dose dependent decrease in E2. After adjust-
ing for age, BMI, years since menopause and testosterone levels, serum E2 levels 
decreased by 1.90 pmol/L per allele copy of this haplotype (p-trend 0.02). Extreme 
genotypes, representing 23% and 27% of the population, varied 3.93 pmol/L. No 
association with serum testosterone was observed. In a subset of 446 women, no 
association with dehydroepiandrosterone sulfate, androstenedione or estrone was 
seen. In men, none of the sex-hormone levels were associated with the ERα PvuII-
XbaI haplotypes.
In conclusion, we have demonstrated a role for genetic variations in the ERα 
gene in determining postmenopausal E2 levels in women. From our fi nding that 
E2 levels are, while estrone (E1) levels are not, associated with these ERα polymor-
phisms, we hypothesize that it is likely that these common sequences variants alter 
expression or activity of 17β-HSD subtype 1 or 7.
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INTRODUCTION
Estradiol (E2) has a general metabolic role that reaches far beyond reproductive 
processes. E2 levels play an important role in a number of diseases. For example, 
withdrawal of the effects of E2 after menopause from non-reproductive tissues such 
as the skeleton, the cardiovascular system, and the brain, constitutes a major risk 
factor for the development of osteoporosis, coronary artery disease and stroke in 
women. On the other hand, continuous exposure to E2 during the postreproductive 
part of life in the form of hormone replacement therapy (HRT) has been shown to 
be a risk factor for the development of coronary artery disease, stroke and breast 
cancer.1 Furthermore, individual variation in E2 levels has been associated with 
differences in the risk of osteoporosis2,3 and breast cancer.4 It is anticipated that this 
individual variation partially results from genetic variation (i.e. polymorphisms) in 
crucial genes that control hormone biosynthesis, metabolism and signal transduc-
tion.
One important candidate gene in determining serum E2 levels is the estrogen 
receptor alpha (ERα, also known as estrogen receptor 1, ESR1) gene. At fi rst glance, 
the importance of the most common of the two estrogen receptor genes (the other 
being the estrogen receptor beta) in E2 biosynthesis may not be obvious. However, 
E2 exerts its effects by binding to estrogen receptors that, once activated, regulate 
the expression of multiple genes. One of the genes E2 and ERα may regulate is 
the aromatase (also known as CYP19) gene, as recently found by Kinoshita et al.5 
Aromatase catalyzes the conversion of C19-steroids to estrogens and is essential for 
E2 biosynthesis. Kinoshita et al. found that E2, through ERα, can modulate CYP19 
gene expression in human breast cancer cells. Modulation of the CYP19 expression 
by E2 has also been shown in other vertebrates.
6
Several single nucleotide polymorphisms (SNP) and variable number tandem 
repeats (VNTR) polymorphisms have been identifi ed in the ERα gene (http://
www.ncbi.nlm.nih.gov). Of the polymorphisms identifi ed so far, the PvuII and 
XbaI SNPs, located in the fi rst intron 397 and 351 basepairs upstream of exon 
2, are the most widely studied. These polymorphisms have previously been as-
sociated with disease phenotypes such as osteoporosis, cardiovascular disease and 
cancer. 7-11 Recently a potential functional signifi cance of the PvuII polymorphisms 
was reported.12 The aim of the present study was to determine if these common 
ERα polymorphisms are associated with serum E2 levels in a population of both 
men and postmenopausal women aged 55 years and older. 
METHODS
Study population
The Rotterdam Study is a population-based, prospective cohort study of men 
and women aged 55 years and over. Rationale and design have been described 
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previously.13 All residents aged 55 or older of Ommoord, a district of Rotterdam, 
The Netherlands, were invited to participate. A total of 7983 men and women 
(78% of those eligible) entered the study. Base-line examinations, including a home 
interview and an extensive physical examination at the research center, took place 
between 1990 and 1993. The Rotterdam Study was approved by the medical eth-
ics committee of the Erasmus Medical Center and written informed consent was 
obtained from all participants. 
We determined serum hormone levels in a gender-stratifi ed random sample 
of 1159 subjects (631 women) who were able to visit the research center and for 
whom blood samples were available. Only subjects of Caucasian origin, as identifi ed 
by having four Caucasian grandparents, were included. All women selected were 
postmenopausal. Participants who used hormone supplements or corticosteroids 
at the time of blood drawing were excluded. Due to the limited amount of plasma 
per participant, not all hormone levels could be measured in all subjects. Serum E2 
and testosterone were determined in all of these participants. Levels of additional 
sex-hormones were available for 808 subjects (446 women). 
Clinical examination
At baseline, interview information, including smoking habits, use of medication 
and age at menopause, was obtained by a trained research assistant. Smoking was 
categorized as current, past or never smoker. Age at menopause responses were 
validated as described previously.14 Anthropometric measurements were obtained at 
the research center. Body mass index (BMI) was calculated as weight in kilograms 
divided by height in meters squared. 
Hormone assays
Non-fasting blood samples were drawn by venapuncture at the baseline ex-
amination in the research center between 08.30 and 16.00 h and time of blood 
draw was noted. Levels of steroid hormones were measured in plasma. For the 
collection of plasma, blood was collected in 5-ml tubes containing 0.5 ml sodium 
citrate solution. All tubes were stored on ice before and after blood sampling. 
Platelet-free plasma was obtained by two-stage centrifugation, fi rst for 10 min. at 
1600 x g at 4°C and then for 30 min at 7000 x g at 4°C. Platelet-free samples were 
immediately frozen in liquid nitrogen and transferred to the laboratory. At the labo-
ratory, plasma samples were stored at -80°C until hormone measurements. For the 
purpose of the present study, plasma levels of E2, testosterone, androstenedione, 
estrone (E1), dehydroepiandrosterone sulfate (DHEAS), and sex hormone binding 
globulin (SHBG) were estimated in 12 separate batches of samples using coated 
tube or double antibody radioimmunoassays purchased from Diagnostic Systems 
Laboratories, Inc. (Webster, TX). The mean minimum detection limit for E2 was 
4.8 pmol/l, which enabled us to study the association with ERα polymorphism at 
very low levels. Non-detectable estradiol was scored as zero. Due to the relatively 
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small volumes of plasma available, all values reported are single sample estimations. 
Intra-assay coeffi cients of variation, determined on the basis of duplicate results of 
internal quality control (QC) serum pools with 3 different levels of each analyte, 
were below 15% for all assays, with the exception of E2 (18%) and E1 (21%). Since 
inter-assay variations were relatively large (between 20 and 30%, with the exception 
of SHBG (14%) and testosterone (19%)) results of all batches were normalized by 
multiplying all concentrations within a batch with a factor, which made results 
for the internal QC pools comparable. This reduced inter-assay variations and 
was considered justifi ed because the patterns of the results of these pools and the 
mean results for male and female sera in one assay batch were very similar. Assays 
were performed blind with respect to information on the subject. Albumin was 
measured using a colorimetric method (KONE Diagnostics, Espoo, Finland). As 
a measure of bioavailable hormones, non-SHBG-bound testosterone and E2 were 
calculated on the basis of hormone, SHBG and albumin levels, and respective af-
fi nity constants according to the method described by Södergård et al.15 and van 
den Beld et al.16
Genotyping
All participants were genotyped for the PvuII and XbaI polymorphisms, lo-
cated 397 and 351 basepairs, respectively, upstream from the start of exon 2 in the 
ERα gene. Genomic DNA was isolated from peripheral leucocytes by standard 
procedures. Genotypes were determined using the Taqman allelic discrimination 
assay. Primer and probe sequences were optimized using the SNP assay-by-design 
service of Applied Biosystems (Nieuwerkerk aan den IJssel, The Netherlands). For 
details see store.appliedbiosystems.com. Reactions were performed on the Taqman 
Prism 7900HT 384 wells format. We used the genotype data for each of the two 
polymorphisms to infer frequency of the haplotype alleles present in the population 
using the program PHASE.17 The alleles were defi ned as haplotypes such as “C-G” 
representing the C-allele for the PvuII SNP and the G-allele for the XbaI SNP as 
described previously.9 The haplotype alleles were coded as haplotype numbers 1 
through 4 in order of decreasing frequency in the population (1 = T-A, 2 = C-G, 3 
= C-A, and 4 = T-G). 
Statistical analysis
One-way analysis of co-variance (ANCOVA) and Pearson’s chi-square tests 
were used to compare baseline characteristics between subjects in our study and 
the entire Rotterdam Study cohort.
The association between PvuII-XbaI haplotypes, sex hormone levels and pos-
sible confounders was evaluated by stratifying subjects by allele copy number 
(0, 1 or 2) for the haplotype of interest and using ANOVA, linear regression or 
Pearson’s chi-square tests. Based on previous analyses we chose haplotype 1 as the 
risk allele.9,14,18,19 To account for possible confounding, we adjusted the analysis of 
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sex-hormone levels for age, BMI, years since menopause and the direct precursor 
for each hormone when available.
Explained variance estimates were calculated by a stepwise linear regression 
model including age, BMI, smoking, years since menopause, testosterone and ERα 
haplotype 1 as independent variables. One hundred times the correlation coeffi -
cient squared was interpreted as the percentage variability in E2 explained by the 
polymorphisms of interest. 
All statistical analyses were performed using SPSS version 11.0.1 (SPSS Inc., 
Chicago, USA).
RESULTS
Baseline characteristics for the approximate 13% of the Rotterdam Study cohort 
that was included in our study, as compared to the entire cohort are shown in Table 
1. Fewer women (6.7%) were included compared to the entire Rotterdam Study 
cohort and participants in our study were 0.6 years younger. Participants of our 
study also tended to smoke more. Figure 1 shows the distribution of E2 values 
for men and women in our study as plotted against age. There was a signifi cant 
association between E2 levels and age in both men and women. 
We observed the four possible PvuII-XbaI haplotype alleles in the following 
frequencies: haplotype 1 (T-A) 52.5%, haplotype 2 (C-G) 35.5%, haplotype 3 (C-A) 
11.9% and haplotype 4 (T-G) in only 1 allele in 2,318 chromosomes. Genotype 
distributions were in Hardy-Weinberg equilibrium (HWE) and similar between 
genders and across age categories.
Figure 1. 
Measured estradiol levels in 631 female and 528 male participants, including linear 
regression line, correlation coeffi cient and p-values
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As observed previously,14 in the 631 postmenopausal women, a trend was 
observed for a later age at menopause per allele copy of haplotype 1 (Table 2). 
PvuII-XbaI haplotype 1 was associated with decreased serum E2 levels in an allele-
dose dependent manner; per copy of haplotype 1 E2 levels were 1.68 pmol/L lower 
(p-trend 0.05). After adjusting for age, BMI, years since menopause, and smoking, 
genotype dependent differences increased slightly and serum E2 levels decreased by 
1.90 pmol/L per allele copy of haplotype 1 (p-trend 0.02, Table 2). Extreme geno-
types differed 3.93 pmol/L (p=0.02). In this group ERα haplotype 1 explained 
an additional 1% above the effect of age, BMI, smoking, and age at menopause in 
the variation of E2 level (R square change 0.01, p=0.02). After excluding the 187 
women with E2 levels below the mean detection limit of 4.8 pmol/L, haplotype 1 
was still signifi cantly associated, per copy of haplotype 1 the serum E2 was 1.94 
pmol/L lower (p-trend=0.04). ERα haplotype 2 showed a similar signifi cant, but 
opposite allele-dose effect on serum E2 levels in women: per copy of haplotype 2 
E2 levels were 1.74 pmol/L higher (p-trend 0.05). The results remained similar after 
adjustment for age, BMI, years since menopause, smoking and testosterone levels. 
ERα haplotype 3 was not associated with serum E2 levels (results not shown). None 
of the ERα haplotypes was associated with serum testosterone (Table 2).
In the 528 men in our study PvuII-XbaI haplotypes were not associated with 
serum E2 or testosterone levels (Table 2 for haplotype 1). 
Within a subset of 446 postmenopausal women and 362 men, serum levels of 
other sex-hormones were also determined. As observed in the larger sample, in this 
Table 1. Characteristics of 1159 study participants compared to the entire 
Rotterdam Study cohort
Study
Rotterdam
Study P-value
Numbers (%) 1159 (12.7%) 7983
Women (%) 631 (54.4%) 4878 (61.1%) < 0.001a
Age (years) 69.7 (0.3) 70.3 (0.1) 0.05b
BMI (kg/m2) 26.2 (0.1) 26.2 (0.04) 0.9c
Age at menopause (yrs) 48.8 (0.2) 48.8 (0.08) 0.9b
Years since menopause (yrs) 21.7 (0.2) 21.7 (0.08) 0.9b
Smoking (%) 0.07a
Current 24.4% 22.6%
Past 42.4% 40.7%
Values are expressed as mean (standard error or percentage)
a Chi-square
b ANCOVA adjusted for gender
c ANCOVA adjusted for age and gender
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subset PvuII-XbaI haplotypes were not signifi cantly associated with age, BMI, age at 
menopause, years since menopause or smoking. Furthermore the larger sample of 
1159 participants was not statistically different from this subset of 808 participants 
in any of the above mentioned baseline characteristics. A signifi cant association be-
tween PvuII-XbaI haplotype 1 and serum E2 levels, as well as bioavailable E2 levels, 
was also observed in postmenopausal women in this subset, but not in men (Table 
3). No association between any of the PvuII-XbaI haplotypes and DHEA sulfate, 
androstenedione, E1, testosterone or free testosterone was observed in either men 
or women. 
DISCUSSION
The present population-based association study demonstrates that in postmeno-
pausal women ERα PvuII-XbaI haplotype 1 is associated with decreased serum E2 
levels in an allele-dose dependent manner. Homozygous carriers of haplotype 1 
constitute approximately one quarter of the population and have 3.93 pmol/L lower 
E2 levels as compared to non-carriers. This is a 22% reduction in E2 level. 
Our a priori hypothesis for studying the association between ERα gene poly-
morphisms and E2 levels was driven by recent evidence that ERα can modulate 
CYP19 expression in breast cancer cells.5 The authors of that experimental study 
found that in human breast cancer cells E2 up-regulates aromatase gene expression 
via ERα. We hypothesized that ERα gene polymorphisms may modulate the effect 
of E2 on CYP19 expression. Indeed, the ERα gene polymorphisms we studied were 
associated with E2 levels. However, aromatase not only catalyzes the conversion of 
testosterone to E2, but also the conversion of androstenedione to E1. If CYP19 ex-
pression is modulated by ERα polymorphisms then we would expect serum E1 levels 
to be infl uenced in parallel with levels of E2. Apart from chance, there is another 
explanation for this fi nding. When studying our results we noticed that, carriers 
of haplotype 1 did not have lower E1 levels. In fact, we observed a non-signifi cant 
trend in the opposite direction; carriers of haplotype 1 had higher E1 levels. This led 
us to hypothesize that it is not CYP19 that is infl uenced by these polymorphisms, 
but one of the 17β-hydroxysteroid dehydrogenase (17β-HSD) subtypes. 17β-HSD 
subtypes 1 and 7, which have been detected in a number of human non-gonadal 
tissues, selectively catalyze the transformation of E1 into E2.
20 Although regulation 
of 17β-HSD by E2 or ERα has not been shown so far, our results do suggest a role 
for ERα in 17β-HSD expression or activity. Future research will be necessary to 
show if this hypothesis is true.
How do these specifi c polymorphisms infl uence ERα gene expression and 
consequently serum E2 levels? The PvuII and XbaI polymorphisms have been an 
important area of research in diseases such as osteoporosis, cardiovascular disease, 
and cancer.7-11 A number of hypotheses for the functional signifi cance of these 
polymorphisms have been reported in the literature. Given their location, 397 and 
ERα polymorphisms and sex-hormones
131
351 basepairs upstream from the start of exon 2, possible functional mechanisms 
include changed ERα expression via altered binding of transcription factors and 
infl uence on alternative splicing of the ERα gene. Both these mechanisms can be 
a direct result of either of these polymorphisms or through linkage disequilibrium 
with a truly functional, but so far unknown, sequence variation elsewhere in the 
ERα gene. The fi rst mechanism was recently supported by fi ndings of Herrington 
et al.10 and were confi rmed in our own laboratory (manuscript in preparation). 
Herrington et al. showed that the T-allele of the PvuII RFLP eliminates a functional 
binding site for the transcription factor B-myb. This implies that the presence of 
this allele may result in lower ERα transcription. Our study reports that the PvuII 
T-allele, represented in haplotype 1, is associated with decreased serum E2 levels 
in an allele dose-dependent manner in postmenopausal women. This suggests that 
the potentially lower ERα expression caused by the PvuII T-allele leads to a lower 
expression of an enzyme in the estrogen synthesis pathway, such as 17β-HSD, and, 
subsequently, reduced E2 synthesis. These fi ndings are further supported by the 
observation in our study population, as well as in others, that this T-allele of the 
PvuII polymorphism is associated with increased risk of osteoporosis,9 decreased 
risk of osteoarthritis19 and hysterectomy,14 lower BMI,21 shorter stature,18 and later 
age at menopause.14 These phenotypes are known to be related to decreased E2 ef-
fects. The fact that the XbaI polymorphism A-allele is also associated with E2 levels 
may be due to linkage disequilibrium with the PvuII SNP or another functional 
polymorphism, or to functional signifi cance of the XbaI polymorphism itself. 
We observed the association between ERα polymorphisms and E2 levels only in 
postmenopausal women and not in men. A number of explanations arise. First, in 
contrast to women, men do not experience a cessation of gonadal function similar to 
menopause. Elderly men still have a largely intact hypothalamic-pituitary-gonadal 
(HPG) axis and E2 still plays an important role in the regulation of gonadotropin 
release. Therefore, in men the infl uence of ERα polymorphisms on enzymes in-
volved in the peripheral biosynthesis of E2 may be less important. Secondly, in men 
E2 levels are three times higher than in postmenopausal women; therefore, levels of 
ligand for the ERα may be suffi ciently high so that differences in ERα expression 
may not infl uence feed-back to other genes. Thirdly, the serum levels of the direct 
precursors to E2 in the biosynthesis pathway are a great deal higher in men than in 
postmenopausal women of the same age. Perhaps, in the presence of larger amounts 
of E2 precursors, genotype dependent differences in 17β-HSD expression may not 
lead to changes in E2 levels. Finally, in men testosterone is the main precursor to 
E2 and although the conversion of androstenedione to testosterone is also catalyzed 
by 17β-HSD, this is another subtype and not the subtypes 1 and 7 that catalyze the 
conversion of estrone to E2.
In interpreting the clinical implications of these results we must consider two 
important aspects. First, plasma levels of E2 do not necessarily refl ect local tissue 
levels. The circulating E2 level in postmenopausal women originates in extrago-
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nadal sites where it also acts locally. If this peripherally produced E2 escapes local 
metabolism, it enters the circulation. However, plasma levels of E2 are important 
in the pathology of a number of diseases. Individual variation in circulation levels 
of E2 has been shown to infl uence the risk of diseases such as osteoporosis
2,3 and 
breast cancer.4 Secondly, the variance in E2 levels explained by these ERα poly-
morphisms is 1%. Clearly the impact of this polymorphism on absolute E2 levels is 
not great. However, it is expected that a large number, perhaps hundreds, of genes 
and “low penetrance” polymorphisms will contribute to individual variation in E2 
levels. Each of these polymorphisms will thus explain only a small fraction. For 
example, polymorphisms in genes encoding other enzymes in the estradiol synthe-
sis pathway, such as the CYP19 gene encoding aromatase, will likely contribute to 
individual estradiol levels. Furthermore, interactions between these polymorphisms 
and environmental factors will also prove to be important. Although the contribu-
tion of these ERα polymorphisms to the variance in E2 levels may be low, its impact 
may be much greater. Average E2 levels for the extreme genotypes are above and 
below 15.5 pmol/L. Our research group has recently shown that individuals with 
E2 below this “cut-off” value have an increased risk of osteoporosis.
3 These fi nd-
ings suggest that the genotype dependent differences in E2 levels created by these 
polymorphisms may be clinically signifi cant.
The only other study showing an association between ERα gene polymorphisms 
and sex-hormone levels found an association with increased androstenedione and 
not E2.
22 This is in contrast to our fi ndings. Zofkova et al., in a study of 114 post-
menopausal women of Czech origin, found that the PvuII and XbaI polymorphism 
were not signifi cantly associated with E2 levels. Although the association was not 
signifi cant in their study, the PvuII T-allele and XbaI A-allele did also show a trend 
for lower E2 levels. Perhaps, the power of that study was insuffi cient to show a 
signifi cant association. Zofkova et al. did fi nd a signifi cant association between 
these alleles and higher androstenedione levels. We were not able to replicate these 
results in our larger study.
There are limitations to genetic association studies. First, they can be infl uenced 
by population stratifi cation or heterogeneity. This is especially true for case-control 
studies in a population of mixed racial origin. However, for our study a population-
based cohort study-design was chosen and all subjects were of Dutch Caucasian 
origin and had similar social backgrounds. Furthermore, the PvuII-XbaI genotypes 
were in Hardy-Weinberg equilibrium and haplotype frequencies were similar to 
those found in studies of other Caucasian subjects.23 Therefore, our study popula-
tion may be considered ethnically homogeneous and representative of the Dutch 
population. However, to be included in our study, participants had to be mobile 
enough to visit the research center to donate a blood sample. This will have led to 
a health selection bias, as observed in the fi nding that our subjects are somewhat 
younger that the entire Rotterdam Study cohort. However, such a healthy-responder 
bias will presumably not be genotype-dependent and we believe it will not have led 
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to bias in our results. Another limitation of association studies is the defi nition of 
the phenotype of interest. We used an E2 assay with an very low detection limit 
(4.8 pmol/L), and we excluded all participants with medication, such as hormone 
replacement therapy and corticosteroids, that could have infl uenced the hormone 
levels measured. However, due to the small volumes of plasma available, we were 
not able to run the assay in duplicate. Although the single sample measurement will 
have led to less precise estimations of plasma levels, this will only have led us to 
underestimate the strength of the association. 
In conclusion, this population-based study shows a signifi cant reduction in 
circulating E2 levels in carriers of ERα PvuII-XbaI haplotype 1 (“T-A”) in an al-
lele-dose dependent manner in postmenopausal women. The association was not 
explained or infl uenced by a number of known confounders such as age, years 
since menopause, BMI, smoking or levels of the precursor testosterone. From our 
fi ndings that E2 levels are, while E1 levels are not, associated with these ERα poly-
morphisms, we hypothesize that it is likely that these common sequences variants 
alter 17β-HSD expression or activity.
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ABSTRACT
Individual variation in postmenopausal estradiol (E2) level is an important de-
terminant of diseases such as breast cancer and osteoporosis. A large portion of this 
variation may be determined by genetic variations (i.e. polymorphisms) in genes 
that control hormone biosynthesis. The aim of this study was to determine if a 
common, possibly functional polymorphism, located in exon 10 (a T to C substitu-
tion in the 3’UTR) of the aromatase (CYP19) gene is associated with variation in 
serum estradiol levels in the general population. 
In 719 postmenopausal women and 589 men from the Rotterdam Study, a 
population-based cohort study of individuals 55 years and older, CYP19 genotypes 
and serum E2 levels were determined. The C-allele, which was previously related 
to decreased CYP19 mRNA expression by others, was signifi cantly associated with 
decreased serum E2 in postmenopausal women in an allele-dose dependent man-
ner. Serum E 2 levels decreased by 2.23 pmol/L per C-allele copy (p-trend 0.005); 
extreme genotypes varied 4.53 pmol/L. In a subset of 836 participants DHEA-sul-
fate, androstenedione, testosterone, bioavailable testosterone, estrone (E1) and bio-
available E2 were determined. In women, the C-allele was associated with decreased 
serum E1 and bioavailable E2 levels (p-trend 0.0001 and 0.001, respectively). In 
men, no association between the CYP19 polymorphism and sex-hormone levels 
was observed.
We previously demonstrated the estrogen receptor (ER) alpha gene PvuII-XbaI 
haplotype 1 to be associated with a 2 pmol/L decrease in E2 levels in postmeno-
pausal women. An additive effect of the CYP19 exon polymorphism and ER alpha 
haplotype 1 on E2 levels was observed. There was a 40% reduction in E2 levels in 
homozygous carriers of both risk alleles as compared to non-carriers. 
In conclusion, we have demonstrated a role for a polymorphism located in exon 
10 of the CYP19 gene in determining postmenopausal E2 and E1 levels.
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INTRODUCTION
Fluctuation of serum estradiol (E2) levels is a characteristic feature of the female 
reproductive cycle. During the reproductive years, the ovaries are the principal 
source of blood E2 levels and circulating levels are controlled by a sensitive feed-
back mechanism, the hypothalamic-pituitary-gonadal (HPG) axis, to maintain 
cycle regularity and reproductive function. However, after menopause the ovaries 
stop producing E2, this feedback mechanism ceases to function, and women 
are dependent on peripheral aromatization of adrenal androgens to produce E2 . 
The peripheral conversion to estrogens is insuffi cient to produce circulating E2 
levels resembling those before menopause and, consequently, circulating E2 levels 
in postmenopausal women are drastically reduced. After menopause E2 levels in 
women are 3 times lower than in men. Postmenopausal withdrawal of the effects of 
E2 from non-reproductive tissues such as the skeleton, the cardiovascular system, 
and the brain, is a major risk factor for the development of osteoporosis, coronary 
artery disease and stroke.1-5 
Large individual variations in postmenopausal E2 levels can be observed and 
this individual variation in endogenous E2 exposure has been shown to result in 
differences in the risk of diseases such as osteoporosis and breast cancer.6-8 It can 
be assumed that, aside from known environmental factors such as smoking and 
body weight, individual variation in E2 levels can also be determined by genetic 
variations (i.e. polymorphisms) in genes that affect hormone biosynthesis. These 
polymorphisms could, therefore, infl uence the risk of hormone related disease. 
Thus, unraveling the genetic origins of variations in E2 levels will not only give 
important information about the physiology of hormone biosynthesis, but may also 
provide new insights into the etiology of these diseases. A logical candidate gene 
to study for its effects on E2 levels is the aromatase (CYP19) gene. Aromatase cata-
lyzes the rate limiting step in the biosynthesis of E2, the conversion of androgens 
to estrogens.
In 1994, Sourdaine et al. identifi ed a potentially interesting polymorphism in 
the CYP19 gene.9 Recently, Kristensen et al. showed that this C-T substitution, 
located in the untranslated region (UTR) of exon 10 (rs10046), is frequently found 
in Caucasians (~50%) and is associated with increased aromatase mRNA levels and 
a switch from the adipose promoter to ovary promoter.10 The aim of the present 
study was to determine if this common CYP19 polymorphism is associated with 
serum E2 and E1 levels in a population of both men and postmenopausal women 
aged 55 years and older. 
Polymorphisms in CYP19 alone may cause variation in E2 levels, but presumably 
they also do so through interactions with other polymorphisms. Recently, our group 
has found that two polymorphisms in the estrogen receptor alpha gene (ERα) are 
associated with serum E2 levels.
11 Therefore, the second aim of our study was to 
determine if there is interaction between these two genes in infl uencing E2 levels.
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METHODS
Study population
The Rotterdam Study is a population-based, prospective cohort study of men 
and women aged 55 years and over. Rationale and design have been described 
previously.12 All residents age 55 or older of Ommoord, a district of Rotterdam, 
The Netherlands, were invited to participate. A total of 7983 men and women 
(78% of those eligible) entered the study. Base-line examinations, including a home 
interview and an extensive physical examination at the research center, took place 
between 1990 and 1993. The Rotterdam Study was approved by the medical eth-
ics committee of the Erasmus Medical Center and written informed consent was 
obtained from all participants. 
We determined serum E2 levels in a gender-stratifi ed random sample of 1308 
subjects (719 women) who were able to visit the research center and for whom 
blood samples were available. Only subjects of Caucasian origin, as identifi ed by 
having four Caucasian grandparents, were included. All women selected were 
postmenopausal. Participants who used hormone supplements or corticosteroids 
at the time of blood drawing were excluded. Due to the limited amount of plasma 
per participant, levels of additional sex-hormones were available for 836 subjects 
(473 women). 
 
Clinical examination
At baseline, interview information, including smoking habits and age at 
menopause, was obtained by a trained research assistant during a home interview. 
Smoking was categorized as current, past or never. Age at menopause responses 
were validated as described previously.13 Anthropometric measurements were ob-
tained at the research center. Body mass index (BMI) was calculated as weight in 
kilograms divided by height in meters squared. 
Hormone assays
Non-fasting blood samples were drawn by venapuncture at the baseline exami-
nation in the research center between 0830 and 1600 h. Levels of steroid hormones 
were measured in plasma. For the collection of plasma, blood was collected in 
5-ml tubes containing 0.5 ml sodium citrate solution. All tubes were stored on ice 
before and after blood sampling. Platelet-free plasma was obtained by two-stage 
centrifugation, fi rst for 10 min at 1600 x g at 4 C and then for 30 min at 7000 x g at 4 
C. Platelet-free samples were immediately frozen in liquid nitrogen and transferred 
to the laboratory. At the laboratory, plasma samples were stored at -80°C prior 
to hormone assessment. For the present study, plasma levels of E2, testosterone, 
androstenedione, estrone (E1), dehydroepiandrosterone sulfate (DHEAS), and 
sex hormone binding globulin (SHBG) were estimated in 12 separate batches of 
samples using coated tube or double antibody radioimmunoassays purchased from 
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Diagnostic Systems Laboratories, Inc. (Webster, TX). For the estimation of E2 we 
used an ultra-sensitive assay with a mean minimum detection limit of 4.8 pmol/l, 
which enabled us to study the association with ERα polymorphism at very low 
levels.7 Non-detectable estradiol was scored as zero. Due to the relatively small 
volumes of plasma available, all values reported are single sample estimations. 
Intra-assay coeffi cients of variation, determined on the basis of duplicate results of 
internal quality control (QC) serum pools with 3 different levels of each analyte, 
were below 15% for all assays, with the exception of E2 (18%) and E1 (21%). Since 
inter-assay variations were relatively large (between 20 and 30%, with the exception 
of SHBG (14%) and testosterone (19%)) results of all batches were normalized by 
multiplying all concentrations within a batch with a factor, which made results for 
the internal QC pools comparable. As described previously, this reduced inter-assay 
variations to acceptable levels (all under 18%) and was considered justifi ed because 
the pattern of the results of these pools and the mean results for male and female 
sera in one assay batch showed very similar patterns.14 Assays were performed blind 
with respect to information on the subject. Albumin was measured using a colori-
metric method (KONE Diagnostics, Espoo, Finland). As a measure of bioavailable 
hormones, non-SHBG-bound testosterone and E2 were calculated on the basis of 
hormone, SHBG and albumin levels, and respective affi nity constants according to 
the method described by Södergård et al.15 and van den Beld et al.16
Genotyping
Genomic DNA was isolated from peripheral leucocytes by standard procedures. 
Genotypes were determined using the Taqman allelic discrimination assay. Primer 
and probe sequences were optimized for the CYP19 and ERα gene polymorphisms 
using the SNP assay-by-design service of Applied Biosystems. For details see store.
appliedbiosystems.com. Reactions were preformed on the Taqman Prism 7900HT 
384 wells format. 
All participants were genotyped for the CYP19 exon 10 and ERα PvuII and 
XbaI polymorphisms The CYP19 exon 10 polymorphism is located 1531 basepairs 
downstream of the fi rst nucleotide of the transcription initiation site (ATG). 
Participants were categorized by the presence of the T- or C-allele. The ERα PvuII 
and XbaI polymorphisms are located 397 and 351 basepairs, respectively, upstream 
of the start of exon 2. Haplotypes were constructed for the ERα polymorphisms 
as described previously.17 The ERα PvuII-XbaI haplotype 1 has previously been 
associated with lower serum E2 levels and was analyzed for interaction with the 
CYP19 polymorphism.11 Haplotype 1 represents a T-allele at the PvuII restriction 
site and an A-allele at the XbaI restriction site.
Statistical analysis
One-way analysis of covariance (ANCOVA) and Pearson’s chi-square tests were 
used to compare baseline characteristics between subjects in our study and the 
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entire Rotterdam Study cohort.
The association between CYP19 genotypes, sex-hormone levels and possible 
confounders was evaluated using ANCOVA, linear regression or Pearson’s chi-
square tests. To account for possible confounding, we adjusted the analysis of sex-
hormone levels for age, BMI, years since menopause and the direct precursor for 
each hormone when available.
We allowed for three possible models to explain differences between genotype 
groups, i.e., an allele dose effect, a dominant effect, or a recessive effect. Allele dose 
was defi ned as the number of copies of the allele of interest. 
For the analyses of gene-gene interaction, we categorized participants for both 
the CYP19 polymorphism and ERα haplotype. For each of the 9 possible genotype 
categories mean E2 levels were calculated. Stepwise multiple linear regression was 
used to test for independent predictors for E2 entering, age, years since menopause, 
BMI, smoking, ERα haplotype, and CYP19 genotype into the model.
All statistical analyses were performed using SPSS version 11.0.1 (SPSS Inc., 
Chicago, USA).
Figure 1. 
Association of CYP19 exon 10 polymorphism with E2 levels in 719 postmenopausal 
women. Analysis was adjusted for age (mean ± SE).
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RESULTS
Approximately 16% of the Rotterdam Study cohort was included in our study. 
We compared our study participants to the entire Rotterdam Study cohort and 
found no differences in baseline characteristics (data not shown).
In the 1308 participants of our study the frequency of the CYP19 exon 10 
C-allele was 47.7%. Genotype distributions were in Hardy-Weinberg equilibrium 
(HWE) and similar between genders and across age categories.
In the 719 postmenopausal women, age was signifi cantly associated with CYP19 
genotype (Table 1), therefore we adjusted all analyses for age. None of the other 
baseline characteristics was associated with CYP19 genotype (Table 1). The C-allele 
was associated with decreased serum E2 levels in an allele-dose dependent man-
ner (Figure 1). Mean serum E 2 levels decreased by 2.23 pmol/L per C-allele copy 
(p-trend 0.005, adjusted for age); extreme genotypes varied 4.53 pmol/L. Further 
adjustments for the number of years since menopause, BMI, and smoking did 
not change the results (p-trend 0.006). In the 589 men in our study, the CYP19 
polymorphism was not associated with serum E2 levels (results shown for subset 
in Table 2). 
Within a subset of 473 postmenopausal women and 363 men, serum levels of 
other sex-hormones were also determined. In line with the observations in the 
larger set, the CYP19 C-allele was signifi cantly associated with lower serum E2 
levels in postmenopausal women, but not in men (Table 2). Furthermore, the C-
allele was also signifi cantly associated with serum E1 and free E2 levels in women. 
Testosterone, free testosterone, androstenedione and dehydroepiandrosterone 
(DHEA) sulfate levels were not signifi cantly associated with CYP19 genotype. The 
associations with E1 and E2 levels were adjusted for the direct precursors, andro-
stenedione and testosterone, respectively, along with age, years since menopause, 
BMI, and smoking. These adjustments did not change the results. In men, the 
CYP19 polymorphism was not associated with any of the sex-hormone levels we 
analyzed (Table 2).
When we further stratifi ed the 719 female participants by ERα PvuII-XbaI 
haplotype 1 as well as CYP19 genotype, we observed an additive effect of both 
genotypes on E2 levels. The mean E2 levels of homozygous carriers of both the 
CYP19 C-allele and ERα haplotype 1 was 8.86 pmol/L lower than non-carriers 
(p=0.004, Figure 2). When both genotypes were taken together in a multivariate 
regression model there was no signifi cant interaction between the CYP19 geno-
type and ERα PvuII-XbaI haplotype 1. In a multiple linear regression model, we 
investigated the relation between E2 and the ERα and CYP19 polymorphisms, 
age, years since menopause, BMI, and smoking. Years since menopause, BMI, and 
the ERα and CYP19 polymorphisms were signifi cant predictors of E2. The model 
shown in Table 3 explained 7.5% of the variance in E2 in postmenopausal women. 
BMI accounted for the majority of the total variance  (2.7%). The CYP19 exon 10 
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Table 3. Predictors of estradiol in 719 women
Predictor Coeffi cient R2 p-value
Age -0.136 0.024 0.2
Years since menopause -0.212 0.030 0.03
BMI 0.624 0.057 0.00002
Smoking 0.792 0.059 0.08
ERα PvuII-XbaI haplotype 1 -1.657 0.066 0.04
CYP19 exon 10 polymorphism -2.064 0.075 0.008
Constant 15.069 - 0.03
Figure 2. 
Effect of CYP19 polymorphism and ERα haplotype 1 on E2 levels in 719 post-
menopausal women. Numbers in the bars represent the number of women in each 
genotype category.
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polymorphism accounted for approximately 1% of the variance in E2 and the ERα 
and CYP19 polymorphisms together accounted for 1.6%.
DISCUSSION
The present population-based study demonstrates that in postmenopausal 
women a polymorphism located in exon 10 of the CYP19 gene is associated with de-
creased serum E1, E2 and bioavailable E2 levels in an allele-dose dependent manner. 
There was a 26% reduction in these hormone levels in homozygous carriers of the 
C-allele as compared to non-carriers. This polymorphism explained approximately 
1% of the variance of E2 in postmenopausal women. Furthermore, we observed an 
additive effect of the CYP19 exon polymorphism and the ERα haplotype 1 on E2 
levels. There was a 40% reduction in E2 levels in homozygous carriers of both risk 
alleles as compared to non-carriers. Together polymorphisms in these two genes 
explained 1.6% of the variance of E2.
Aromatase catalyzes the rate limiting step in the peripheral biosynthesis of E2, 
the conversion of androgens to estrogens, and is therefore essential for maintain-
ing E2 levels after menopause. Polymorphisms in the gene encoding this enzyme, 
CYP19, have been associated with risk of a number of diseases which are known to 
be related to endogenous E2 levels such as breast cancer, endometriosis, endometrial 
cancer, and osteoporosis.18-23 However, previous studies on this subject are rare and 
inconsistent. The mechanism of action for these associations with polymorphisms 
in the CYP19 gene is most likely via effects on circulating and/or local E2 levels. 
The T-allele of the CYP19 exon 10 polymorphism was associated with higher E2 
levels in an allele-dose dependent manner, but how does this particular polymor-
phism cause such variation? Kristensen et al. found that the T-allele was associated 
with higher CYP19 mRNA levels and a switch from the normally used adipose 
promoter to the more potent ovarian promoter.10 The T-allele was also associated 
with breast cancer in this study. These fi ndings suggest that the T-allele causes 
higher expression of CYP19, accelerated production of estrogen and, therefore, 
higher risk of developing estrogen dependent tumors. However, we cannot rule 
out the possibility that this polymorphism acts merely as a marker through LD 
with a truly functional variation elsewhere in the gene. A recently published com-
prehensive haplotype analysis found that the CYP19 locus contains fi ve blocks of 
LD. One of these blocks spans the entire coding region of the CYP19 gene and 
includes the exon 10 polymorphism we studied, the (TTTA)n  VNTR and many 
other polymorphisms. Therefore, linkage between the exon 10 polymorphism and 
another functional polymorphism in this haplotype block as the source of our 
results can not be excluded.
Several single nucleotide polymorphisms (SNP) and variable number tandem 
repeats (VNTR) polymorphisms have been identifi ed in CYP19, the gene encod-
ing aromatase (http://www.ncbi.nlm.nih.gov). Of the polymorphisms identifi ed, 
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the tetranucleotide repeat polymorphism, (TTTA)n, in intron 5 has been the most 
well-studied so far. This polymorphism has been associated with breast cancer, 
endometriosis, endometrial cancer, and osteoporosis.18-22 Although, it has been 
speculated that the (TTTA)n polymorphism may have a direct functional signifi -
cance in mRNA splicing and therefore in cellular aromatase activity,19 there is not 
evidence to support this theory and based on the location of this repeat polymor-
phism, this proposed functional signifi cance is not likely. If this polymorphism is a 
marker of risk it is probably because it is in linkage disequilibrium (LD) with a truly 
functional polymorphism elsewhere in the aromatase gene. Kristensen et al. have 
shown strong linkage between this polymorphism and the (TTTA)n VNTR.
10 The 
exon 10 polymorphism we have studied may be the functional polymorphism that 
is driving the associations observed with the (TTTA)n VNTR. 
There are two previous studies of CYP19 gene polymorphisms and sex-hormone 
levels in postmenopausal women and the results are contradictory, possibly because 
both studies investigated the (TTTA)n polymorphism.
18,24 As discussed above, it is 
likely that the (TTTA)n VNTR polymorphism is not functionally signifi cant in itself, 
but acts as a marker through LD with a truly functional polymorphism elsewhere 
in the gene. This may explain why Haiman et al.18 did observe an association with 
E2 and E1 levels while Probst-Hensch et al.
24 did not. The fi rst study was performed 
among Caucasians, while the latter study investigated the association with E1 in 
African-American subjects. LD is known to vary widely between ethnic groups and 
especially in the African-American race there is greater genetic diversity.
We observed the association with estrogen levels only in postmenopausal 
women and not in men. In contrast to women, men do not experience a sudden 
cessation of gonadal function similar to menopause. Elderly men still have a largely 
intact hypothalamic-pituitary-gonadal (HPG) axis and E2 may still play important 
role in the regulation of gonadotropin release. Therefore, in men, the infl uence of 
polymorphisms in enzymes involved in the peripheral biosynthesis of E2 may be 
less important. 
Are these genotype dependent differences clinically signifi cant? To answer this 
question we must consider two important aspects of this study. First, plasma levels 
of E2 do not necessarily refl ect local tissue levels because circulating E2 levels in 
postmenopausal women originate in extragonadal sites where E2 also acts locally. If 
this peripherally produced E2 escapes local metabolism, it can enter the circulation. 
However, individual variation in postmenopausal circulating E2 levels have been 
shown to infl uence the risk of diseases such as osteoporosis6,7 and breast cancer risk,8 
indicating that circulating E2 is an important determinant of disease. Secondly, the 
variance in E2 levels explained by the CYP19 polymorphism is approximately 1%. 
Clearly the impact of this polymorphism is not large. However, it is expected that 
a large number, perhaps hundreds, of genes and “low penetrance” polymorphisms 
will contribute to individual variation in E2 levels. Each of these polymorphisms 
will thus explain only a small fraction. Although this polymorphism’s contribution 
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to the variance in E2 levels may be low, its impact may be much greater since aver-
age E2 levels for the extreme genotypes may be just above or below cut-off values 
that lead to difference in disease susceptibility. 
Interactions between polymorphisms are also likely to be important determinants 
of individual variation in E2 levels. Our research group has previously reported an 
association between polymorphisms in the ERα gene and postmenopausal E2 lev-
els.11 The observed association may be due to the infl uence of these polymorphisms 
on expression or activity of the enzyme 17β-hydroxysteroid dehydrogenase (17β-
HSD) subtype 1 or 7. We observed that haplotype 1, which represents a T-allele and 
an A-allele, respectively, at the PvuII and XbaI restriction sites, was associated with 
a 22% reduction in E2 levels. These fi ndings are similar to the results we report 
here for the C-allele of the CYP19 exon polymorphism. Since interaction or synergy 
between polymorphisms in different genes is expected to play a role in phenotype 
variation in the general population, we investigated what portion of the variance 
in E2 levels is explained by these polymorphisms. We observed an additive effect 
of these polymorphisms, but no signifi cant interaction. This is not surprising since 
these polymorphism infl uence different enzymes in the E2 biosynthesis pathway, 
namely the conversion of E1 to E2 and the conversion of androgens to estrogens. 
There are limitations to genetic association studies. First, they can be infl uenced 
by population stratifi cation or heterogeneity. This is especially true for case-control 
studies in a population of mixed racial origin. However, for our study a population-
based cohort study-design was chosen and all subjects were of Dutch Caucasian 
origin and had similar social backgrounds. Furthermore, the CYP19 genotypes 
were in Hardy-Weinberg equilibrium and genotype frequencies were similar to 
those found in studies of other Caucasian populations.10,25 Therefore, our study 
population may be considered ethnically homogeneous and representative of the 
Dutch population. Another limitation of association studies is the defi nition of 
the phenotype of interest. We used assays with extremely low detection limits, 4.8 
pmol/l, and excluded all participants with medication, such as hormone replace-
ment therapy and corticosteroids, that could have infl uenced the hormone levels 
measured. However, due to the small volumes of plasma available, we were not 
able to run the assay in duplicate. Although the single sample measurement will 
have led to less precise estimations of plasma levels, this will only have led us to 
underestimate the strength of the association. 
In conclusion, this population-based study shows a signifi cant reduction in 
circulating E1, E2, and bioavailable E2 levels in carriers of the C-allele of a polymor-
phism located in exon 10 of the CYP19 gene in an allele-dose dependent manner 
in postmenopausal women. The association was not explained or infl uenced by a 
number of known confounders such as age, years since menopause, BMI, smok-
ing or precursor levels. We also observed an additive effect of the CYP19 exon 
polymorphism and the PvuII and XbaI polymorphisms in the ERα gene.
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ABSTRACT
There are a large number of known polymorphisms in the estrogen receptor 
alpha (ERα) gene. The most well-studied polymorphism so far is the PvuII C/T 
polymorphism located 397 basepairs upstream of the start exon 2, in exon 1. The T-
allele of this polymorphism, which has an allele frequency of 54% in the Caucasian 
population, has previously been associated with diseases ranging from osteoporosis 
to cardiovascular disease. Recently, it was reported that the PvuII T-allele leads 
to the loss of a binding site for the transcription factor B-myb in monkey kidney 
(CV1) cells. Regulation of transcription may differ between cells of various origins, 
and as we have studied the association of this ERα polymorphism with skeletal 
phenotypes, the aim of this study was to determine whether this process could also 
be demonstrated in human osteoblasts.
For this study we used the human osteoblast cell line MG-63. MG-63 cells were 
cotransfected with luceriferase reporter constructs carrying either the PvuII T- or 
C-allele and a B-myb expression plasmid or a negative control. In the presence of 
the B-myb expression plasmid, the PvuII C-allele gave a more than 40-fold induc-
tion of luciferase activity compared to the almost 10-fold induction of MG-63 cells 
cotransfected with the T-allele (p-value 0.004). 
In conclusion, this study demonstrates that the previously reported fi nding that 
in the presence of B-myb the ERα gene PvuII RFLP C-allele leads to augmented 
ERα expression can also be demonstrated in human osteoblasts. It is hypothesized 
that carriers of the T-allele will be less sensitive to the effects of estradiol due to 
presence of lower numbers of ERα. 
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INTRODUCTION
Current generation of estrogen defi ciency models in mice with targeted disrup-
tion of the estrogen receptor α (ERα, also known as estrogen receptor 1, ESR1) 
gene provides insight into the role of estrogen in the pathophysiology of a number 
of diseases outside the reproductive tract.1 The discovery of a male with a disrup-
tive mutation in the ERα gene leading to complete resistance to estrogen and the 
consequential occurrence of bone and cardiovascular disease has established the 
importance of estrogen in humans as well.2 The pleiotrophy in effects of estradiol 
beyond the reproductive tissues led the hypothesis that more frequent mutations 
in the ERα gene, i.e., polymorphisms, may be related to differences in the risk 
of diseases such as osteoporosis in the general population. Indeed, many studies 
have reported associations between polymorphisms in the ERα gene with diseases 
ranging from osteoporosis3 to cardiovascular disease.4 
The fi rst polymorphism to be discovered in the ERα gene and the most well-
studied so far is the PvuII restriction fragment length polymorphism (RFLP) located 
397 basepairs upstream of the start exon 2, in intron 1. Recent history has seen the 
discovery of a number of other polymorphisms, but none have been as consistently 
associated with different phenotypes as the PvuII RFLP. The T-allele of the PvuII 
RFLP, alone or in combination with the XbaI polymorphism (located 351 basepairs 
upstream of exon 2), has been associated with a number of phenotypes known to be 
related to decreased estradiol effects. These associations include an increased risk of 
osteoporosis,3 myocardial infarction,4 and stroke,5 decreased risk of osteoarthritis6 
and hysterectomy,7 lower BMI,8 shorter stature,9 and later age at menopause.7 
Given the socioeconomic impact of the diseases the PvuII RFLP has been as-
sociated with and the great frequency in which this polymorphism is present in the 
Caucasian population (T-allele frequency is 54%) it is important to fi nd if there is a 
functional signifi cance of this C to T substitution. Until recently, the PvuII RFLP 
was not in itself expected to be functionally signifi cant to the expression of the 
ERα protein. The observed associations with disease phenotypes were predicted to 
be due to linkage disequilibrium with a functional polymorphism elsewhere in the 
ERα gene or perhaps even in another gene in the surrounding genome. However, 
recently Herrington et al. suggested that the C-allele in the PvuII RFLP creates a 
possible binding site for the transcription factor B-myb (Figure 1).10 If this allele 
is present this could lead to increased transcription of the ERα gene. However, 
when the T-allele is present this B-myb binding site is absent, leading to a lower 
transcription rate of the ERα gene. Therefore, carriers of the T-allele would be at 
a higher risk of diseases, such as osteoporosis, that are known to result from lower 
estradiol effects. 
Herrington et al. tested the functionality of this RFLP in monkey kidney cells 
(CV1 cells) and human embryonic kidney cells (293T cells).10 However, regulation 
of transcription may differ between cells of various origins, and as we have studied 
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the association of this ERα polymorphism with skeletal phenotypes,3,9 the aim of 
this study was to determine whether this process could also be demonstrated in 
human osteoblasts. For this purpose we tested the functionality of this RFLP in a 
human osteosarcoma cell line (MG-63 cells).
MATERIALS & METHODS
Vector plasmids
In total fi ve different plasmids were used. A B-myb expression plasmid and 
a negative control were cloned into a pcDNA3 plasmid from Invitrogen using 
HindIII-EcoRI restriction enzyme recognition sites (provided by Dr. Roger Watson, 
Imperial College School of Medicine, London). The clones containing the C- or the 
T-allelewere a generous gift from Dr. D. McDonald (Duke University). They were 
subcloned into a PGL3-Luc vector. The three constructs created were: TATA-Luc 
(negative control) and a TATA box plus the 28 base pair sequence that contain the 
ERα PvuII T-allele (C allele-TATA-Luc) or the C-allele (T allele-TATA-Luc). 
Cell transfections
MG-63 cells are established as an osteoblastic cell line from a human osteosar-
coma. The cells were grown in α-MEM (5% penicillin/streptomycin, 2.39 g HEPES 
(C8H18N2O4S)/500 ml, 0.898 µM CaCl2, 10% FCS, pH 7.5) at 37°C. Cultures of 
MG-63 cells in the 6-11th passage were cotransfected with 200 ng B-myb expression 
Figure 1. 
The -397 T/C RFLP in intron 1 creates a potential B-myb binding site in the pres-
ence of the C-allele, while in the presence of the T-allele the transcription factor 
binding site is absent.
Exon 2
T-allele: ATGTCCCAGCTGTTTTATGCTTTGTCTC
C-allele: ATGTCCCAGCCGTTTTATGCTTTGTCTC 


-397 T/C SNP
Intron 1
Potential -myb binding site
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plasmid or the B-myb negative control and 100 ng of either one of the 3 different 
luciferase reporter constructs with 1 μl FuGENE (Roche), creating six different 
conditions. 
Luciferase activity was measured using a beetle luciferin substrate. To release 
the luciferase from the cells, they were pre-lysed with 75µl pre-lysis buffer (25 mM 
Tris; 15% glycerol; 1% Triton X-100; 1mM DTT) with 8mM MgCl2 freshly added. 
After 10 minutes of shaking, 50ul was put in a Costar 96-wells white assay plate, 
together with 50ul (16mg/ml) Steady-Glo luciferase assay substrate (Promega) in 
Steady-Glo luciferase assay buffer. The released photons were measured at the 
Packard Topcount 3.01 Microplate Scintillation Counter.
All transfection experiments were carried out in triplicate and luciferase activ-
ity results were averaged and standard deviations were calculated. Fold activation 
was calculated for each of the three luciferase reporter constructs by dividing the 
normalized luciferase activity of the cells cotransfected with the B-myb expres-
sion plasmid by the normalized luciferase activity of the cells cotransfected with 
the negative control for the B-myb expression plasmid. Statistical signifi cance was 
calculated with the student-T test by comparing the reporter construct carrying the 
C-allele to the T-allele construct.
RESULTS
Cotransfection of the MG-63 cells with the B-myb expression vector and the 
luciferase reporter C-allele construct gave a more than 40-fold increase in luciferase 
activity compared to the approximately 10-fold increase in MG-63 cells cotrans-
fected with the T-allele construct or the negative control luciferase construct 
(Figure 2). This difference was statistically signifi cant when we compared the T-
allele construct to the C-allele construct (p-value 0.003 for normalized luciferase 
activity and 0.004 for fold activation). The T-allele construct was similar to the 
negative control luciferase construct in luciferase activity (p-value 0.7 for normal-
ized luciferase activity and 0.8 for fold activation).
DISCUSSION
With these transfection experiments in MG-63 cells we have shown that the 
PvuII RFLP C-allele constitutes a binding site for the transcription factor B-myb, 
while the T-allele does not. B-myb induces a 4-fold higher expression in the pres-
ence of the C-allele when compared to the T-allele of the negative control luciferase 
construct. These fi ndings suggest that in the presence of B-myb the PvuII C-allele 
may lead to higher ERα expression compared to the T-allele. Therefore, it is tempt-
ing to hypothesize that carriers of the T-allele will be less sensitive to the effects of 
estradiol due to presence of smaller numbers of estrogen receptors α. These fi nd-
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ings are very similar to the results Herrington et al. obtained in their experiment 
in human and monkey kidney cells (CV1 and 293T cells).10 In this study we have 
shown that these same fi ndings can also be obtained in a human bone cell-line, the 
human osteosarcoma MG-63 cells.
The ERα PvuII RFLP T-allele has been associated with a number of phenotypes 
known to be related to decreased estradiol effects. These associations include an 
increased risk of osteoporosis,3 myocardial infarction,4 and stroke,5 decreased risk 
of osteoarthritis,6 and hysterectomy,7 lower BMI,8 shorter stature,9 and later age at 
menopause.7 Even before these data and the data by Herrington et al. reported that 
the PvuII RFLP may lead to augmented ERα expression, the associations found in 
disease phenotypes led to the suggestion that carries of the PvuII T-allele were less 
sensitive to estradiol. The results from this study support this previously postulated 
hypothesis. We now hypothesize that carriers of the T-allele are more susceptible to 
osteoporosis, for example, due to lower ERα expression in bone and consequently 
decreased sensitivity to estradiol.
The transcription factor B-Myb is expressed in all cell lines analyzed so far 
regardless of their embryonic origin and expression is stringently coupled to 
the proliferative state of the cell.11-13 Although the exact function of the B-myb 
transcription factor is unknown, a number of studies have provided evidence to 
support the notion that B-Myb is required for cell cycling and may be essential 
to the proliferation of many different tissues.13 More interestingly, B-myb expres-
sion is in itself responsive to estrogen activation,14 therefore, a signal-amplifying 
Figure 2. 
Normalized luciferase activity and fold activation for the three reporter construct 
and the B-myb expression plasmid and the negative control B-myb plasmid.
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system producing augmented responses to estrogen has been suggested previously 
by Herrington et al.10
Our fi ndings confi rm the fi ndings reported Herrington et al. that the ERα PvuII 
RFLP C-allele creates a bindings site for the transcription factor B-myb, while the 
T-allele does not. Furthermore, our study demonstrates that these results can also 
be obtained in human osteoblasts. This is of great interest since the PvuII RFLP 
has previously been associated with a number of bone related phenotypes including 
osteoporosis. However, B-myb is only one of a great many transcription factors 
likely to play a role in osteoblast function. Therefore, we can not be certain that this 
is a functional process in normal bone cells. To prove that this process takes place 
in normal bone cells under normal conditions further studies will be needed. 
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The objective of the studies presented in this thesis was to determine the role of candidate genes within the estrogen signaling pathway in common diseases 
of the elderly. Two candidate genes that play a pivotal role in this pathway were 
chosen: the estrogen receptor alpha (ERα, also known as ESR1) and the aromatase 
(CYP19) gene. Potentially functional polymorphisms in these genes were identifi ed 
by consulting publicly available polymorphism databases and literature. Association 
studies were performed with bone and cardiovascular phenotypes, and sex-hor-
mone levels. The shortcomings and merits of the individual studies presented have 
been discussed in the previous chapters. In this discussion, the main fi ndings of 
this thesis are brought together and placed in a broader perspective. Differences in 
penetrance of the risk alleles between genders are discussed and an attempt is made 
to indicate the relevance of these fi ndings for clinical practice. Finally, suggestions 
are made for future research.
6.1 BONE
Osteoporotic fractures, the clinical endpoint of osteoporosis, are associated 
with increased morbidity, mortality and high socio-economic costs.1,2 Due to in-
creased life expectancy fracture incidence is increasing over time, hereby increasing 
the population burden of fractures.1 Many different risk factors for osteoporosis, 
including genetic risk factors, have been identifi ed. Since up to 80% of individual 
variation in bone mineral density (BMD) is estimated to be heritable,3,4 a large 
effort is being made worldwide to determine the genetic origins of osteoporosis. 
Figure 1 gives a general representation of the role of gene polymorphisms in a 
complex disease such as osteoporosis. Gene polymorphisms may infl uence fracture 
risk through a number of different pathways. These pathways may be as diverse 
as BMD or an individual’s risk of falling. A number of environmental factors may 
modify fracture risk alone or in combination with gene polymorphisms. Such a 
representation can also be made for other complex diseases.
6.1.1 Epidemiology
The fi rst chapter in the section on bone discusses the incidence of non-vertebral 
fractures in the Rotterdam Study and the relation with BMD. Hip, wrist and upper 
humerus fractures are the most frequent fractures in elderly men and women and 
they are the fractures that are most clearly related to osteoporosis. Since collecting 
data on incident fractures is time-consuming, expensive and requires a long-term 
follow-up study-design, many genetic association studies use BMD as a surrogate 
phenotype for osteoporosis. A prerequisite for this method is that BMD accurately 
predicts who will fracture. However, our study has shown that this provision is not 
absolutely true. While each standard deviation decrease in BMD does increase the 
risk of fracture, only 21 to 34% of all fractures occur in men and women with a 
BMD that is considered to be in the osteoporotic range (T-score < -2.5). Therefore, 
we conclude that although it is time-consuming and expensive it is essential to test 
Chapter 6
166
candidate genes in osteoporosis by investigating the clinical outcome of osteopo-
rosis, i.e., fractures, and not just surrogate markers. However, these markers for 
osteoporosis may help us in determining how (genetic) risk factors for osteoporosis 
increase fracture risk. In later stages, when a candidate gene has been shown to 
be related to fracture risk, these markers, such as BMD or fall risk, can help in 
determining the pathway through which the increased risk in incurred. 
In this study the incidence of non-vertebral fractures in the Rotterdam study is 
well documented. However, the incidence of clinically diagnosed vertebral fractures 
was not included. The reason for this is that only about one third of all vertebral 
fractures spontaneously come to clinical attention.5 Therefore, the incidence rate 
calculated from studying clinically diagnosed vertebral fracture would be highly 
underestimated and the relation to BMD inaccurate. The incidence of radiologi-
cally detected vertebral fractures in the Rotterdam Study and its relation to BMD 
has previously been well documented by van der Klift et al.6
6.1.2 Estrogen receptor α gene and bone
Some of the most striking consequences of estradiol (E2) resistance are seen 
in bone. In 1994, a man with a loss-of-function mutation in the ERα gene was 
Figure 1. 
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reported.7 Lack of functional α estrogen receptors in this young adult male led to 
absence of the pubertal growth spurt, delayed bone maturation, unfused epiphyses, 
continued bone growth into adulthood, and low bone mineral density (BMD). The 
pivotal role of ERα in bone development is also seen in mouse ERα knockout 
models where males and females show low BMD and pathological bone growth.8,9 
The ERα gene is therefore a logical candidate gene to study in bone development 
and osteoporosis. 
The PvuII and XbaI SNPs are the fi rst known polymorphisms in the ERα gene 
and by far the most studied. These polymorphisms are located 397 and 352 base 
pairs, respectively, upstream of the start of exon 2 in intron 1 and are named after the 
presence of a binding site for the restriction enzymes PvuII and XbaI, respectively, 
when the variant allele is present. Since they were fi rst presented in the literature 
these SNPs have been known under a number of different names and codes. The 
PvuII polymorphism is also commonly known as c.454-397T>C, IVS1-397 T/C 
and rs2234693, and the XbaI polymorphism is also known as c.454-351A>G SNPs, 
IVS1-351 A/G and rs9340799. 
Given their intronic location, the PvuII and XbaI polymorphisms were not in 
themselves expected to be functionally signifi cant to the expression of the ERα 
protein. The observed associations with disease phenotypes were expected to be 
due to linkage disequilibrium (LD) with a truly functional polymorphism else-
where in the ERα gene or perhaps even in another gene in the surrounding area. 
Therefore, we and other research groups determined direct haplotypes for these 
two polymorphisms. In so doing we could increase the “genetic resolution” at that 
locus and have a better chance of pinpointing the real culprit, the disease-causing, 
functionally signifi cant polymorphism. The objective is to explore the genomic 
region by combining information from multiple markers. While the degree of LD 
between each of these polymorphisms and the true disease-causing mutation may 
be large, the LD between the combined haplotype of these SNPs is by defi ni-
tion larger. Therefore, by using haplotypes we can more correctly predict the real 
disease-causing mutation. Due to strong LD between these SNPs, out of the four 
possible haplotypes only three were seen frequently in the Caucasian population. 
6.1.3 Stature and osteoporosis
The ERα PvuII-XbaI haplotype 1 is strongly associated with shorter stature, 
lower lumbar spine BMD and increased risk of vertebral fractures in postmeno-
pausal women, but not in men. A so-called allele-dose effect was observed in these 
associations, i.e., the associations increased in magnitude with increasing allele 
copy number. When such an allele-dose dependent effect, rather than a dominant 
or recessive effect, is observed in a complex disease researchers are most confi dent 
that a true genetic association is present. A linear relation can be expected to ex-
ist between gene expression rate and the clinical effect of that gene. Therefore, a 
polymorphism with an important infl uence on, for example, the expression of the 
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ERα protein can be expected to demonstrate an allele dose-response. 
Since we had observed that the ERα polymorphisms were associated with in-
creased vertebral fracture risk in elderly, this was a likely explanation for the fi nding 
that carriers of haplotype 1 were shorter. Therefore, we excluded all individuals 
who had a vertebral fracture at the time of height measurement. This did not infl u-
ence the association we had found.
6.1.4 Menopausal status and ERα polymorphisms associations
After we had excluded all participants with vertebral fractures from the height 
analysis, however, the possibility still remained that the association was not caused 
by differences in linear bone growth earlier in life, but by age-related changes in the 
spine such as kyphosis or vertebral fractures that did not meet the McCloskey-Kanis 
criteria. Therefore, we verifi ed our fi nding in a group of 1500 premenopausal women. 
In this group we observed the same association as in postmenopausal women. Not 
only did we validate our fi ndings in postmenopausal women, but these fi ndings 
also indicate that the difference in stature caused by the ERα polymorphisms oc-
curred earlier in life, most likely at puberty, rather than after menopause. During 
puberty small differences in circulating estradiol levels have great consequences. 
Estradiol levels will stimulate bone growth at one level, but will cause closure of 
the epiphyses and cessation of growth at a slightly higher level. Therefore, it is 
imaginable that genotype dependent differences in ERα expression and, therefore, 
estradiol sensitivity may lead differences in linear bone growth. 
In this same group of premenopausal women we also looked for ERα genotype 
related differences in lumbar spine BMD, such as we had seen in the postmeno-
pausal women. This fi nding could not be reproduced in premenopausal women 
(data not presented in this thesis), indicating that the genotype-dependent changes 
in BMD are most likely related to menopausal status. We hypothesize that geno-
type-dependent differences in BMD occur after menopause when estradiol levels 
are greatly decreased. We were unable to examine the association with vertebral 
fractures in premenopausal women since the number of vertebral fractures prior to 
menopause is so low that the statistical power for such an analysis was insuffi cient. 
Taking these results together, we hypothesize that in times of rapidly changing 
estradiol levels, such as at puberty and after menopause, tissues are most sensitive 
to genotype-dependent differences in ERα expression. A graphic representation of 
this effect is shown in fi gure 2.
6.1.5 ERα polymorphisms: an independent risk factor for osteoporosis
One intriguing and clinically important aspect of the association we observed 
between ERα polymorphisms and vertebral fracture risk is that this increased risk 
is independent of BMD. This implies that the increased risk of vertebral fractures is 
not caused by the genotype-dependent differences in lumbar spine BMD. Through 
what other parameter of bone strength does the ERα gene infl uence fracture risk? 
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Perhaps bone geometry or micro-architecture play in important role? Our fi nding 
that PvuII-XbaI haplotype 1 is not only associated with height, but also with verte-
bral body size, show that ERα polymorphisms infl uence bone geometry. However, 
the genotype-dependent differences in vertebral body size did not explain the in-
creased vertebral fracture risk, just as BMD in itself had not explained it either. On 
the other hand, we used DEXA scans to calculate vertebral body size. This method 
is crude and based on the assumption that the vertebral body is a perfect cube. It is 
the imperfection of this calculation that may have decreased the statistical power 
of this analysis. Other parameters of vertebral body geometry that we have not 
been able to measure may be paramount in conveying the increased fracture risk 
by ERα polymorphisms. More specialized DEXA scans and sophisticated software 
for bone structural analysis such as the method recently employed at the hip may 
help determining the role of the ERα in bone geometry in the future.10
6.1.6 ERα polymorphisms and fracture risk
A priori, we had hypothesized that the estrogen pathway candidate genes would 
determine osteoporotic fracture risk, including vertebral as well as non-vertebral 
fractures. However, ERα polymorphisms were only associated with vertebral frac-
ture risk and not with other osteoporotic fracture types, such as hip, wrist or upper 
humerus. Furthermore the associations found with BMD were strongest at the 
lumbar spine, as compared to the femoral neck. This is in line with previous data 
Figure 2. 
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showing a higher response to estrogen replacement therapy at the lumbar spine in 
contrast to the femoral neck.11-14 The vertebral body is rich in trabecular bone which 
has a higher rate of bone turnover than cortical bone because trabecular bone 
presents relatively more surface per unit of bone volume. The higher bone turnover 
rate of trabecular bone may be the reason why the effect of the ERα gene is more 
pronounced in the vertebral body.
Several studies in women have reported inconsistent associations between 
polymorphisms in the ERα gene and BMD.14-23 The existence of ethnic differences 
between the populations, the case-control designs and a health-based selection 
bias in several studies could explain such discordant fi ndings. The present study 
confi rms data of a number of previous studies.15,16,22,24 In contrast, two other studies 
found the PvuII-XbaI haplotype 3 (Px) to be associated with decreased BMD,17,18 
whereas others showed no association.19,21,25 Statistical reasons (such as lack of 
power and study design) could contribute to the discordant results published so far. 
In addition, our fi ndings together with those of others suggest that there could be 
allelic heterogeneity at the ERα locus among different populations. This should be 
accompanied by differences in genotype distributions, which we indeed found when 
we studied the allelic frequencies among different ethnic populations. The two 
Asian populations studied18,21 showed different frequencies of the 2nd (PX) and 3rd 
(Px) haplotype compared to the Caucasian populations, while in the small African 
study sample the haplotype 1 (px) was present at lower frequency. A different degree 
of LD between the polymorphism studied and the true functional polymorphism 
in the different populations might be another reason for the inconsistent results 
concerning association studies between ERα variations and bone characteristics. 
6.1.7 Gender differences
An intriguing aspect of the studies on bone presented in this thesis is that all as-
sociations were signifi cantly observed in women, while in men no associations seen. 
There are two major reasons this gender difference may occur. The fi rst is based 
on circulating estradiol levels. An important difference between men and women is 
the dynamics of circulating estradiol levels. During the reproductive years estradiol 
levels in women are many times higher than in men. However, after the cessation 
of gonadal function at menopause estradiol levels in women are approximately 3 
times lower than in men. If ERα PvuII-XbaI haplotype 1 decreases expression of 
ERα, sensitivity to estradiol may be decreased because there are fewer α receptors 
for estradiol present in each cell. In postmenopausal women, circulating estradiol 
is so low that a difference in estradiol sensitivity may be clinically relevant. Such 
lower effective estradiol signaling could eventually translate to increased risk of 
osteoporosis and cardiovascular disease. In men, circulating estradiol levels are still 
suffi ciently high for genotype dependent differences in ERα expression not to lead 
to differences in estradiol effectiveness. The second reason for the observed gender 
differences might be that men may be able to compensate for differences in estra-
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diol sensitivity by means of an intact HPG-axis. This compensation mechanism 
may also occur in premenopausal women since their HPG-axis is also intact. 
6.1.7 Distinguishing the effects of the different polymorphic sites
Three polymorphisms within the ERα gene have been studied in this thesis: 
the PvuII and XbaI polymorphisms in intron 1 and the TA-repeat in the promoter 
region. At the start of the research described in this thesis, we suspected that even 
though the PvuII and XbaI polymorphisms showed strong associations with differ-
ent phenotypes, they were not functionally involved in regulating the expression 
of ERα. Our hypothesis was that the associations observed with the ERα PvuII 
polymorphism are driven by LD with a truly functional polymorphism elsewhere 
in the ERα gene. In searching for this functional polymorphism, we tested a vari-
able number of tandem repeat (VNTR) polymorphism located 1 kb upstream of 
the fi rst exon at –1118 bp from the transcription start site and –1351 bp from the 
translation start site. The TA-repeat is located in front of the B-promoter (fi gure 3); 
a promoter speculated to be important in ERα expression in bone.26,27 It is conceiv-
able that the number of TA-repeats in that region may change the transcription rate 
of ERα mRNA. Furthermore, as is seen in other populations, in The Rotterdam 
Study strong LD exists between the intron 1 PvuII and XbaI polymorphic sites and 
the TA-repeat VNTR, located approximately 35 kb upstream of these polymor-
phisms.15,17,28,29 Therefore, linkage with the TA-repeat may explain the associations 
found with the PvuII and XbaI polymorphism.
In the studies on bone, we determined both the PvuII-XbaI haplotype and the 
TA-repeat genotype in our cohort. The TA-repeat polymorphism showed a bi-
modal distribution. Between 9 and 33 TA-repeats were present in individuals in the 
Rotterdam Study, while 13 through 15 repeats and 21 through 24 repeats were seen 
Figure 3. 
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most often. When genotyping the TA-repeat based on the individual TA-repeat 
alleles numbers the genotype groups were very small and the statistical power to 
discern a risk allele was limited. However, when we examined the associations for 
each TA-repeat allele separately we noticed that a bimodal distribution could also 
be discerned in the associations. Female carriers of alleles with a low number of 
TA-repeats (<(TA) 18) were consistently shorter, had a lower BMD and had more 
vertebral fractures than carriers of the high number of TA-repeats (≥(TA)18) (Table 
1). To increase the statistical power of our study, we genotyped the Rotterdam 
Study cohort by grouping in categories of high and low TA-repeat number. We 
hypothesize that the number of TA-repeats in that region may change the tran-
scription rate of ERα B-promoter. Perhaps the presence of a low or high number 
of TA-repeat changes the 3-dimensional positioning of the B-promoter and may 
augment the transcription rate.
The alleles with a low number of TA-repeats are in strong LD with the PvuII-
XbaI haplotype 1. It is, therefore, possible that the associations observed for 
the PvuII-XbaI haplotype are driven by LD with the TA-repeat polymorphism. 
However, it may also be the other way round. To distinguish the individual role of 
each of these polymorphisms we used long-range haplotyping. In this method the 
haplotypes in which the polymorphic sites are not in linkage are the most informa-
tive. Specifi cally, alleles that carry a low number of TA-repeats, but do not carry 
the PvuII-XbaI haplotype 1 and the other way round (high number of TA-repeats 
and haplotype 1) can tell us which polymorphic site is causing shorter stature and 
osteoporosis. Unfortunately, the LD between these polymorphic sites is so strong 
that we were unable to distinguish the different effects of the two polymorphic 
sites. Even though the cohort of more than one thousand individuals used for 
these analyses is quite large, the statistical power was insuffi cient. However, the 
association studies with the long range haplotypes tend to suggest that both sites 
are contributing, since the long range haplotype defi ned by carrier status for both 
the PvuII-XbaI as well as the TA-repeat VNTR risk alleles shows the strongest 
effects on stature and osteoporosis. Larger (meta-analysis) studies are necessary to 
prove this hypothesis.
When we continued our research we realized that it would be most effi cient 
to choose one these polymorphisms to test in the entire Rotterdam Study cohort. 
The TA-repeat polymorphism can only be determined by an expensive and time-
consuming (3000 samples in three weeks) fragment sizing method, while the PvuII 
and XbaI polymorphisms can be genotyped with the inexpensive and fast (3000 
samples in one day) TaqMan method. Since LD between these polymorphisms 
is very strong, we chose to continue our research with only the PvuII and XbaI 
polymorphisms.
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Table 1. Association bone parameters with individual TA-repeat alleles. 
TA-repeat 
alleles
Number of 
carriers
Δ % 
Vertebral 
fractures
Δ Lumbar 
spine BMD Δ Height
Δ Vertebral 
area
11 17 +3.6 -0.02 -1.74 -0.23
12 9 . 0 -2.89 -0.61
13 158 +7.9 -0.03 -0.99 -0.24
14 597 +3.3 -0.01 -0.21 +0.09
15 203 +2.7 -0.01 -0.64 -0.31
16 58 +5 -0.01 -0.17 -0.21
17 75 +3.7 +0.02 -0.26 0.09
18 28 -5.3 +0.01 -0.49 -0.31
19 89 -3.8 +0.01 -0.4 -0.2
20 70 -5.4 -0.02 +0.75 +0.28
21 206 -3.6 +0.02 +1.54 +0.33
22 203 -1.5 +0.02 +0.19 +0.01
23 249 -3.4 +0.01 +0.56 +0.09
24 175 -5.7 +0.03 +0.82 +0.19
25 41 -0.8 -0.03 -0.52 -0.29
26 25 -5.3 +0.02 -0.22 0
27 4 . +0.01 +0.46 -1.02
Δ = (carriers of the test TA-repeat allele) – (non-carriers)
6.2 CARDIOVASCULAR DISEASE
6.2.1 Ischemic heart disease
Aside from osteoporosis, another striking manifestation of estradiol resistance 
in the ERα defi cient male is the presence of premature atherosclerotic coronary 
artery disease and endothelial dysfunction.30 Not only the human estradiol resis-
tance model, but also mouse ERα-knockout models have shown the importance 
of ERα in vascular physiology.31-35 It was speculated that ERα polymorphisms may 
infl uence cardiovascular disease risk in the general population. In the Rotterdam 
study, we reported that the ERα PvuII-XbaI haplotype 1 is signifi cantly associated 
with an increased risk of myocardial infarction in postmenopausal women.
There was a two-fold increased risk of myocardial infarction in female carriers 
of ERα haplotype 1. We assumed that if the ERα polymorphism increased the risk 
of myocardial infarction then they would also increase the risk of other ischemic 
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heart disease events such as revascularization procedures (CABG and PTCA) and 
death due to chronic ischemic heart disease. When we combined these forms of 
ischemic heart disease (IHD) we found that ERα haplotype 1 also increased the 
risk approximately two-fold in postmenopausal women. The combined ischemic 
heart diseases variable included approximately 50% more cases then myocardial 
infarction alone thereby increasing the statistical power of the study signifi cantly. 
Although the statistical power was limited when studying the revascularization 
procedures and death due to chronic ischemic heart disease categories separately, 
similar non-signifi cant trends were observed. These fi ndings support our theory 
that ERα gene variants infl uence ischemic heart disease, in every form, and confi rm 
our fi ndings for myocardial infarction.
Further analyses revealed that ERα polymorphisms most strongly infl uenced 
the risk of fatal ischemic heart disease. Homozygous carriers of ERα haplotype 
1 had a 6 times increased risk of fatal ischemic heart disease as compared to non-
carriers. Furthermore, the fi rst year cumulative mortality after IHD was two times 
higher in women homozygous for haplotype 1 as compared to non-carriers. This is 
mainly due to genotype-dependent differences in mortality within the fi rst month 
after an IHD event. 
A number of possible indirect as well as direct ERα-dependent mechanisms 
via which estradiol may exert their cardioprotective effects have been presented in 
the literature.36,37 Some of the protective effects of estradiol could potentially be 
mediated through systemic effects.36 However, ERα PvuII-XbaI genotypes were 
not associated with differences in a number of cardiovascular risk factors such 
as hypertension, hypercholesterolemia and diabetes mellitus. This implies that it 
is not through these pathophysiological pathways that ERα gene polymorphisms 
infl uence ischemic heart disease.
One plausible functional mechanism for the infl uence of ERα ischemic heart 
disease is through endothelial derived nitric oxide (NO) synthesis. Normal en-
dothelium secretes nitric oxide, which both relaxes vascular smooth muscle and 
inhibits platelet activation.38 One of the effects relevant to the development of ath-
erosclerosis is that NO prevents the activation of platelets that are in close contact 
with the endothelium of the vessels. As platelets can recruit infl ammatory cells, 
the inhibition of platelet activation helps prevent atherosclerosis. In addition, by 
dilating blood vessels, NO prevents coronary spasms that take place at the level of 
plaques and result in ischemia.39 As discussed previously in chapter 3, estradiol and 
the ERα gene are both essential to vascular NO production by increasing synthesis 
and release.40-43 The short-term coronary vasodilatory effects of estradiol in humans 
are largely mediated by increased NO production.44 In cultured endothelial cells, 
physiological concentrations of estradiol cause a rapid release of NO;45,46 a reaction 
which is blocked by specifi c estrogen receptor antagonists.40 Furthermore, ERα can 
directly induce mRNA expression of the enzyme responsible for the production of 
vascular NO, endothelial NO synthase.40 This proposed mechanism could explain 
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why the association is independent of known cardiovascular risk factors. Taken 
together, we hypothesize that female carriers of haplotype 1 have lower expression 
of ERα, therefore, estradiol is less effective in preventing ischemia in these women. 
Female carriers of haplotype 1 are more likely to suffer an ischemic event and such 
an event is more likely to be fatal.
6.2.2 Stroke
If these ERα SNPs infl uence ischemic heart disease risk then one could hypoth-
esize that other vascular tissues may also be predisposed to occlusion and ischemia. 
We had previously hypothesized that ERα SNPs infl uence ischemia through vas-
cular NO production. Knockout mice defi cient in endothelial NO synthase are 
highly sensitive to focal cerebral ischemia.47 Therefore, we hypothesized that ERα 
polymorphisms may infl uence stroke risk. 
Within a subset of almost 1000 individuals from the Rotterdam Study (the 
Rotterdam Scan Study), MRI scans of the brain were available. At baseline of the 
Rotterdam Scan Study (between 1995 and 1996), MRI were evaluated for the pres-
ence of cerebral infarcts and white matter lesions; the latter being strongly related 
to cerebral small vessel disease. Although, the large majority (84%) of strokes 
diagnosed in this manner is silent (that is there are no clinical manifestations) they 
are still clinically quite relevant. The presence of a silent stroke is a major risk 
factor for the occurrence of a new stroke and of cognitive decline.48,49 However, 
Similar to what we had found in ischemic heart disease, strokes identifi ed by MRI 
(in particular the lacunar subtype) and white matter lesions were strongly increased 
in female carriers of ERα PvuII-XbaI haplotype 1. 
Within the Rotterdam Study, the incidence of many common diseases in the 
elderly has been well documented. Aside from ischemic heart disease, informa-
tion on incident strokes has also been collected. As we had seen for ischemic 
myocardial infarction there was an increased risk of stroke in female carriers of 
haplotype 1 (hazard ratio homozygous carriers compared to non-carriers was 1.4, 
95% confi dence interval 0.9-2.1). However, statistical signifi cance was not reached 
and these results were not described in detail in this thesis. There are a number of 
reasons why this may have occurred. First, data collection for stroke was not as 
extensive as for ischemic heart disease, therefore, the statistical power of the study 
was lower. Second, the later onset of stroke as compared to ischemic heart disease 
makes genetic comparisons between individuals diffi cult. Third, in contrast to 
MRI defi ned stroke, clinically diagnosed stroke includes a large variety of subtypes. 
These include the major subdivision between cerebral hemorrhages and cerebral 
infarctions. Within the ischemic strokes there are also a number of subtypes such as 
stroke due to cardioembolism, stroke secondary to intracerebral and extracerebral 
large artery disease, and small vessel disease arising from occlusion of the deep 
perforating arterioles. Different classifi cation methods can be employed to identify 
different stroke subtypes, however, a signifi cant number (approximately 40% in 
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the Rotterdam Study) are of unknown cause. The variety of stroke subtypes/phe-
notypes is likely to refl ect different etiologies, including different genetic etiologies. 
Therefore, the results of our study of clinical strokes may be diluted by pheno-
type heterogeneity. However, the majority of MRI defi ned stroke are lacunar in 
origin (75%), which is the most common form of cerebral small vessel disease.49,50 
Therefore, association studies MRI defi ned stroke suffer from inaccuracy due to 
phenotype heterogeneity. 
6.2.3 Opposing effects in men?
In our study population, ERα PvuII-XbaI haplotype 1 was associated with lower 
lumbar spine BMD, increased risk of vertebral fractures, decreased height, and 
increased risk of ischemic heart disease, lacunar cerebral infarcts and white matter 
lesions in women, but not in men. A recent study by Shearman et al. from the 
Framingham Heart Study reported an decreased risk of cardiovascular disease in 
men carrying the PvuII T-allele.51 The association was only reported for men in the 
cohort, as women contributed very few cases (5 myocardial infarctions in women 
and 14 ischemic heart disease events). Therefore, no conclusions can be drawn 
from this study about the association in women. This is seemingly in contrast to 
our fi ndings that the T-allele prevents IHD in women in our study. However, there 
is not a clear confl ict with the seemingly opposite results reported by Shearman et 
al. since the men in our study showed a non-statistical trend for IHD and stroke 
opposite to the women. Furthermore, the men in the Rotterdam Study were much 
older than the men from Framingham Heart Study and we know that effects of 
(genetic) risk factors often change in older cohorts. Moreover, the effect of ERα on 
cerebral white matter lesions was statistically signifi cant and opposite in men and 
women. 
A great many explanations can be given for these seemingly contradictory fi nd-
ings between men and women. It is intriguing to hypothesize that such opposite 
effects observed in men and women may be due to different pathophysiological 
mechanisms between genders. The most obvious difference between men and 
postmenopausal women is the cessation of gonadal function in women. Perhaps 
the presence of an intact hypothalamic-pituitary-gonadal (HPG) axis in men leads 
to protection of the ERα PvuII T-allele on cardiovascular disease, while in post-
menopausal women, who are completely dependent on peripheral conversion to 
estradiol, an opposing effect occurs. We reported an association between haplotype 
1 and lower estradiol levels in postmenopausal women, a fi nding which may be in 
line with lower lumbar spine BMD, increased risk of vertebral fractures, decreased 
height, and increased risk of ischemic heart disease, lacunar cerebral infarcts and 
white matter lesions reported in women. This study also reported a non-signifi cant 
trend in the opposite direction in men, male carriers of haplotype 1 tended to have 
higher estradiol levels then their non-carrier counterparts. It is hypothesized that 
the reason for such an opposite effect is that elderly men, in contrast to postmeno-
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pausal women, still have a largely intact hypothalamic-pituitary-gonadal (HPG) 
axis and estradiol still plays an important role in the regulation of gonadotropin 
release. These fi ndings fi t with our observation that these polymorphisms seem 
to play a protective role against cerebrovascular disease in men, but are a risk fac-
tor in women. Future research and in particular meta-analyses of large data sets 
are needed to establish whether there are truly opposing effects of the ERα PvuII 
polymorphism in men and women. 
6.3 SEX-HORMONE LEVELS
6.3.1 Estrogen receptor α gene
As we and other studies have previously reported, female carriers of PvuII-XbaI 
haplotype 1 are at an increased risk of a number of diseases associated with reduced 
estradiol effects. We hypothesize that this is due to reduced expression of ERα and 
thus decreased end-organ estradiol sensitivity. Alternatively, ERα genotype depen-
dent differences in estradiol production may also partially explain the observed 
associations with these diseases. 
Human and mouse ERα knockout models both have elevated serum levels of 
estradiol levels.52,53 This is not an unexpected fi nding since sex-hormone produc-
tion is regulated by the HPG axis, a system upon which estradiol negatively feeds 
back. Therefore, resistance to estradiol, due to lack of functional ERα, may lead to a 
higher “set-point” in the HPG-axis and, consequently, higher circulating estradiol 
levels. However, a prerequisite for this effect is the presence of an intact HPG-axis. 
However, the main characteristic of menopause is the cessation of gonadal function 
and the ineffectiveness of the HPG-axis. Postmenopausal women are, therefore, 
completely dependent on peripheral synthesis of estradiol.
One of the most important enzymes in the peripheral conversion of estradiol 
Figure 4. 
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is aromatase. This enzyme, produced by the gene CYP19, is responsible for the 
conversion of androgens to estrogens. It has recently been reported that estradiol, 
through ERα, can modulate CYP19 gene expression in human breast cancer cells 
through a positive feed-back system.54 This fi nding is not only seen in humans, but 
has also been shown for other vertebrates.55 It is tempting to hypothesize that if ERα 
expression is reduced, the expression of CYP19 may also be reduced. Therefore, 
postmenopausal carriers of haplotype 1, who are less sensitive to estradiol, may 
have lower expression of aromatase and, consequently, lower circulation estradiol 
levels. This is what we observed in our study of postmenopausal women from the 
Rotterdam Study. ERα PvuII-XbaI haplotype 1 was associated with signifi cantly 
lower estradiol levels in postmenopausal females, while in males no association 
was observed. We can, therefore, conclude that postmenopausal female carriers 
of haplotype 1 appear to be more susceptible to certain diseases not only due to 
decreased end-organ sensitivity to estradiol, but also due to decreased circulating 
estradiol levels. 
We had expected estradiol levels in women to be infl uenced by ERα polymor-
phisms due to the effect of ERα on CYP19 expression. In that case we would 
also expect circulating estrone (E1) levels to be affected in the same direction 
since aromatase not only catalyzes the conversion of testosterone to estradiol, but 
also the conversion of androstenedione to estrone (Figure 4). Unexpectedly, we 
observed an opposite effect; carriers of haplotype 1 had higher estrone levels in an 
allele-dose dependent manner. Although this association was not signifi cant, it is 
strange that the direction of the association was the other-way-round. This led us 
to consider that it is not CYP19 expression that is infl uenced by ERα, but one of the 
17β-hydroxysteroid dehydrogenase (17β-HSD) subtypes. 17β-HSD subtypes 1 and 
7, which have been detected in a number of human non-gonadal tissues, selectively 
catalyze the conversion of estrone into estradiol.56 Although regulation of 17β-HSD 
by estradiol or ERα has not been shown so far, our results do suggest a role for ERα 
in 17β-HSD expression or activity.
The variance in estradiol level explained by the ERα PvuII-XbaI haplotype in 
postmenopausal women is only 1%. However, the difference in circulating estradiol 
between extreme genotypes (17.5 pmol/L in non-carriers versus 14.1 pmol/L in 
homozygous carriers) may be clinically signifi cant. A recent study in the Rotterdam 
cohort reported that individuals with estradiol levels below a “cut-off” value of 15.5 
pmol/L have an increased risk of osteoporosis 57. These fi ndings suggest that the 
genotype dependent differences in estradiol levels created by these polymorphisms 
may be clinically relevant.
6.3.2 Aromatase (CYP19) gene
Genes that determine the variance in circulating estradiol levels in postmeno-
pausal women may also be involved in determining the risk of diseases such as 
osteoporosis57,58 and breast cancer.59 As discussed previously, the enzyme aromatase 
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catalyzes the rate-limiting step in the synthesis of estradiol. Within the gene encod-
ing aromatase, CYP19, a number of polymorphisms have been documented. One 
very interesting polymorphism is located in exon 10 in the 3’UTR. Although this 
single nucleotide polymorphism (SNP) does not lead to an amino acid variation in 
the gene, its location in the 3’UTR could imply it is important for CYP19 mRNA 
stability. In fact it has been reported that the T-allele of this C-T substitution is 
associated with increased aromatase mRNA levels and a switch from the adipose 
promoter to ovarian promoter.60 The exact mechanism for the switch in promoter is 
uncertain. Kirstensen et al. speculated that two different folding patterns for the 3’ 
end of the CYP19 transcript occur depending on the nucleotide in the polymorphic 
position. 
The aim of our study was to determine if this SNP in the CYP19 gene could 
influence estradiol levels in postmenopausal women. Female carriers of the C-al-
lele, the allele associated with significantly lower CYP19 mRNA expression, had 
lower estradiol levels in an allele-dose dependent manner. In men, no association 
with estradiol was observed. An explanation for this finding may be that in elderly 
men, the HPG-axis is still largely intact and, thus, men still rely on neuroendocrine 
driven estradiol production. Through negative feedback the quantity of sex-hor-
mones synthesizes is thus regulated by gonadotropins. In contrast, in postmeno-
pausal women a negative feedback system no longer exists. Therefore, estradiol 
production is more dependent on aromatase expression. 
6.4 FUNCTIONALITY OF ERα PVUII POLYMORPHISM
In view of the fact that the PvuII and XbaI polymorphisms have been associ-
ated with many different phenotypes by different research groups their possible 
functional significance to ERα expression have been amply speculated about. Given 
their location, 397 and 351 basepairs upstream from the start of exon 2, possible 
functional mechanisms include altering ERα expression via altered binding of tran-
scription factors and influencing alternative splicing of the ERα gene. Both these 
mechanisms can be a direct result of either of these polymorphisms or through LD 
with a truly functional, but so far unknown, sequence variation elsewhere in the 
ERα gene. The first mechanism was recently supported by findings of Herrington 
et al.,61 who showed that the T-allele of the PvuII RFLP eliminates a functional 
binding site for the transcription factor B-myb. This suggests that presence of this 
allele may result in lower ERα transcription. This mechanism has previously been 
reported in the collagen type Iα1 (COLIA1) gene, where a change in a transcription 
factor binding site caused by a polymorphism in intron was shown to alter gene 
expression.62 
Herrington et al. tested the functionality of this SNP in monkey kidney cells 
(CV1 cells) and human embryonic kidney cells (293T cells).61 However, regulation 
of transcription may differ between cells of various origins, therefore, we have stud-
ied functional aspects of the ERα polymorphism in human osteoblasts. We found 
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that in a human osteosarcoma cell line (MG-63 cells) the PvuII C-allele creates a 
binding site for the transcription factor B-myb. However, these in vitro studies can 
not simply be translated to in vivo mechanisms. In these experiments MG-63 cells 
were used as a reaction unit; the cell’s own B-myb reserves were not used since the 
transcription factor was cotransfected into the cells. If we had observed a signifi -
cant increase in luciferase expression in C-allele cells that were not cotransfected 
with B-myb (B-myb negative control) then we could have concluded that the PvuII 
C-allele leads to higher ERα expression in human bone cells. However, we did 
not observe this. There may be many reasons why we could not observe such an 
increased expression. These include the fact that B-myb expression is most likely 
cell-cycle related and that increased expression caused by the PvuII C-allele may be 
very small (but nonetheless signifi cant to the function of the cell) and, therefore, 
undetectable in these experiments. Furthermore, B-myb is only one of a great many 
transcription factors likely to play a role in osteoblast function. Therefore, we can 
not be certain that this is a functional process in normal bone cells.
The fi ndings by Herrington et al.61 and this study that the PvuII polymorphism 
T-allele may lead to lower expression of ERα are in line with observations in our 
study population, as well as in others, that the T-allele is associated with a number 
of phenotypes that are known to be related to low estradiol levels and therefore 
low estradiol activity. These phenotypes include an increased risk of osteoporosis, 
decreased risk of osteoarthritis and hysterectomy, shorter stature, and later age at 
menopause.28,29,63,64
If the PvuII polymorphism is truly the functional SNP, are the associations 
reported for the XbaI SNP not driven solely by LD? We studied the PvuII-XbaI 
haplotype and not the PvuII polymorphism alone. Although the mechanism 
sketched above is very plausible it is by no means a certainty. Many other possible 
functional mechanisms are still possible, including LD with a functional poly-
morphism. Therefore, haplotyping a gene locus is the best way to increase genetic 
resolution at that point in the genome. However, since the presence of haplotype 4 
is negligible, haplotype 1 fully represents the PvuII polymorphism. Therefore, the 
associations with ERα haplotype 1 reported in this thesis are exactly the same as 
for the PvuII polymorphism alone. 
A next step in proving support for the functional signifi cance of the PvuII 
polymorphism would be to show that it is this polymorphism that is driving the 
associations with the PvuII-XbaI haplotype. However, since LD between the PvuII 
and XbaI polymorphisms is so strong is not possible to distinguish the effects of 
PvuII and XbaI even in a cohort 6600 individuals such as the Rotterdam Study. The 
statistical power needed for such an effort can only be realized by doing large meta-
analyses. A meta-analysis of more than fi ve thousand women from 30 study cohorts 
has recently shown that it may be the XbaI polymorphism which is driving the 
haplotype associations with BMD.65 In this meta-analysis, only the XbaI A-allele 
was signifi cantly associated with lower BMD, while the association with the PvuII 
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polymorphism T-allele was not signifi cant associated with decreased BMD. More 
studies of this magnitude are needed to verify these fi ndings. At this moment, a 
large European collaboration (GENOMOS) is underway in which the ERα PvuII 
and XbaI polymorphisms are genotyped in more than 20.000 women and 5000 
fracture cases are available. This study will hopefully answer these questions. 
There are also other plausible mechanisms for a functional signifi cance of the 
PvuII or the XbaI polymorphism. One of these is that one or both of these poly-
morphisms may infl uence alternative splicing of the ERα gene. Several studies have 
demonstrated the expression of an exon 1-truncated human ERα isoform (46-kDa 
ERα) in both endothelial cells and osteoblasts.66-70 Two recent studies have shown 
that this ERα isoform, primarily located at the plasma membrane, specifi cally binds 
estradiol and mediates acute estradiol actions, in particular eNOS activation, more 
effi ciently that the full-length (66-kDa) classical ERα.66,69 Furthermore, this trun-
cated ERα isoform is unable to mediate transcriptional responses to estradiol. This 
unique ability of the truncated ERα isoform to mediate acute but not transcriptional 
responses to estradiol suggests that it may play an important role in rapid estradiol 
signaling. The location of the PvuII and XbaI polymorphisms 397 and 351 basepairs 
from the start of exon 2, the transcription start site for the exon 1-truncated ERα 
isoform, suggests that these polymorphisms may infl uence alternative splicing 
and/or transcription and, therefore, infl uence the 46-kDa to 66-kDa ERα ratio. 
Further studies are needed to support this hypothesis.
We can not exclude the possibility that the observed associations with the ERα 
TA-repeat, PvuII and XbaI polymorphisms are driven by LD with another, so far 
unknown, functional polymorphism. LD seems to have a block-like structure in 
genes. For example, in the aromatase gene a haplotype block exists that spans a por-
tion of the promoter region and entire coding region.71 Since such strong linkage 
exists between the polymorphisms in the promoter region and the fi rst intron, we 
have likely found such a block in the ERα gene. Another functional polymorphism 
may be located somewhere within this block which drives the associations we 
observed. Sequencing of the promoter and coding sequence of the ERα gene will 
be necessary to fi nd this potential polymorphism.
6.5 IDENTIFYING POLYMORPHISMS
We identifi ed polymorphisms in the candidate genes in our studies by consult-
ing polymorphism and literature databases. This is an inexpensive and fast method 
to fi nd polymorphisms when compared to sequencing. But how thorough is it? 
So far, the public SNP consortium has identifi ed 1.4 million polymorphisms.72 
Although each collection contains a modest false-positive rate (10–15%), the false-
negative rate is of greater concern.73 Because the SNP collection was not based on 
the sequence of a large number of subjects, numerous lower frequency (<10%) 
SNPs, especially those that are specifi c to a single population, were not detected. A 
more comprehensive sequencing effort (84 ethnically diverse individuals) has been 
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carried out for 313 genes and 720 kb of genomic sequence.74 Only 2% of the SNPs 
identifi ed are in the public SNP database, suggesting that there are many more SNPs 
than the roughly 1.2 million SNPs in this database. Are we employing the right 
method by consulting these databases? As stated previously, LD seems to have a 
block-like structure in genes. It has been suggested that a judiciously chosen subset 
of SNPs can identify most of the genetic variation in any genomic region through 
haplotypes.75 A previous study has demonstrated that, within LD blocks, more than 
90% of the diversity of common haplotypes (>5%) may be captured by six to eight 
common SNPs and that these common haplotypes explain the vast majority of 
genetic variation contributed by unmeasured or undiscovered SNPs.76 Therefore, 
in the initial stages of studying a candidate gene, choosing polymorphisms through 
the SNP databases may be the most effi cient method to determine if a gene of 
interest is indeed involved in determining the phenotype. By choosing a number 
of polymorphisms spaced similarly a good representation of the polymorphisms in 
the gene can be tested. If associations with one or more of the polymorphisms are 
observed, such as for the promoter and intron 1 polymorphisms in the ERα gene in 
our studies, in the next step fi ne mapping of the region should take place to fi nd the 
disease causing locus. During the fi ne mapping stage, the region containing the as-
sociated polymorphisms should be sequenced to identify all present polymorphism. 
For the ERα gene, sequencing of the region surrounding the TA-repeat, PvuII and 
XbaI polymorphisms will be the next step in identifying the disease causing locus. 
6.6 CLINICAL RELEVANCE
The question being raised in all areas of genetic association research today is: 
“What is the clinical relevance?” The importance and relevance to human biol-
ogy of identifying and characterizing genes for complex disorders has been clearly 
demonstrated. However, research still has a long way to go before we are able to 
use the knowledge obtained so far in clinical practice. We can envision that in the 
future polymorphisms such as the ERα polymorphisms discussed in this thesis will 
be used to predict risk for the general population. For example, a general practitio-
ner may opt to treat mild hypercholesterolemia or hypertension more quickly in a 
female patient who also carriers PvuII-XbaI haplotype 1 than in a woman who does 
not carry the risk allele. However, to use such polymorphisms in general practice 
more must be known about that particular sequence variant and its functional 
signifi cance to gene expression. Another example of how polymorphisms may be 
clinically relevant in the future is in identifying women who will benefi t most treat-
ments such as hormone replacement therapy.
Even though the polymorphisms discussed in this thesis are by no means ex-
ploitable in clinical practice at this moment, the associations described do have a 
number of characteristics that make them potentially very interesting to clinicians. 
First, the frequency of haplotype 1 is quite high; approximately one quarter of the 
Caucasian population is homozygous carrier of haplotype 1, one half is heterozy-
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gous carrier and one quarter is homozygous carrier. Secondly, the disease pheno-
types this haplotype is associated with, osteoporosis and cardiovascular disease, 
are common disorders in the elderly. Taken together with the high frequency of 
the haplotype, the population-attributable risk due to these polymorphisms can be 
quite high. Thirdly, the associations with osteoporosis and cardiovascular disease 
are independent of known risk factors. The increased risk of cardiovascular disease, 
for example, conveyed by the ERα haplotype is not mediated by any of the known 
risk factors such as cholesterol and blood pressure. Therefore, there are no easily 
evaluated parameters that can predict this increased disease risk; the only way to 
identify individuals at an increased risk is through genotyping. 
6.7 FUTURE RESEARCH
There are several factors future researchers should consider in my opinion. With 
respect to genetic association research in general a number of comments should 
be made. Genotyping methods are quickly becoming faster and easier to do. In 
the fi ve years I have been involved in genetic association research giant leaps in 
technology have been made. Just fi ve years ago, months of planning and laboratory 
work proceeded association studies. Today a polymorphism can be genotyped in a 
large cohort within a few hours. We run the risk of publishing false positive results 
purely due to multiple testing, but at the same time we risk missing important 
gene effects, such as interactions with environmental risk factors, due to the large 
amount of data being produced. Therefore, a structured method for studying can-
didate gene pathways should be developed within each research group to prevent 
these pit-falls. 
Within ERα and CYP19 gene research, studies of polymorphism functionality 
will be a main focus in the future. In the last two decades of genetic association 
studies many polymorphisms have been associated with even more phenotypes, but 
the functional background has been largely ignored. Although, dozens of reports of 
associations of ERα gene polymorphisms have been published, the fi rst two studies 
of a possible functional mechanism behind the observed associations have only 
recently been reported. The general opinion today is that an explanation for the 
functional mechanism behind reported associations is essential. However, simply 
testing the functional signifi cance of polymorphisms is not effi cient. The fi rst step 
must always be to fi rst test a polymorphism for association with the phenotype of 
interest. Without a clinical association functional testing of a polymorphism is of 
no value. 
An area of clinically relevant research for the ERα gene in particular is in 
identifying women who will benefi t most treatments such as hormone replace-
ment therapy. The combined estrogen plus progestin part of the Women’s Health 
Initiative randomized clinical trial was recently stopped early because of an excess 
cardiovascular and breast cancer risk in the active arm compared with the pla-
cebo group.77 This surprising and unexpected fi nding, coupled with the results of 
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other recently completed randomized clinical trials, has dramatically transformed 
opinions concerning use of hormone replacement therapy (HRT). Specifi cally with 
respect to cardiovascular disease, HRT is migrating from a position of presumed 
benefi t to one of confi rmed harm. One important question concerning the car-
diovascular effects of HRT is whether important genetic factors can substantially 
modify individual women’s responses to estrogen treatment. If subgroups of women 
exist who are genetically predisposed to a greater or lesser response to HRT, for 
good or ill, HRT could be directed to women most able to benefi t from it, and 
withheld from women likely to be harmed. Knowledge of such genetic factors may 
also contribute to the understanding of the biological variability in many other 
physiological processes infl uenced by both endogenous and exogenous estrogen. 
Since we have already shown that ERα gene polymorphisms probably infl uence 
sensitivity to estradiol, common sequence variants in the ERα gene may also alter 
the effects of estrogen treatment at the cellular, biochemical, or clinical level in 
postmenopausal women. The fact that only half of all estrogen-receptor-positive 
breast carcinomas are responsive to hormone therapy is additional clinical evidence 
for the existence of estrogen receptor variants that respond in different ways to 
estrogen treatment.78 Recently, several studies have examined the effects of one or 
more ERα polymorphisms on the response to estrogen treatment in randomized 
clinical trials.61 Within the Estrogen Replacement and Atherosclerosis (ERA) trial, 
309 women with coronary artery disease were genotyped for ERα polymorphisms. 
61 Postmenopausal women who carried the ERα PvuII C-allele had a greater effect 
of HRT on HLD cholesterol than non-carriers. In two small clinical trials of the 
effects of estrogen on bone mineral density, the PvuII C allele was associated with 
greater effects of HRT on bone mineral density.14,79 However, a study of 248 Korean 
women found no such association.80 It is of great interest to repeat these studies in 
larger randomized control trials and particularly compare the risk of cardiovascular 
disease in response to HRT treatment between genotype groups.
Verifi cation of reported associations is another area of interest for the future. 
Many hundred to thousands genes are involved in complex disease risk. Since 
each individual gene will only confer a small relative risk in complex disorders, 
replication of results is often diffi cult. The inability to replicate many results has 
led to increasing skepticism about the value of simple association study designs for 
detection of genetic variants contributing to common complex traits. It has been 
suggested that a genetic association should always be replicated before an effect is 
considered valid.81 Large scale collaborations between studies to increase power 
by pooling cohorts will play a key role in the future. The recently set up European 
consortium GENOMOS is an excellent example of such an effort in osteoporosis 
research. 
In this thesis, we have shown that ERα gene polymorphisms lead to differ-
ence in the risk of diseases such as osteoporosis and cardiovascular disease. These 
diseases are evidently related to circulating estradiol levels since their incidence 
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increases after menopause. The incidence of a number of other disorders is also 
increased after menopause including dementia, anxiety disorders, and breast, colon 
and endometrial cancer. Furthermore, the occurrence of menopausal complaints 
such as “hot fl ashes” may also be infl uenced by estrogen pathway genetics. If car-
riers of ERα haplotype 1 are less sensitive to estradiol then perhaps these women 
also have more menopausal complaints. It is plausible that polymorphisms in genes 
involved in estrogen production and signaling may also infl uence the risk of these 
disorders and future research into these associations is of great interest.
Within the estrogen pathway, other candidate genes may prove of great impor-
tance. As stated in the introduction, there are fi ve broad classes of human genes 
of relevance for estrogen production and action. These include genes involved in 
the neuroendocrine regulation of sex-hormone production; enzymes involved in 
the synthesis of estradiol; the estrogen receptors α and β; genes involved in the 
downstream pathways of estrogen action; and genes involved in drug absorption, 
transport, and metabolism. In this thesis we have studied one of the estrogen 
receptors and a protein that catalyzes a rate-limiting step in estradiol production, 
aromatase. However, many other interesting candidate genes remain to be studied. 
The newly identifi ed ERβ gene is one of the most important candidate genes for 
future research. ERβ seems to be an important factor in the mechanism of action of 
estrogen, and it is expressed in many tissues, including the central nervous system, 
the cardiovascular system, the immune system, the urogenital tract, the gastrointes-
tinal tract, the kidneys and the lungs.82-88 Research in knockout mice has suggest an 
antagonistic effect of the ERα and β genes.53,89 For example, while ERα knockout 
mice have decreased BMD and tend to show more aggression, ERβ knockout mice 
tend to have higher BMD and show less aggression. This ying-yang effect of these 
genes implies that polymorphisms in the ERβ gene may have an important and 
clinically relevant effect. Many other candidate genes in this pathway can also be 
identifi ed. One method to choose these genes is to determine the rate-limiting pro-
tein in each step of estradiol production and action. For neuroendocrine regulation 
of sex-hormone production the gene encoding gonadotropin releasing hormone 
(GnRH) may then be the fi rst candidate gene to examine.
In conclusion, with the rapid advancement of new technologies for high 
throughput genotyping and a greater understanding of the molecular mechanisms 
involved in conveying disease risk there are a great number of directions future 
research should focus. However, we must keep in mind that now, more than ever, 
knowledge about biological explanations for observed associations should not be 
ignored, but sought after actively. An approach, such as the one used for the studies 
in this thesis, where observed associations and functional experiments are brought 
together to create a unifying explanation for the fi ndings reported may be a good 
example of how to approach genetic research in complex diseases in the future. 
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Estradiol, one of the sex hormones responsible for gender dimorphism and reproduction, is a pleitropic hormone with widespread biological actions far 
beyond human reproduction alone. Several lines of evidence suggest that estradiol 
may be instrumental in the etiology of diseases such as osteoporosis and cardio-
vascular disease. In searching for candidate genes for these diseases the estrogen 
signaling pathway is an obvious area of research. Two candidate genes that play a 
pivotal role in this pathway were chosen: the estrogen receptor alpha (ERα, also 
known as ESR1) and the aromatase (CYP19) gene. This thesis aims to elucidate 
the role of common sequence variations (polymorphisms) in these candidate 
genes in determining the incidence of estrogen related diseases and phenotypes 
in the general population. The diseases and phenotypes discussed in this thesis 
are related to bone, cardiovascular disease and circulating hormone levels. Most 
studies presented in this thesis were based on data from the Rotterdam Study, a 
large prospective population-based cohort study in the Netherlands. Participants 
of this study were men and women aged 55 years or over living in Ommoord, a 
suburb of Rotterdam.
In chapter 2, studies of the association between estrogen receptor α gene 
polymorphisms and bone phenotypes such as vertebral fracture risk, bone mineral 
density (BMD) and stature are presented. The overall fracture incidence in the 
Rotterdam Study and the correlation with BMD are discussed in chapter 2.1. In 
summary, hip, wrist and upper humerus fractures are the most frequent fractures 
in both men and women. In many genetic association studies due to logistic or 
fi nancial reasons BMD is used as a surrogate marker for osteoporosis instead of 
fractures. While each standard deviation decrease in BMD does increase the risk 
of fracture, only 21 to 34% of all fractures occur in men and women with a BMD 
that is considered to be in the osteoporotic range (T-score < -2.5). Therefore, we 
conclude that although it is time-consuming and expensive, it is essential to inves-
tigate the clinical outcome of osteoporosis, i.e., fractures, when testing candidate 
genes for osteoporosis. 
In chapter 2.2, the association between the ERα PvuII, XbaI and TA-repeat 
polymorphisms and osteoporosis is presented. One of the haplotype alleles span-
ning the PvuII and XbaI polymorphic sites (ERα haplotype 1 (PvuII T-allele and 
XbaI A-allele)) is associated with decreased lumbar spine BMD and an increased 
risk of vertebral fractures in postmenopausal women. The impact of this haplotype 
on the incidence of osteoporosis in the general population may be considerable 
since the risk allele is quite common. Approximately one quarter of the population 
is homozygous carrier of the risk allele, 50% is heterozygous carrier and one quarter 
is non-carrier. An interesting aspect of the association with vertebral fracture risk 
is that it is independent of BMD. Therefore, it appears that it is not only through 
BMD that ERα infl uences fracture risk, but also through another aspect of bone 
quality that is not refl ected in BMD measurements. One of these parameters may be 
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bone geometry or microarchitecture. In contrast to the fi ndings in postmenopausal 
women, no association with osteoporosis was observed in men. 
The same ERα haplotype allele associated with osteoporosis is also associated 
with shorter stature and smaller lumbar vertebral body area in women, as described 
in chapter 2.3. The association with stature was not only seen in the postmeno-
pausal participants of the Rotterdam Study, but also in the pre- and perimenopausal 
participants of the Eindhoven Study. These fi ndings indicate that the effects of 
the ERα gene polymorphisms on height occur prior to menopause, perhaps at 
puberty.
Chapter 3 focuses on the association between ERα polymorphisms and car-
diovascular disease. In postmenopausal women, the same ERα haplotype allele as-
sociated with osteoporosis was found to increase the risk of ischemic heart disease, 
including myocardial infarction, approximately two-fold (chapter 3.1). This ERα 
risk allele is an independent risk factor for ischemic heart disease since the associa-
tion was unaffected by known cardiovascular risk factor such as weight, cholesterol 
and hypertension. As observed previously for the bone phenotypes, no associations 
were observed in men. Further analysis revealed that the ERα risk allele is most 
strongly associated with fatal ischemic heart disease events. Female carriers of ERα 
haplotype 1 are not only twice as likely to suffer a myocardial infarction, they are 
also twice as likely to die from it. 
In chapter 3.2 MRI (Magnetic Resonance Imaging) defi ned stroke and cerebral 
white matter lesions are studied. Similar to what was found for ischemic heart dis-
ease, in postmenopausal women ERα PvuII-XbaI haplotype 1 is also an independent 
risk factor for the presence of brain infarcts on MRI. In particular, lacunar infarcts, 
a stroke subtype thought to be largely due to ischemic cerebral small vessel disease, 
were signifi cantly associated with ERα haplotype 1. Furthermore, in women ERα 
haplotype 1 was also associated with increased severity of white matter lesions which 
are also considered to be caused by ischemic small vessel disease. An intriguing 
aspect of these associations with cerebral vascular disease is that while haplotype 
1 is a risk factor in women, it appears to be a protective factor in men. This is 
possibly also seen in the association with ischemic heart disease, where haplotype 1 
- although it is not statistically signifi cant – seems to have a protective effect in men. 
The protective effects of ERα haplotype 1 on cardiovascular disease in men in have 
also recently reported in the literature in the Framingham Heart Study, lending 
further support to our fi ndings.1 However, further research is needed to clarify the 
gender specifi c mechanisms behind this association.
Individual variation in postmenopausal estradiol levels is an important deter-
minant of diseases such as osteoporosis. A large part of the individual variation 
may be determined by genetic variations (i.e. polymorphisms) in genes that control 
hormone biosynthesis. Studies of the infl uence of genetic variations in the ERα 
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and aromatase (CYP19) genes on circulating sex-hormone levels are presented in 
chapter 4. The ERα haplotype 1, previously associated with osteoporosis, stature 
and cardiovascular disease is also associated with decreased circulating estradiol 
levels in postmenopausal women (chapter 4.1). In men no association was ob-
served, perhaps due to the presence of an intact hypothalamic-pituitary-gonadal 
(HPG) axis in men, as opposed to postmenopausal women. From our fi nding that 
estradiol (E2) levels are, while estrone (E1) levels are not, associated with these 
ERα polymorphisms, we hypothesize that it is likely that these common sequences 
variants alter expression or activity of the enzyme 17β-HSD subtype 1 or 7. This 
enzyme is responsible for the conversion of estrone to estradiol. The variance in 
postmenopausal estradiol level explained by the ERα PvuII-XbaI haplotype is only 
1%. However, the difference in circulating estradiol between extreme genotypes 
(17.5 pmol/L in non-carriers versus 14.1 pmol/L in homozygous carriers) may 
be clinically signifi cant. A recent study in the Rotterdam cohort reported that 
individuals with estradiol levels below a “cut-off” value of 15.5 pmol/L have an 
increased risk of osteoporosis. These fi ndings suggest that the genotype dependent 
differences in estradiol levels created by these polymorphisms may be clinically 
relevant. 
The association of a possibly functional polymorphism in the aromatase 
(CYP19) gene with circulating estrogen levels in postmenopausal women is dis-
cussed in chapter 4.2. The CYP19 polymorphism was associated with estradiol as 
well as estrone levels in postmenopausal women. This fi ndings is in line with the a 
priori hypothesis that variations in CYP19 expression will infl uence all conversions 
catalyzed by the aromatase enzyme. In men, who still have an intact HPG axis, no 
associations with sex-hormone levels were observed.
Three polymorphisms within the ERα gene have been studied in this thesis: 
the PvuII and XbaI polymorphisms in intron 1 and the TA-repeat in the promoter 
region. Until recently it was suspected that although these polymorphisms show 
strong associations with different phenotypes they do not have functional con-
sequences on ERα expression. The observed associations with among others 
osteoporosis were though to be most likely due to linkage disequilibrium with a 
functional polymorphism elsewhere in the ERα gene or perhaps even in another 
gene in the surrounding area. However, the fi ndings reported in chapter 5.1 pro-
vide the alternative hypothesis that the PvuII polymorphism may be functionally 
signifi cant to ERα expression. The presence of the PvuII T-allele (the allele also 
present in ERα PvuII-XbaI haplotype 1) eliminates a functional binding site for the 
transcription factor B-myb. This suggests that presence of this allele may result in 
lower ERα transcription. It is hypothesized that carriers of the T-allele (and also 
ERα haplotype 1) will be less sensitive to the effects of estradiol due to the presence 
of a lower number of estrogen receptors.
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In the general discussion in chapter 6, the results described in this thesis are 
brought together and placed in a broader perspective. The different clinical pheno-
types associated with the candidate genes are compared to the known functional 
studies. The discussion also focuses on the gender differences observed in the 
genetic association studies and the possible biological basis. In addition, the signifi -
cance of this research in clinical practice is discussed. Finally, recommendations for 
future research are given.
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Oestradiol, één van de geslachtshormonen verantwoordelijk voor geslachts-differentiatie en voortplanting, is een pleiotroop hormoon met een vers-
cheidenheid aan biologische functies buiten alleen de voortplanting. Verschillende 
bewijsvoeringen suggereren dat oestradiol cruciaal zou kunnen zijn in de etiologie 
van ziekten zoals osteoporose (botontkalking) en hart- en vaatziekten. Bij het 
zoeken naar kandidaatgenen voor deze ziekten is de oestrogeen signaal transductie 
een voor de hand liggend onderzoeksgebied. Uit de verschillende genen betrokken 
bij de oestrogeen signaal transductie zijn twee kandidaatgenen onderzocht die 
een centrale rol spelen in deze signaal transductie. Het betreft het oestrogeen 
receptor alfa (ERα, ook wel bekend als ESR1) en het aromatase (CYP19) gen. Dit 
proefschrift richt zich op het verhelderen van de rol van veel voorkomende DNA 
sequentievarianten (polymorfi smen) in deze kandidaatgenen bij het bepalen van de 
incidentie van oestrogeen gerelateerde ziekten en individuele variatie in fenotypen 
in de bevolking. De ziekten en fenotypen die behandeld worden zijn osteoporose, 
hart- en vaatziekten, lichaamslengte en circulerend geslachtshormoon spiegels. De 
meeste studies die hier gepresenteerd worden zijn gebaseerd op het Rotterdamse 
ERGO-onderzoek (Erasmus Rotterdam Gezondheid en Ouderen), internationaal 
bekend als “the Rotterdam Study”. Dit is een groot prospectief bevolkingsonderzoek 
onder mannen en vrouwen van 55 jaar en ouder uit de Rotterdamse deelgemeente 
Ommoord.
In hoofdstuk 2 worden de associaties tussen polymorfi smen in het ERα gen en 
botfenotypen zoals risico op wervelinzakkingen (vertebrale fracturen), bot mineraal 
dichtheid (BMD) en lichaamslengte gepresenteerd. De algehele incidentie van frac-
turen binnen het ERGO-onderzoek en de correlatie met BMD wordt bestudeerd 
in hoofdstuk 2.1. Samenvattend komen heup, pols en proximale humerus facturen 
het meeste voor bij zowel mannen als vrouwen. Om logistieke en fi nanciële re-
denen wordt bij veel genetische associatie studies BMD in plaats van fractuurrisico 
gebruikt als surrogaat marker voor osteoporose. Terwijl iedere standaard deviatie 
vermindering in BMD inderdaad lijdt tot een toename in fractuurrisico, ontstaan 
slechts respectievelijk 21% en 34% van alle fracturen in mannen en vrouwen met 
een BMD welke geacht wordt binnen het osteoporotische gebied te liggen (T-score 
< -2.5). Wij concluderen dat, alhoewel het tijdrovend en duur is, het essentieel is 
om de klinische gevolgen van osteoporose te bestuderen wanneer we de kandidaat-
genen onderzoeken. 
In hoofdstuk 2.2 wordt de associatie tussen de ERα PvuII-, XbaI- en TA-repeat 
polymorfi smen en osteoporose bestudeerd. Van combinaties van deze drie poly-
morfi smen komen drie varianten (“haplotype allelen” genoemd) voor in de bevolk-
ing: haplotype 1, -2, en -3. Één van de haplotype allelen, ERα haplotype 1 (PvuII 
T-allel en XbaI A-allel) is bij postmenopauzale vrouwen geassocieerd met verlaagde 
lumbale wervelkolom BMD en een toegenomen risico op wervelinzakkingen. De 
invloed van dit haplotype op de incidentie van osteoporose in de algemene bevolk-
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ing kan aanzienlijk zijn, aangezien het risico allel frequent voorkomt. Ongeveer 
een kwart van de bevolking is homozygoot drager van het risico allel, 50% is 
heterozygoot drager en een kwart draagt het risico allel niet. Een interessant aspect 
van de gevonden associatie met wervelinzakkingen is dat het onafhankelijk is van 
BMD. Het is dus niet alleen via BMD dat het ERα het risico van wervelinzakkingen 
beïnvloed maar ook en met name via andere aspecten van bot kwaliteit. Één van 
de aspecten zou bot geometrie of microarchitectuur kunnen zijn. In tegenstelling 
tot de bevinding bij postmenopauzale vrouwen, werd er bij mannen geen associatie 
met osteoporose gevonden van dit risicoallel. 
Hetzelfde ERα haplotype dat een risicofactor is voor osteoporose, is ook geasso-
cieerd met een kortere lichaamslengte en een kleiner werveloppervlak in vrouwen 
zoals beschreven in hoofdstuk 2.3. Deze associatie werd niet alleen gezien in de 
postmenopauzale deelnemers aan het ERGO-onderzoek maar werd ook gezien 
in pre- en perimenopauzale deelnemers van de Eindhoven Perimenopauzale 
Osteoporose Studie (EPOS). Deze bevindingen tonen aan dat de effecten van het 
ERα gen op lichaamslengte al voor de menopauze ontstaan, waarschijnlijk tijdens 
de puberteit.
Hoofdstuk 3 richt zich op de associatie tussen ERα polymorfi smen en hart- 
en vaatziekten. Bij postmenopauzale vrouwen veroorzaakt hetzelfde ERα hap-
lotype welke geassocieerd is met osteoporose een twee maal verhoogd risico op 
ischemische hartziekten waaronder hartinfarcten (hoofdstuk 3.1). Aangezien de 
relatie niet wordt beïnvloed door bekende risicofactoren voor hart- en vaatziekten 
zoals gewicht, cholesterol en hypertensie is dit ERα risico allel een onafhankelijke 
risicofactor voor ischemische hartziekten. Nader onderzoek onthulde dat het ERα 
risico allel de sterkste relatie had met fatale hartinfarcten. Vrouwelijke dragers van 
ERα haplotype lopen niet alleen een twee maal verhoogde kans om een hartinfarct 
te krijgen, zij hebben ook een twee maal verhoogde kans om te overlijden aan het 
hartinfarct. 
In hoofdstuk 3.2 worden beroerten en cerebrale witte stof afwijkingen bestu-
deerd die met behulp van MRI (Magnetic Resonance Imaging) zijn vastgesteld. 
Net als wat gevonden werd bij ischemische hartziekten, werd bij postmenopauzale 
vrouwen gevonden dat het ERα haplotype 1 ook een onafhankelijke risicofactor 
is voor het bestaan van herseninfarcten op de MRI. Lacunaire infarcten in het 
bijzonder waren geassocieerd met het ERα risico allel. Het lacunaire herseninfarct 
is een subtype herseninfarct grotendeels veroorzaakt wordt door ischemie van de 
kleine cerebrale vaten. Bovendien was ERα haplotype 1 bij vrouwen ook geasso-
cieerd met de ernst van cerebrale witte stof afwijkingen welke ook geacht wordt 
veroorzaakt te worden door ischemie van de kleine cerebrale vaten. Een intrigerend 
aspect aan deze bevindingen voor cerebrale vaatziekten is dat terwijl haplotype 1 
een risicofactor is voor postmenopauzale vrouwen het een beschermende factor 
is voor mannen. Dit wordt ook tot op zekere hoogte gezien in de associatie met 
Samenvatting
207
ischemische hartziekten waar haplotype 1 een beschermende werking had bij man-
nen, alhoewel deze bevinding niet statistisch signifi cant is. Dit beschermende effect 
van ERα haplotype 1 op hart- en vaatziekten bij mannen werd recent ook gerap-
porteerd in de Framingham Heart studie, die onze bevindingen dus ondersteunt.1 
Verder onderzoek zal nodig zijn om de geslachtspecifi eke mechanismen van deze 
bevindingen te identifi ceren.
Individuele variatie in postmenopauzale oestradiol spiegels zijn deels bepalend 
voor ziekten zoals osteoporose. Een groot deel van de individuele variatie wordt 
waarschijnlijk veroorzaakt door genetische variaties (polymorfi smen) in genen 
welke de geslachtshormoon synthese reguleren. Studies naar de invloed van het 
ERα en aromatase (CYP19) gen op circulerende geslachtshormoon spiegels wor-
den gepresenteerd in hoofdstuk 4. Het ERα haplotype 1, eerder geassocieerd met 
osteoporose, lichaamslengte en hart- en vaatziekten, werd gerelateerd aan verlaagde 
circulerende oestradiol spiegels in postmenopauzale vrouwen (hoofdstuk 4.1). Bij 
mannen werd geen associatie gevonden, mogelijk ten gevolgen van het bestaan van 
een intacte hypothalamus-hypofyse-gonade (HHG) as in mannen, in tegenstelling 
tot de situatie bij postmenopauzale vrouwen. Uit onze bevindingen dat oestradiol 
(E2) spiegels, in tegenstelling tot oestron (E1) spiegels, gerelateerd zijn met het 
ERα haplotype 1 allel stellen wij de hypothese op dat dit haplotype de expressie 
of activiteit van het 17β-HSD (subtype 1 of 7) enzym beïnvloedt. Dit enzym is 
verantwoordelijk voor de conversie van oestron naar oestradiol. De variatie in 
postmenopauzale oestradiol spiegels welke veroorzaakt worden door het ERα 
PvuII-XbaI haplotype 1 allel is slechts 1%. Echter het verschil in oestradiol spie-
gels (17,5 pmol/L in niet dragers versus 14,1 pmol/L in homozygoot dragers) zou 
klinisch signifi cant kunnen zijn. Een recente studie binnen het ERGO-onderzoek 
rapporteerde dat individuen met een oestradiol spiegel beneden de grenswaarde 
van 15,5 pmol/L een verhoogde kans op osteoporose hadden. De bevindingen sug-
gereren dat de genotype-afhankelijke verschillen in oestradiol spiegels veroorzaakt 
door deze ERα gen polymorfi smen dus klinisch relevant zouden kunnen zijn.
De associatie tussen een mogelijk functioneel polymorfi sme in het aromatase 
(CYP19) gen en de circulerende oestradiol spiegels wordt behandeld in hoof-
stuk 4.2. Het CYP19 polymorfi sme was niet alleen geassocieerd met oestradiol 
spiegels maar ook met oestron spiegels. Deze bevinding is in overeenstemming met 
de a-priori hypothese dat variaties in CYP19 expressie alle conversies gekatalyseerd 
door het aromatase enzym zouden beïnvloeden. In mannen, waarin de HHG-as 
nog intact is, werden geen associaties met geslachtshormoon spiegels gevonden.
Drie polymorfi smen binnen het ERα gen werden bestudeerd in dit proefschrift: 
de PvuII en XbaI polymorfi smen in intron 1 en de TA-repeat in het promotor 
gebied. Tot recent werd aangenomen dat alhoewel deze polymorfi smen sterk geas-
socieerd zijn met verschillende fenotypen ze geen functionele gevolgen hebben 
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voor ERα expressie. De waargenomen associaties met onder andere osteoporose 
werden geacht het gevolg te zijn van “koppeling” tussen deze polymorfi smen en 
een werkelijk functioneel polymorfi sme elders in het ERα gen of mogelijk zelfs in 
een omliggend gen. De bevindingen die in hoofdstuk 5.1 worden gerapporteerd 
suggereren echter de alternatieve hypothese dat het PvuII polymorfi sme functionele 
gevolgen voor ERα expressie zou kunnen hebben. De aanwezigheid van het PvuII 
T-allel (het allel van het PvuII polymorfi sme dat ook aanwezig is in het PvuII-XbaI 
haplotype 1 allel) elimineert een functionele bindingsplaats voor de transcriptiefac-
tor B-myb. Hierdoor zou de aanwezigheid van het T-allel resulteren in een lagere 
ERα transcriptie. De hypothese is dat dragers van het T-allel hierdoor minder ge-
voelig zullen zijn voor de effecten van oestradiol door de aanwezigheid van minder 
receptoren (ERα) voor dit hormoon.
In de algemene discussie in hoofdstuk 6 worden de resultaten beschreven in dit 
proefschrift samengebracht en geplaatst in een breder perspectief. De verschillende 
klinische fenotypen welke geassocieerd werden met de kandidaatgenen worden in 
verband gebracht met de functionele studies. Tevens worden de geslachtsverschil-
len waargenomen in de genetische associatie studies en de mogelijke biologische 
verklaringen hiervoor besproken. De relevantie van dit onderzoek voor de kliniek 
wordt besproken en tenslotte worden aanbevelingen gedaan voor toekomstig 
onderzoek.
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Het dankwoord, één van de laatste onderdelen van dit proefschrift en misschien wel één van de belangrijkste delen. Niet alleen omdat dit mijn plek is om 
mensen persoonlijk te bedanken die dit proefschrift mogelijk hebben gemaakt 
maar ook omdat, zoals elke promovendus weet, dit het hoofdstuk van je boekje is 
dat het meest wordt gelezen. Zonder de bijdrage van vele mensen binnen en buiten 
deze faculteit op het zakelijke maar ook het persoonlijke vlak was dit proefschrift er 
niet gekomen. Mijn dank gaat uit naar iedereen maar er is slechts ruimte om enkelen 
te noemen.
Allereerst mijn promotor en tevens opleider Prof.dr. H.A.P. Pols. Beste Huib, 
als student geneeskunde klopte ik bij je aan om onderzoek te doen. Ik begon met 
het invoeren van gegevens en promoveerde snel naar de epidemiologie en het 
genetische lab. Jouw enthousiasme voor zowel het vak als het onderzoek werkten 
zeer aanstekelijk en ik was dan ook blij toen je mij de kans bood om de twee te 
combineren tijdens mijn opleiding. Ik heb bewondering voor je grote betrokkenheid 
bij elke promovendus, op het professionele en het persoonlijke vlak. Dit ondanks de 
grootte die je onderzoeksgroep en afdeling met de jaren heeft gekregen. Gelukkig 
eindigt onze samenwerking niet na het verschijnen van dit boekje en hoop ik in de 
komende jaren nog veel van je te mogen leren.
Mijn copromotor, Dr. A.G. Uitterlinden. Beste André, jij kunt met je eeuwige 
geduld, je gezonde dosis humor en je talent om in werkelijk elke situatie iets 
positiefs te zien, het beste naar voren halen in een van nature ietwat dramatisch 
type als mijzelf. Je hebt mij een waardering voor de genetica gegeven die ik altijd zal 
houden. Het enthousiasme dat je hebt voor ons onderzoek werkt altijd inspirerend 
en ik hoop dat ik in de toekomst nog veel met je mag samenwerken. 
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Mijn tweede promotor, Prof.dr. A. Hofman. Beste Bert, als hoofd van de 
afdeling Epidemiologie & Biostatistiek gaf je mij niet alleen een werkplek maar was 
je kritische blik onmisbaar voor dit proefschrift. Jouw capaciteit om de zaken van 
een hele andere kant te bekijken gaf vaak nieuwe inspiratie.
Alle onderzoeksmedewerksters op het centrum in Ommoord wil ik bedanken 
voor hun onmisbare bijdrage aan het ERGO-onderzoek en de gezelligheid tijdens 
de uitschrijfdiensten. Hierbij wil ik met name Lydia en Pauli noemen voor het 
maken van alle botmassametingen en röntgenfoto’s. Alle deelnemers en huisartsen 
die betrokken zijn bij het ERGO-onderzoek wil ik hartelijk bedanken voor hun 
belangeloze deelname. Bovendien wil ik op deze plaats de technische en secretariële 
ondersteuning op de faculteit danken.
I want to thank Prof.dr. M.L. Simmoons, Prof.dr. F.H. de Jong and Prof.dr. S.H. 
Ralston for their participation in the dissertation committee. 
Sinds ik begon hier op de afdeling Epidemiologie als student is er enerzijds veel 
veranderd, anderzijds ook helemaal niet. De gezichten zijn veranderd en computers 
worden steeds sneller en mooier maar de gezelligheid die blijft. Toen ik hier begon 
zeven jaar geleden viel ik onder de supervisie van Angelique Weel. Beste Angelique, 
hartelijk dank voor alle geduld die je had om statistiek uit te leggen aan een student 
die daar nog veel te weinig kaas van had gegeten. Vier jaar later kwam ik terecht in 
een hele andere “bottengroep” op de epidemiologie. Marjolein en Arjan, wij hebben 
samen heel wat broodjes bij Coenen gegeten en lang gekletst aan de koffiebar. Arjan, 
hartelijk dank voor jouw hulp bij mijn eerste pogingen statistiek te bedrijven en 
voor je nuchtere kijk op alle zaken. Marjolein, onze wegen zullen nog vaak kruisen 
denk ik. Ik denk in ieder geval met veel plezier terug aan de congressen waar we zijn 
geweest als de “osteoporettes” van Huib. 
De afgelopen drie jaar heb ik met veel plezier onze kamer gedeeld met Simone 
van der Plas. Beste Simone, wat hebben wij gekletst de afgelopen jaren, op het werk 
maar ook op borrels, etentjes, feestjes, enz. Van politiek tot make-up, alles is de 
revue gepasseerd. Ik heb je gemist het afgelopen half jaar!
Er is een grote groep promovendi met wie ik tijdens mijn promotie met veel 
plezier heb samengewerkt. Enkelen wil ik hier in het bijzonder noemen. De 
“farmaco-epi” kamer was soms bijna een tweede werkplek. Mariette en Gysèle 
bedankt dat jullie er altijd weer waren om mijn verhalen aan te horen en om  met 
name de laatste maanden van stress vakkundig op te vangen. De laatste maanden 
van het afronden van mijn proefschrift en het layouten van dit boekje heb ik veel 
hulp gehad van de mannen van de “neuro” kamer, Ewout, Niels en Tom. Met Hok 
Hay Oei heb ik niet alleen het hoofdstuk over hartinfarcten geschreven maar heb 
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ik ook de dagelijkse perikelen van het einde van de promotie gedeeld. Het laatste 
halfjaar van mijn promotie heb ik de kamer gedeeld met twee nieuwe gezichten. 
Fernando en Wietske, bedankt voor de gezellige laatste maanden en veel succes bij 
jullie onderzoek.
Naast de epidemiologie waren het genetische lab van André Uitterlinden en het 
“botten” lab van Hans van Leeuwen mijn tweede werkplek. Hans van Leeuwen 
heeft mij veel geleerd over cel biologische mechanismen. Tijdens de afgelopen drie 
jaar was de begeleiding door Joyce van Meurs onmisbaar. Joyce, jou kennis van 
de biologie, genetica en met name de oestrogeen receptor hebben mij vaak op het 
goeie spoor gezet. Pascal, Wendy, Bina, Mila en Fang wil ik hartelijk bedanken voor 
hun hulp bij het bepalen van de tien-duizenden genotypes die voor dit onderzoek 
zijn gebruikt. Marjolein, Irene, Bram, Marco, Cok, Holger, Max, Fernando en 
Marijke en alle andere mensen van onze bottengroep wil ik hartelijk danken voor 
hun bijdrage tijdens alle werkbesprekingen.
Een aantal mensen wil ik danken voor hun bijdrage aan dit onderzoek. Marjolein 
van der Klift en Chris de Laet hebben een grote bijdrage geleverd aan het hoofdstuk 
over fractuur incidentie. Hok Hay Oei, Rogier Nijhuis en Jacqueline Witteman wil 
ik danken voor hun hulp bij de analyse en interpretatie van de cardiovasculaire 
studies. Ewout van Dijk, Niels Prins, Tom den Heijer en Monique Breteler hebben 
mij geholpen bij het neurologische deel van dit proefschrift. De commentaren van 
Frank de Jong waren essentieel bij het analyseren van de geslachtshormoon data. 
Zonder de hulp van Hans van Leeuwen, Holger Jahr, Marco Eijken en Lisette Stolk 
was het onderzoek naar de functionaliteit van het PvuII polymorfisme niet mogelijk 
geweest. De klinische inzichten van Carola Zillikens hebben mij vaak anders naar 
de data doen kijken en ik wil haar hartelijk danken voor de tijd en energie die zij 
gestoken heeft in het lezen van mijn manuscripten.
De dames van het secretariaat van Prof. Pols, Marielle, Karin, Edith en Thea, 
wil ik danken voor de altijd gezellige ontvangst. 
Naast mijn oude collega’s wil ik hier bij voorbaat alvast mijn nieuwe collega’s 
bedanken voor hun geduld. Na drie jaar statistiek en labwerk hoop ik snel weer de 
draad van het klinische werk te kunnen oppakken maar een geroutineerde assistent 
ben ik zeker nog niet. 
Op deze plek wil ik ook de mensen bedanken van wie de meeste nog nooit een 
letter van dit proefschrift hebben gelezen: mijn vrienden en familie. Zonder een 
grote dosis gezelligheid thuis en tussen vrienden kan niemand goed werk afleveren 
en zeker niet promoveren. 
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Ka, Kris, Lies, Jo en Ing, alhoewel we al jaren niet meer met elkaar in huis 
wonen is onze vriendschap nog steeds even hecht. Hartelijk dank voor de ontelbare 
etentjes, feestjes, telefoontjes en kopjes thee. Frédèrique, wat kunnen wij lekker 
tutten samen, kletsen over van alles met een kopje thee op de bank, dank je wel. 
Katelijn, vriendinnen sinds we zes zijn en nu was je in januari mijn ceremoniemeester. 
Dank je wel voor je vriendschap de afgelopen 24 (!) jaar. Je proefschrift afronden 
twee dagen voor je huwelijk brengt heel wat stress met zich mee. Gelukkig zijn heel 
veel taken uit handen van deze regelneef genomen door ons “bruidspersoneel”. 
Lies, Luc, Kat, Vels, Katelijn, Ka, Daph, Beijn en Boudewijn, het was een geweldig 
huwelijk mede dankzij jullie.  
Op 16 juni zal ik worden bijgestaan door twee goeie vriendinnen. Ka, het is 
deze zomer 10 jaar geleden dat wij samen in het natuurkunde zomer klasje zaten 
in Utrecht. Sindsdien zijn wij “Jut en Jul”. Ik ben blij dat je straks naast me staat. 
Mariette, “mede-osteoporette”, al drie jaar doen we op de epi alles samen. Van 
besprekingen tot congressen, het is altijd gezellig. Ik hoop dat je deze zomer een 
heerlijk zwangerschapsverlof tegemoet gaat en ik ben blij dat je we nog vele jaren 
collega’s zullen blijven.
Lieve familie en schoonfamilie, ik wil jullie hartelijk danken voor alle steun en 
nodige afleiding de afgelopen jaren. In het bijzonder wil ik Femke Snelting hartelijk 
danken voor haar hulp bij het layouten van dit proefschrift.
Aan mijn ouders en mijn zusje, Daphne, heb ik veel te danken. Jullie uitgesproken 
trots en onvoorwaardelijke steun in studie, werk en privé zijn voor mij een drijfveer 
in alles wat ik doe.
Tenslotte mijn Ro: Hoe moet je iemand bedanken die er altijd voor je is, door 
dik en dun? Dat kan ook niet, behalve dan te zeggen: ik hou van je.
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